Page last updated: 2024-10-29
avapro and Hypertension
avapro has been researched along with Hypertension in 456 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to probe the effects of low-dose irbesartan and hydrochlorothiazide in combination with levamlodipine at different times on the circadian rhythm of blood pressure, matrix metalloproteinases (MMPs), and tissue inhibitors of metalloproteinases (TIMPs) levels in patients with non-dipper hypertension (NDH)." | 9.69 | Effect of administration of low-dose irbesartan and hydrochlorothiazide combined with levamlodipine at different times on the circadian rhythm of blood pressure and the levels of MMPs and TIMPs in non-dipper patients with grade 1 and 2 hypertension. ( Chen, J; Dong, G; Ge, M; Liu, H; Luo, Y; Wang, J; Yan, P; Zhang, J, 2023) |
| "A once-daily combination product of irbesartan and atorvastatin provided an effective, safe, and more compliable treatment for patients with coexisting hypertension and hyperlipidemia." | 9.22 | Blood Pressure and Cholesterol-lowering Efficacy of a Fixed-dose Combination With Irbesartan and Atorvastatin in Patients With Hypertension and Hypercholesterolemia: A Randomized, Double-blind, Factorial, Multicenter Phase III Study. ( Chae, SC; Cho, DG; Chung, MH; Ha, JW; Han, GR; Hyon, MS; Jo, SH; Kim, CH; Kim, DW; Kim, KS; Kim, SH; Kim, YD; Lee, HL; Lee, NH; Lee, SC; Lee, SY; Oh, BH; Park, CG; Ryu, GH; Seung, KB; Yoon, MH, 2016) |
| "5 mg hydrochorothiazide + 5 mg amlodipine, 86 patients with resistant hypertension were randomized to the add-on 25 mg spironolactone (MRB group, n = 46) or 5 mg ramipril (RASB group, n = 40) groups for 12 weeks." | 9.19 | Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. ( Azizi, M; Bobrie, G; Chatellier, G; Frank, M; Ménard, J; Perdrix, L; Plouin, PF, 2014) |
| "In a multi-center, single-arm, prospective study, we investigated the efficacy and safety of the fixed irbesartan/hydrochlorothiazide combination in Chinese patients with moderate to severe hypertension." | 9.17 | Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension. ( Dai, QY; Huang, QF; Li, Y; Ma, GS; Sheng, CS; Wang, JG, 2013) |
| "org: NCT01238705) in 160 women (18-60 years) with mild or moderate hypertension, randomized to a once-daily treatment with felodipine combined with irbesartan or metoprolol for 48 weeks." | 9.16 | Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension. ( Bai, F; Lin, X; Ma, R; Xu, D; Yang, L; Yu, J; Zhao, F, 2012) |
| "Recent studies from our laboratory indicate that chlorthalidone triggers persistent activation of the sympathetic nervous system and promotes insulin resistance in hypertensive patients, independent of serum potassium." | 9.16 | Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. ( Adams-Huet, B; Arbique, D; Auchus, RJ; Price, A; Raheja, P; Vongpatanasin, W; Wang, Z, 2012) |
| " Therefore, we investigated the effects of irbesartan treatment on plasma levels of the AGEs N(ε)(1-carboxymethyl)lysine (CML) and N(ε)(1-carboxyethyl)lysine (CEL) in hypertensive patients with type 2 diabetes and microalbuminuria." | 9.15 | Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. ( Engelen, L; Ferreira, I; Hovind, P; Parving, HH; Persson, F; Rossing, P; Schalkwijk, CG; Stehouwer, CD; Teerlink, T, 2011) |
| "The MPI was measured at baseline and after 48 weeks of antihypertensive treatment in 93 participants of the SILVHIA trial, where individuals with primary hypertension and left ventricular hypertrophy were randomized to double blind treatment with either irbesartan or atenolol." | 9.14 | The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SI ( Arnlöv, J; Kahan, T; Liljedahl, S; Lind, L, 2009) |
| " After a 1-month washout period, 26 patients with type 2 diabetes, hypertension, and albuminuria (>100 mg/day) were randomly assigned to four 2-month treatment periods in random order with placebo, 300 mg aliskiren once daily, 300 mg irbesartan once daily, or the combination using identical doses." | 9.14 | Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. ( Boomsma, F; Danser, AH; Frandsen, E; Juhl, T; Parving, HH; Persson, F; Reinhard, H; Rossing, P; Schalkwijk, C; Stehouwer, CD, 2009) |
| "This prospective, double-blind, multicenter trial compared the safety and tolerability of irbesartan/hydrochlorothiazide (HCTZ) fixed-dose combination therapy with irbesartan monotherapy in patients with severe hypertension (seated diastolic blood pressure (SeDBP) >or=110 mm Hg, mean BP 172/113 mm Hg at baseline)." | 9.14 | Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension. ( Bhaumik, A; Franklin, SS; Lapuerta, P; Neutel, JM; Oparil, S, 2009) |
| "The angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood." | 9.12 | Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. ( Bianchetti, MG; Fossali, E; Konrad, M; Rizzi, M; Simonetti, GD; von Vigier, RO, 2006) |
| "This study evaluated the anti-hypertensive and metabolic effects of moxonidine, a selective imidazoline II-receptor agonist that lowers BP by central inhibition of the sympathetic nervous system, and moxonidine plus the angiotensin II-receptor blocker irbesartan in patients with type 2 diabetes mellitus and mild hypertension." | 9.12 | Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. ( Cicero, AF; D'Angelo, A; Derosa, G; Fassi, R; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Salvadeo, S, 2007) |
| "Patients with mild to moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind fashion to treatment with either the angiotensin II type 1 receptor antagonist irbesartan (n = 48) or the beta(1)-adrenergic receptor blocker atenolol (n = 49) as monotherapy." | 9.11 | Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. ( Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Syvänen, AC, 2004) |
| "We determined the association between the TGF-beta1 genotype and regression of LV mass in 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, randomized in a double-blind study to receive treatment for 48 weeks with either the AT1-receptor antagonist irbesartan or the beta1-adrenoceptor blocker atenolol." | 9.11 | Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Billberger, K; Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Michaelsson, K; Nyström, F; Ohman, KP; Syvänen, AC, 2004) |
| "We administered placebo, losartan 100 mg/day, irbesartan 300 mg/day, and candesartan 16 mg/day during 2 months to 122 patients with mild to moderate hypertension." | 9.11 | Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. ( Ahn, JY; Ahn, TH; Chung, WJ; Han, SH; Jin, DK; Kang, WC; Kim, HS; Koh, KK; Park, GS; Shin, EK, 2004) |
| "We determined the preproendothelin-1 genotype using minisequencing in 102 patients with essential hypertension and LV hypertrophy verified by echocardiography, randomized in a double-blind fashion to treatment with either the AT1-receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol." | 9.11 | Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Michaëlsson, K; Nyström, F; Ohman, KP; Syvänen, AC, 2004) |
| "The objective of this trial was to compare the metabolic effects of long-term treatment with doxazosin to those of irbesartan in patients with type 2 diabetes and hypertension." | 9.11 | Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, R; Gaddi, A; Mugellini, A, 2005) |
| "To analyse the control rate of irbesartan/hydrochlorothiazide (HCTZ) combination tablets (COAPROVEL) in the treatment of patients with mild to moderate primary hypertension." | 9.11 | [The control rate of irbesartan/hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension]. ( Chen, J; Jing, S; Sun, NL, 2005) |
| "Effects of an antagonist of AT-1 receptors for angiotensin-II (Ang-II) irbezantane on the NO-synthase and arginase ways of the metabolism of L-arginine were studied in plasma and erythrocytes of the patients with arterial hypertension." | 9.10 | [Effect of irbesartan, an antagonist of AT-1 receptors for angiotensin II, on L-arginine metabolism in arterial hypertension]. ( Berdyshev, AH; Bukhanevich, OM; Hula, NM; Kosiakova, HV; Kotsiuruba, AV; Mishchenko, LA; Radchenko, VV; Svishchenko, IeP, 2002) |
| "One hundred and two patients with essential hypertension and left ventricular hypertrophy were allocated randomly to groups to receive double-blind treatment with either irbesartan (n = 49) or the beta(1)-adrenergic receptor blocker, atenolol ( n= 53)." | 9.10 | The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, KP, 2002) |
| "We determined the B2BKR genotype of 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, included in a double-blind study to receive treatment for 48 weeks with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol." | 9.10 | B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Michaëlsson, K; Nyström, F; Ohman, KP, 2003) |
| "The aim of this study was to comparatively assess the effects of irbesartan and amlodipine monotherapies on left ventricular mass index (LVMI) in patients with mild to moderate untreated hypertension and echocardiographically determined left ventricular hypertrophy (LVH)." | 9.10 | Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. ( Fedele, F; Fera, MS; Ferri, FM; Gaudio, C; Giovannini, M; Pannarale, G; Puddu, PE; Vittore, A; Vizza, CD, 2003) |
| "The goal of this study was to assess the effect of a once-daily fixed combination of irbesartan 300 mg/hydrochlorothiazide (HCTZ) 25 mg on the circadian blood pressure profile in patients with essential hypertension that was not controlled with full-dose single therapy or low-dose combined therapy." | 9.10 | Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. ( Bragulat, E; Calvo, C; Coca, A; de la Sierra, A; Gómez, E; López-Paz, JE; Sierra, C; Sobrino, J, 2003) |
| " A search of MEDLINE to date, however, reveals no randomized, double-blind studies using ambulatory BP monitoring (ABPM) to compare the BP-lowering efficacy of irbesartan and enalapril in a large number of patients ( > 200) with essential hypertension." | 9.10 | A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambula ( Aguilera, MT; Calvo, C; Coca, A; de la Sierra, A; García-Puig, J; Gil-Extremera, B; Marín, R; Martín-Hidalgo, A, 2002) |
| "Patients with essential hypertension and echocardiographically diagnosed LVH were included in a double-blind study to receive treatment with either the angiotensin II type 1 receptor (AT1-receptor) antagonist irbesartan (n = 41), or the beta-1 adrenergic receptor blocker atenolol (n = 43) as monotherapy for 3 months." | 9.10 | Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol ( ( Hägg, A; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, P, 2002) |
| "Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the beta1-adrenergic receptor blocker atenolol (n = 43)." | 9.10 | Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. ( Hägg, A; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, P, 2002) |
| "The purpose of this study was to assess the safety and antihypertensive dose-response effects of irbesartan and hydrochlorothiazide (HCTZ) in patients with mild-to-moderate hypertension." | 9.09 | Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. ( Guthrie, R; Kassler-Taub, K; Kochar, M; Reeves, RA; Triscari, J, 1999) |
| "Thirty-four patients (28 men and six women) with mild-to-moderate essential hypertension (diastolic blood pressure 90-120 mmHg) were randomized to once daily 150-300 mg irbesartan or 50-100 mg atenolol in a double-blind fashion, preceded by a placebo run-in period." | 9.09 | Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. ( Hägg, A; Kahan, T; Lind, L; Millgård, J; von zur Mühlen, B, 2001) |
| "In this double-blind, randomized study, an antihypertensive regimen based on irbesartan, an angiotensin II receptor antagonist, reduced systolic and diastolic blood pressure by 40/30 mm Hg at week 12 in patients with severe hypertension; this reduction was at least equivalent to that of a regimen using enalapril up to 40 mg." | 9.08 | Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators. ( Flack, JM; Krieger, EM; Larochelle, P; Marbury, TC; Reeves, RA; Sareli, P, 1997) |
| "In this multicenter, double-blind study, the antihypertensive efficacy and safety of irbesartan were compared with those of atenolol in patients with mild-to-moderate hypertension." | 9.08 | Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. ( Haworth, D; Hoglund, C; Kassler-Taub, K; Kerwin, L; Martin, A; Masson, C; Osbakken, M; Simon, T; Stumpe, KO, 1998) |
| "To compare the anti-hypertensive efficacy, safety, and tolerability of irbesartan with those of the full dose range of enalapril in patients with mild-to-moderate hypertension." | 9.08 | A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. ( Kassler-Taub, K; Kerwin, L; Mimran, A; Nys, M; Osbakken, M; Owens, D; Ruilope, L, 1998) |
| "The primary objectives of this double-blind study were to compare the antihypertensive efficacy and tolerability of irbesartan and losartan, two angiotensin II (AT1 subtype) receptor antagonists with different pharmacokinetic profiles in patients with mild-to-moderate hypertension." | 9.08 | Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. ( Adler, E; Elliott, W; Kassler-Taub, K; Littlejohn, T; Ruddy, T, 1998) |
| "The SILVER (Study of Irbesartan in Left VEntricular hypertrophy Regression) trial is designed to test the hypothesis that the newly developed angiontensin-II receptor antagonist, irbesartan, will produce a greater reduction in left ventricular (LV) mass than felodipine ER, in a population of hypertensive patients defined by seated diastolic blood pressure (SeDBP) in the range 95-115 mmHg or seated systolic blood pressure (SeSBP) in the range 160-200 mm Hg." | 9.08 | Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression. ( Agabiti Rosei, E; Bregman, B; Brudi, P; Clairefond, P; Cohen, A; Dubourg, O; Gosse, P; Guéret, P; Williams, B, 1998) |
| "Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential hypertension." | 8.85 | Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. ( Falvey, H; Lowy, A; Müller, E; Nixon, RM, 2009) |
| "Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago." | 8.83 | Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria. ( Gavras, H; Ribeiro, AB, 2006) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 8.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "We investigated serum uric acid changes and incident hyperuricemia in relation to the achieved blood pressure (BP) after 12 weeks of antihypertensive therapy with the irbesartan/hydrochlorothiazide combination." | 8.02 | Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination. ( Huang, QF; Li, Y; Wang, JG; Zhang, D, 2021) |
| "To compare the potential beneficial effects of the angiotensin converting enzyme inhibitor (ACEI) benazepril and the angiotensin II receptor 1 blocker (ARB) irbesartan on vaginal vascular remodeling and fibrosis in female spontaneously hypertensive rats (SHRs)." | 7.96 | Protective effects of irbesartan and benazepril against vaginal vascular remodeling and fibrosis in female spontaneously hypertensive rats. ( Li, N; Liang, W; Ma, R; Wang, Q; Yu, J; Yu, X; Zhao, X; Zhao, Y, 2020) |
| "00 mmol/L, body mass index 29) of men with mild to moderate hypertension, for irbesartan, the total treatment cost was euro 15,146, for losartan euro 15,696 and for valsartan euro 15,613; the quality-adjusted life years (QALYs) were irbesartan 12." | 7.77 | Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. ( Ekman, M; Fragoulakis, V; Maniadakis, N; Papagiannopoulou, V; Yfantopoulos, J, 2011) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 7.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| "Essential hypertension is frequently associated with insulin resistance of skeletal muscle glucose transport, and angiotensin II (ANGII) can contribute to the pathogenesis of both conditions." | 7.73 | Selective angiotensin II receptor antagonism enhances whole-body insulin sensitivity and muscle glucose transport in hypertensive TG(mREN2)27 rats. ( Diehl, CJ; Henriksen, EJ; Kim, JS; Saengsirisuwan, V; Sloniger, JA, 2005) |
| "Angiotensin II (Ang II) can induce cardiac fibrosis, but the underlying mechanisms are incompletely understood." | 7.72 | Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. ( Belloni, AS; Kreutz, R; Nussdorfer, GG; Paul, M; Pessina, AC; Rossi, GP; Seccia, TM, 2003) |
| "The present study assessed the cost effectiveness of irbesartan, an angiotensin II receptor antagonist, and amlodipine, a calcium channel blocker, in the treatment of Canadian patients with diabetic nephropathy and hypertension." | 7.72 | Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. ( Coyle, D; Rodby, RA, 2004) |
| "Compared with untreated controls, omapatrilat and I + H significantly attenuated hypertension [male control, 198." | 7.72 | Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. ( Beattie, E; Dominiczak, AF; Graham, D; Hamilton, C; Spiers, A, 2004) |
| "Diabetic spontaneously hypertensive rats developed albuminuria and had a reduction in both gene and protein expression of nephrin when compared with control rats." | 7.71 | Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. ( Allen, TJ; Boner, G; Bonnet, F; Cao, Z; Cooper, ME; Kawachi, H, 2001) |
| " Both drugs equally reduced SBP in the last 6 h of the dosing interval and homogeneously reduced SBP throughout the 24 h." | 6.82 | Zofenopril or irbesartan plus hydrochlorothiazide in elderly patients with isolated systolic hypertension untreated or uncontrolled by previous treatment: a double-blind, randomized study. ( Arca, M; Berra, S; Bucci, M; Calabrò, P; Fulgheri, PL; Ghione, S; Modesti, PA; Omboni, S; Pirvu, O; Popescu, E; Portaluppi, F; Pozzilli, P; Taddei, S; Velican, VG; Villani, GQ; Vladoianu, M; Volpe, M, 2016) |
| " There were no differences between 4 dosing regimens in laboratory and clinical parameters of safety and tolerability." | 6.79 | [Fixed irbesartan/amlodipine combination: efficacy and safety of the use of four dosing regimens in patients with arterial hypertension]. ( Kobalava, ZhD, 2014) |
| "Aliskiren treatment led to a 60% decrease in PRA from baseline, whereas irbesartan increased PRA by 99% (both P<0." | 6.76 | Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. ( Bartlett, M; Dole, WP; Hanefeld, M; Jung, T; Krone, W; Meyer, HF; Prescott, MF; Rajman, I; Yeh, CM, 2011) |
| " Treatment-emergent adverse event rates were similar between treatment groups regardless of the presence of diabetes or body mass index (BMI) status." | 6.76 | A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review. ( Neutel, JM, 2011) |
| "Thus, 115 hypertensive patients with left ventricular hypertrophy were randomized to receive double-blind irbesartan or atenolol, with additional therapy if needed." | 6.71 | Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Kahan, T; Lind, L; Malmqvist, K; Nyström, F; Ohman, KP, 2003) |
| "Patients with hypertension and left ventricular hypertrophy (n = 66) with a seated diastolic BP 90-115 mmHg (average of three measurements one minute apart by nurses)." | 6.70 | Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study. ( Kahan, T; Malmqvist, K; Nyström, F; Ohman, KP, 2002) |
| "Primary aldosteronism is a specifically treatable and potentially curable form of secondary hypertension." | 6.70 | Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. ( Chiandussi, L; Milan, A; Morello, F; Mulatero, P; Paglieri, C; Rabbia, F; Veglio, F, 2002) |
| "Losartan has been shown to increase urinary uric acid excretion and hence to lower serum uric acid levels." | 6.70 | Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. ( Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G, 2001) |
| " At week 6, the dosage of irbesartan or placebo was doubled for seated diastolic blood pressure > or = 90 mmHg." | 6.69 | The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. ( Lin, CS; MacNeil, D; Osbakken, M; Rosenstock, J; Rossi, L, 1998) |
| "Essential hypertension is often accompanied by abnormalities of the coagulation/fibrinolytic system, predisposing to a procoagulant state." | 6.69 | Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. ( Hatzizacharias, AN; Krespi, PG; Kyriakidis, MK; Makris, TK; Stavroulakis, GA; Triposkiadis, FK; Tsoukala, CG; Votteas, VV, 2000) |
| "Stroke is a major cause of mortality and disability worldwide." | 6.49 | Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. ( Ito, T; Kawahara, K; Kikuchi, K; Maruyama, I; Miura, N; Morimoto-Yamashita, Y; Murai, Y; Tanaka, E; Tancharoen, S, 2013) |
| "Arterial hypertension is an independent risk factor for cardiovascular diseases and one of the major causes for mortality worldwide." | 6.45 | Rational of the use of aliskiren in hypertension and beyond. ( Savvatis, K; Schultheiss, HP; Tschöpe, C; Westermann, D, 2009) |
| "Candesartan is a novel high-affinity type 1 AT(1)-receptor blocker characterized by prolonged binding to and slow dissociation from the receptor." | 6.42 | [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension]. ( Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM, 2004) |
| "This study aimed to probe the effects of low-dose irbesartan and hydrochlorothiazide in combination with levamlodipine at different times on the circadian rhythm of blood pressure, matrix metalloproteinases (MMPs), and tissue inhibitors of metalloproteinases (TIMPs) levels in patients with non-dipper hypertension (NDH)." | 5.69 | Effect of administration of low-dose irbesartan and hydrochlorothiazide combined with levamlodipine at different times on the circadian rhythm of blood pressure and the levels of MMPs and TIMPs in non-dipper patients with grade 1 and 2 hypertension. ( Chen, J; Dong, G; Ge, M; Liu, H; Luo, Y; Wang, J; Yan, P; Zhang, J, 2023) |
| "Angiotensinogen is the sole precursor of angiotensin peptides and has a key role in the pathogenesis of hypertension." | 5.69 | Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. ( Bakris, GL; Casey, S; Cheng, Y; Desai, AS; Foster, D; Huang, SA; Rhyee, S; Robbie, GJ; Sweetser, MT; Taubel, J; Webb, DJ, 2023) |
| " Urinary norepinephrine excretion and oxidative stress in the brain were decreased in both IRB and IRB/TCM groups without any adverse effect on the metabolic profile." | 5.42 | Combining irbesartan and trichlormethiazide enhances blood pressure reduction via inhibition of sympathetic activity without adverse effects on metabolism in hypertensive rats with metabolic syndrome. ( Hirooka, Y; Nishihara, M; Sunagawa, K, 2015) |
| "Compared with the placebo-treated group, proteinuria was significantly lower in the irbesartan- and efonidipine-treated groups, but not in the amlodipine-treated group." | 5.36 | Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Takai, S, 2010) |
| "825), high-dose CCBs combined with ARBs controlled hypertension without elevation of serum uric acid." | 5.34 | Assessment of suitable antihypertensive therapies: Combination with high-dose amlodipine/irbesartan vs triple combination with amlodipine/irbesartan/indapamide (ASAHI-AI study). ( Hasebe, N; Koyama, S; Maruyama, J; Morimoto, H; Nakagawa, N; Nakamura, Y; Ogawa, Y; Ohta, T; Saijo, Y; Sato, N; Takeuchi, T; Uekita, K, 2020) |
| " We conducted a multicenter randomized clinical trial to compare the efficacy of switching from the daily administration of a single-pill fixed-dose combination of irbesartan (100 mg) and amlodipine (5 mg) to irbesartan (100 mg) with an increased dose of amlodipine (10 mg) (HD group, n=62) or irbesartan (100 mg) and amlodipine (5 mg) with 1 mg of indapamide (D group, n=63) in patients with poorly controlled hypertension." | 5.24 | The effects of increasing calcium channel blocker dose vs. adding a diuretic to treatment regimens for patients with uncontrolled hypertension. ( Asayama, K; Harasawa, S; Hirayama, A; Kushiro, T; Ohkubo, T; Oiwa, K; Okubo, K; Takahashi, A; Tanabe, A; Tani, S, 2017) |
| "The present study was aimed at comparing the antihypertensive efficacy, tolerability, and side effects profile of nebivolol/hydrochlorothiazide (NH) vs irbesartan/hydrochlorothiazide (IH) combination in elderly patients with isolated systolic hypertension (ISH)." | 5.24 | Multicenter Randomized Double-Blind Comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the Treatment of Isolated Systolic Hypertension in Elderly Patients: Results of the NEHIS Study. ( Brambilla, G; Dell'Oro, R; Fici, F; Grassi, G; Mancia, G; Seravalle, G; Trevano, FQ; van Bortel, L, 2017) |
| "A single-pill fixed-dose combination therapy with irbesartan 100 mg/day and amlodipine 5 mg/day was superior to the combination of valsartan 80 mg/day and amlodipine 5 mg/day with respect to significant decreases in BP, serum UA and TG in patients with hypertension." | 5.22 | Efficacy and safety of two single-pill fixed-dose combinations of angiotensin II receptor blockers/calcium channel blockers in hypertensive patients (EXAMINER study). ( Adachi, S; Fujisawa, K; Inoue, T; Kusumoto, T; Miura, S; Motozato, K; Saku, K; Shiga, Y, 2016) |
| "A once-daily combination product of irbesartan and atorvastatin provided an effective, safe, and more compliable treatment for patients with coexisting hypertension and hyperlipidemia." | 5.22 | Blood Pressure and Cholesterol-lowering Efficacy of a Fixed-dose Combination With Irbesartan and Atorvastatin in Patients With Hypertension and Hypercholesterolemia: A Randomized, Double-blind, Factorial, Multicenter Phase III Study. ( Chae, SC; Cho, DG; Chung, MH; Ha, JW; Han, GR; Hyon, MS; Jo, SH; Kim, CH; Kim, DW; Kim, KS; Kim, SH; Kim, YD; Lee, HL; Lee, NH; Lee, SC; Lee, SY; Oh, BH; Park, CG; Ryu, GH; Seung, KB; Yoon, MH, 2016) |
| "A total of 48 patients with untreated hypertension were randomly assigned to irbesartan (ARB group, n=26) and amlodipine (CCB group, n=22)." | 5.19 | Long-term effects of irbesartan on plasma aldosterone concentration and left atrial volume in hypertensive patients. ( Fujiwara, S; Fukui, M; Goda, A; Hirotani, S; Komamura, K; Koshiba, M; Lee-Kawabata, M; Masaki, M; Masuyama, T; Nakabo, A; Otsuka, M; Sugahara, M; Tsujino, T, 2014) |
| "In previously monotherapy-treated, uncontrolled patients with hypertension, zofenopril 30-60 mg + HCTZ 12." | 5.19 | Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients. ( Agabiti-Rosei, E; Manolis, A; Omboni, S; Zava, D, 2014) |
| "5 mg hydrochorothiazide + 5 mg amlodipine, 86 patients with resistant hypertension were randomized to the add-on 25 mg spironolactone (MRB group, n = 46) or 5 mg ramipril (RASB group, n = 40) groups for 12 weeks." | 5.19 | Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. ( Azizi, M; Bobrie, G; Chatellier, G; Frank, M; Ménard, J; Perdrix, L; Plouin, PF, 2014) |
| "In a multi-center, single-arm, prospective study, we investigated the efficacy and safety of the fixed irbesartan/hydrochlorothiazide combination in Chinese patients with moderate to severe hypertension." | 5.17 | Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension. ( Dai, QY; Huang, QF; Li, Y; Ma, GS; Sheng, CS; Wang, JG, 2013) |
| "Of the pleiotropic effect related parameters investigated, urinary 8-isoprostane, fasting serum insulin and homeostasis model assessment of insulin resistance index were more suppressed after 4 weeks treatment with irbesartan than after candesartan and valsartan therapy, respectively." | 5.17 | Relationship between the receptor occupancy profile and pleiotropic effects of angiotensin II receptor blockers. ( Ando, H; Fujimura, A; Hosohata, K; Saito, T; Ushijima, K, 2013) |
| "org: NCT01238705) in 160 women (18-60 years) with mild or moderate hypertension, randomized to a once-daily treatment with felodipine combined with irbesartan or metoprolol for 48 weeks." | 5.16 | Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension. ( Bai, F; Lin, X; Ma, R; Xu, D; Yang, L; Yu, J; Zhao, F, 2012) |
| "Recent studies from our laboratory indicate that chlorthalidone triggers persistent activation of the sympathetic nervous system and promotes insulin resistance in hypertensive patients, independent of serum potassium." | 5.16 | Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. ( Adams-Huet, B; Arbique, D; Auchus, RJ; Price, A; Raheja, P; Vongpatanasin, W; Wang, Z, 2012) |
| " Therefore, we investigated the effects of irbesartan treatment on plasma levels of the AGEs N(ε)(1-carboxymethyl)lysine (CML) and N(ε)(1-carboxyethyl)lysine (CEL) in hypertensive patients with type 2 diabetes and microalbuminuria." | 5.15 | Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. ( Engelen, L; Ferreira, I; Hovind, P; Parving, HH; Persson, F; Rossing, P; Schalkwijk, CG; Stehouwer, CD; Teerlink, T, 2011) |
| "We examined the effects of ARB administration on hyperinsulinemia-associated capillary density by measuring baseline skin capillary density, capillary density during reactive hyperemia (hyperemic capillary recruitment), and capillary density during venous congestion in 17 hypertensive individuals in the basal state, during a hyperinsulinemic euglycemic clamp, and during a hyperinsulinemic clamp with acute ARB administration (600 mg irbesartan), acute calcium channel blockade (CCB; 10mg felodipine ER), as a control for the reduction in blood pressure, or placebo." | 5.15 | Acute angiotensin II receptor blockade improves insulin-induced microvascular function in hypertensive individuals. ( de Leeuw, PW; Houben, AJ; Jonk, AM; Schaper, NC; Serné, EH; Smulders, YM; Stehouwer, CD, 2011) |
| "The MPI was measured at baseline and after 48 weeks of antihypertensive treatment in 93 participants of the SILVHIA trial, where individuals with primary hypertension and left ventricular hypertrophy were randomized to double blind treatment with either irbesartan or atenolol." | 5.14 | The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SI ( Arnlöv, J; Kahan, T; Liljedahl, S; Lind, L, 2009) |
| " After a 1-month washout period, 26 patients with type 2 diabetes, hypertension, and albuminuria (>100 mg/day) were randomly assigned to four 2-month treatment periods in random order with placebo, 300 mg aliskiren once daily, 300 mg irbesartan once daily, or the combination using identical doses." | 5.14 | Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. ( Boomsma, F; Danser, AH; Frandsen, E; Juhl, T; Parving, HH; Persson, F; Reinhard, H; Rossing, P; Schalkwijk, C; Stehouwer, CD, 2009) |
| "This prospective, double-blind, multicenter trial compared the safety and tolerability of irbesartan/hydrochlorothiazide (HCTZ) fixed-dose combination therapy with irbesartan monotherapy in patients with severe hypertension (seated diastolic blood pressure (SeDBP) >or=110 mm Hg, mean BP 172/113 mm Hg at baseline)." | 5.14 | Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension. ( Bhaumik, A; Franklin, SS; Lapuerta, P; Neutel, JM; Oparil, S, 2009) |
| "This post hoc analysis of a 7-week, randomized, double-blind trial evaluated the efficacy and safety of initial irbesartan/hydrochlorothiazide treatment in 468 patients with severe, uncontrolled, hypertension (diastolic blood pressure [DBP] > or =100 mm Hg) at high cardiovascular risk." | 5.14 | Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors. ( Franklin, SS; Neutel, JM, 2010) |
| "Based on results of large-scale controlled trials of irbesartan (I), valsartan (V) and amlodipine (A) (PRIME and MARVAL) we carried out the Markov s modeling of their pharmacoeconomic parameters in arterial hypertension (AH) combined with diabetes mellitus type 2 (DM 2) and microalbuminuria (MAU) projected for 8-years perspective." | 5.13 | [Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus]. ( Belousov, DIu; Belousov, IuB; Shestakova, MV, 2008) |
| "This prospective, double-blind, parallel-group study randomized patients with moderate hypertension (seated systolic blood pressure (SeSBP) 160-179 mm Hg when seated diastolic blood pressure (SeDBP) <110 mm Hg; or SeDBP 100-109 mm Hg when SeSBP <180 mm Hg) 3:1:1 to treatment with irbesartan 300 mg/hydrochlorothiazide (HCTZ) 25 mg combination therapy (n=328), irbesartan 300 mg monotherapy (n=106) or HCTZ monotherapy 25 mg (n=104)." | 5.13 | A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. ( Bhaumik, A; Franklin, SS; Lapuerta, P; Neutel, JM; Ptaszynska, A, 2008) |
| "One-hundred and fifty-six subjects with essential hypertension were randomised to treatment with either irbesartan or atenolol." | 5.13 | Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial. ( Delles, C; Klingbeil, AU; Kolloch, RE; Krekler, M; Ludwig, M; Schmieder, RE; Schneider, MP; Stumpe, KO, 2008) |
| "The angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood." | 5.12 | Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. ( Bianchetti, MG; Fossali, E; Konrad, M; Rizzi, M; Simonetti, GD; von Vigier, RO, 2006) |
| " In 3 open-label studies in which blood pressure was assessed with ambulatory measurement, aliskiren was administered to patients with mild-to-moderate hypertension in combination with hydrochlorothiazide (n=23), ramipril (n=21), or irbesartan (n=23)." | 5.12 | Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. ( Barton, J; Dicker, P; Jensen, C; Mulcahy, D; Nussberger, J; O'Brien, E; Stanton, A, 2007) |
| "Losartan is an optimum choice of medication for patients with mild-to-moderate hypertension complicating hyperuricemia." | 5.12 | [The effects of angiotensin II receptor blockers in hypertensive patients complicating hyperuricaemia]. ( Chen, GL; Dang, AM; Liu, GZ; Zhang, YH, 2006) |
| "This study evaluated the anti-hypertensive and metabolic effects of moxonidine, a selective imidazoline II-receptor agonist that lowers BP by central inhibition of the sympathetic nervous system, and moxonidine plus the angiotensin II-receptor blocker irbesartan in patients with type 2 diabetes mellitus and mild hypertension." | 5.12 | Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. ( Cicero, AF; D'Angelo, A; Derosa, G; Fassi, R; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Salvadeo, S, 2007) |
| "A post hoc pooled analysis of 2 multicenter, randomized, double-blind, active-controlled force-titration studies assessed the antihypertensive efficacy and tolerability of 7 to 8 weeks' once-daily fixed-dose irbesartan/hydrochlorothiazide (HCTZ) 300/25 mg in 796 stage 1 or 2 hypertensive patients according to age (65 years or older or younger than 65) (n=121 or 675) and presence or absence of obesity (n=378 or 414), type 2 diabetes (n=99 or 697), and high World Health Organization-defined cardiovascular risk (n=593 or 202)." | 5.12 | The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk. ( Bhaumik, A; De Obaldia, ME; Lapuerta, P; Neutel, JM; Weir, MR, 2007) |
| "Patients with mild to moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind fashion to treatment with either the angiotensin II type 1 receptor antagonist irbesartan (n = 48) or the beta(1)-adrenergic receptor blocker atenolol (n = 49) as monotherapy." | 5.11 | Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. ( Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Syvänen, AC, 2004) |
| "We determined the association between the TGF-beta1 genotype and regression of LV mass in 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, randomized in a double-blind study to receive treatment for 48 weeks with either the AT1-receptor antagonist irbesartan or the beta1-adrenoceptor blocker atenolol." | 5.11 | Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Billberger, K; Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Michaelsson, K; Nyström, F; Ohman, KP; Syvänen, AC, 2004) |
| " Using treatment-specific probabilities derived from the Irbesartan in Diabetic Nephropathy Trial (IDNT), the cost effectiveness of treating patients with hypertension, type II diabetes and nephropathy with irbesartan, amlodipine or control was calculated using a Markov model." | 5.11 | An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. ( Annemans, L; Bilous, RW; Lamotte, M; Palmer, AJ; Rodby, RA; Roze, S, 2004) |
| "We administered placebo, losartan 100 mg/day, irbesartan 300 mg/day, and candesartan 16 mg/day during 2 months to 122 patients with mild to moderate hypertension." | 5.11 | Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. ( Ahn, JY; Ahn, TH; Chung, WJ; Han, SH; Jin, DK; Kang, WC; Kim, HS; Koh, KK; Park, GS; Shin, EK, 2004) |
| "Forty patients with hypertension were allocated randomly to groups to receive either irbesartan, an inhibitor of angiotensin II type 1 (AT1) receptors (n = 20), or a diuretic (hydrochlorothiazide) (n = 20)." | 5.11 | Enhanced platelet release of superoxide anion in systemic hypertension: role of AT1 receptors. ( Caccese, D; Germanò, G; Lauro, R; Lenti, L; Pignatelli, P; Ragazzo, M; Sanguigni, V; Violi, F, 2004) |
| " The aim of this trial was to compare the effects of irbesartan versus atenolol on LVH in subjects with essential hypertension." | 5.11 | Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project. ( Delles, C; Klingbeil, AU; Kolloch, RE; Krekler, M; Ludwig, M; Schmieder, RE; Schneider, MP; Stumpe, KO, 2004) |
| "We determined the preproendothelin-1 genotype using minisequencing in 102 patients with essential hypertension and LV hypertrophy verified by echocardiography, randomized in a double-blind fashion to treatment with either the AT1-receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol." | 5.11 | Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Michaëlsson, K; Nyström, F; Ohman, KP; Syvänen, AC, 2004) |
| "Patients with mild to moderate primary hypertension and LV hypertrophy were randomized in a double-blind fashion to treatment with either the angiotensin II type 1 receptor antagonist irbesartan (n = 48) or the beta1 adrenoreceptor blocker atenolol (n = 49)." | 5.11 | Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment. ( Kahan, T; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Syvänen, AC, 2004) |
| "A 12-week (4-week single-blind placebo run-in phase followed by an 8-week double-blind active treatment phase) randomized, parallel-group study reported that the recommended starting dose of the angiotensin II receptor antagonist (angiotensin receptor blocker; ARB) olmesartan medoxomil (Benicar(trade mark)) 20 mg/day was more effective than starting doses of losartan potassium (Cozaar) 50 mg/day, valsartan (Diovan) 80 mg/day, or irbesartan (Avapro) 150 mg/day in reducing cuff DBP in patients with essential hypertension." | 5.11 | Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. ( Dubiel, R; Jones, M; Smith, DH, 2005) |
| "Associations between baseline proteinuria and proteinuria reduction by either irbesartan, amlodipine, or control for similar decrements in blood pressure and the cumulative incidence of renal end points were examined using the Kaplan-Meier method in patients enrolled in the Irbesartan Diabetic Nephropathy Trial." | 5.11 | Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. ( Atkins, RC; Braden, G; Briganti, EM; Champion de Crespigny, PJ; DeFerrari, G; Drury, P; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Wiegmann, TB, 2005) |
| "Once-daily oral treatment with aliskiren lowers blood pressure effectively, with a safety and tolerability profile comparable to that of irbesartan and placebo, in patients with mild-to-moderate hypertension." | 5.11 | Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. ( Bedigian, MP; Chiang, Y; Gradman, AH; Lins, RL; Nussberger, J; Schmieder, RE, 2005) |
| "The objective of this trial was to compare the metabolic effects of long-term treatment with doxazosin to those of irbesartan in patients with type 2 diabetes and hypertension." | 5.11 | Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, R; Gaddi, A; Mugellini, A, 2005) |
| "To analyse the control rate of irbesartan/hydrochlorothiazide (HCTZ) combination tablets (COAPROVEL) in the treatment of patients with mild to moderate primary hypertension." | 5.11 | [The control rate of irbesartan/hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension]. ( Chen, J; Jing, S; Sun, NL, 2005) |
| " Inclusion criteria were type 2 diabetes, hypertension > 140/90 mmHg and current treatment with irbesartan or irbesartan/hydrochlorothiazide (HTCZ)." | 5.11 | [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ]. ( Krekler, M; Schmieder, RE, 2005) |
| "Effects of an antagonist of AT-1 receptors for angiotensin-II (Ang-II) irbezantane on the NO-synthase and arginase ways of the metabolism of L-arginine were studied in plasma and erythrocytes of the patients with arterial hypertension." | 5.10 | [Effect of irbesartan, an antagonist of AT-1 receptors for angiotensin II, on L-arginine metabolism in arterial hypertension]. ( Berdyshev, AH; Bukhanevich, OM; Hula, NM; Kosiakova, HV; Kotsiuruba, AV; Mishchenko, LA; Radchenko, VV; Svishchenko, IeP, 2002) |
| "One hundred and two patients with essential hypertension and left ventricular hypertrophy were allocated randomly to groups to receive double-blind treatment with either irbesartan (n = 49) or the beta(1)-adrenergic receptor blocker, atenolol ( n= 53)." | 5.10 | The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, KP, 2002) |
| "We determined the B2BKR genotype of 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, included in a double-blind study to receive treatment for 48 weeks with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol." | 5.10 | B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. ( Hallberg, P; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Michaëlsson, K; Nyström, F; Ohman, KP, 2003) |
| "We evaluated the influence of this polymorphism on the change in left ventricular mass index in 90 patients with essential hypertension and echocardiographically diagnosed left ventricular hypertrophy, randomised in a double-blind study to receive treatment with either the angiotensin II type I receptor antagonist irbesartan or the beta1-adrenoceptor blocker atenolol for 48 weeks." | 5.10 | Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy. ( Hallberg, P; Kahan, T; Kurland, L; Liljedahl, U; Lind, L; Malmqvist, K; Melhus, H; Michaëlsson, K; Nyström, F; Ohman, KP; Syvänen, AC, 2003) |
| "The aim of this study was to comparatively assess the effects of irbesartan and amlodipine monotherapies on left ventricular mass index (LVMI) in patients with mild to moderate untreated hypertension and echocardiographically determined left ventricular hypertrophy (LVH)." | 5.10 | Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. ( Fedele, F; Fera, MS; Ferri, FM; Gaudio, C; Giovannini, M; Pannarale, G; Puddu, PE; Vittore, A; Vizza, CD, 2003) |
| "The goal of this study was to assess the effect of a once-daily fixed combination of irbesartan 300 mg/hydrochlorothiazide (HCTZ) 25 mg on the circadian blood pressure profile in patients with essential hypertension that was not controlled with full-dose single therapy or low-dose combined therapy." | 5.10 | Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. ( Bragulat, E; Calvo, C; Coca, A; de la Sierra, A; Gómez, E; López-Paz, JE; Sierra, C; Sobrino, J, 2003) |
| " A search of MEDLINE to date, however, reveals no randomized, double-blind studies using ambulatory BP monitoring (ABPM) to compare the BP-lowering efficacy of irbesartan and enalapril in a large number of patients ( > 200) with essential hypertension." | 5.10 | A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambula ( Aguilera, MT; Calvo, C; Coca, A; de la Sierra, A; García-Puig, J; Gil-Extremera, B; Marín, R; Martín-Hidalgo, A, 2002) |
| "Patients with essential hypertension and echocardiographically diagnosed LVH were included in a double-blind study to receive treatment with either the angiotensin II type 1 receptor (AT1-receptor) antagonist irbesartan (n = 41), or the beta-1 adrenergic receptor blocker atenolol (n = 43) as monotherapy for 3 months." | 5.10 | Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol ( ( Hägg, A; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, P, 2002) |
| "Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the beta1-adrenergic receptor blocker atenolol (n = 43)." | 5.10 | Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. ( Hägg, A; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, P, 2002) |
| "The primary objective of this study was to compare the change from baseline in mean diastolic ambulatory blood pressure (ABP) at 24 h post dose (trough measurement) after 8 weeks of treatment with irbesartan or valsartan in subjects with mild-to-moderate hypertension." | 5.10 | An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. ( Korlipara, K; Mancia, G; Silvert, B; van Rossum, P; Villa, G, 2002) |
| "The purpose of this study was to assess the safety and antihypertensive dose-response effects of irbesartan and hydrochlorothiazide (HCTZ) in patients with mild-to-moderate hypertension." | 5.09 | Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. ( Guthrie, R; Kassler-Taub, K; Kochar, M; Reeves, RA; Triscari, J, 1999) |
| "The goal of this study was to assess the comparative efficacy and tolerability of the ARB irbesartan and the ACE inhibitor enalapril in patients > or = 65 years of age with mild to moderate hypertension (sitting diastolic blood pressure [DBP], 95 to 110 mm Hg)." | 5.09 | A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension. ( Lacourcière, Y, 2000) |
| "The Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA)." | 5.09 | Regression of left ventricular hypertrophy in human hypertension with irbesartan. ( Edner, M; Hägg, A; Held, C; Kahan, T; Lind, L; Malmqvist, K; Müller-Brunotte, R; Nyström, F; Ohman, KP; Osbakken, MD; Ostergern, J, 2001) |
| "Eighty-six patients with hypertension were randomized to double-blind treatment with either the angiotensin II type 1 receptor antagonist irbesartan or the beta1 adrenergic receptor blocker atenolol and followed for 3 months." | 5.09 | Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. ( Hägg, A; Kahan, T; Karlsson, J; Kurland, L; Lind, L; Malmqvist, K; Melhus, H; Nyström, F; Ohman, KP, 2001) |
| "Thirty-four patients (28 men and six women) with mild-to-moderate essential hypertension (diastolic blood pressure 90-120 mmHg) were randomized to once daily 150-300 mg irbesartan or 50-100 mg atenolol in a double-blind fashion, preceded by a placebo run-in period." | 5.09 | Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. ( Hägg, A; Kahan, T; Lind, L; Millgård, J; von zur Mühlen, B, 2001) |
| "In this double-blind, randomized study, an antihypertensive regimen based on irbesartan, an angiotensin II receptor antagonist, reduced systolic and diastolic blood pressure by 40/30 mm Hg at week 12 in patients with severe hypertension; this reduction was at least equivalent to that of a regimen using enalapril up to 40 mg." | 5.08 | Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators. ( Flack, JM; Krieger, EM; Larochelle, P; Marbury, TC; Reeves, RA; Sareli, P, 1997) |
| "In this multicenter, double-blind study, the antihypertensive efficacy and safety of irbesartan were compared with those of atenolol in patients with mild-to-moderate hypertension." | 5.08 | Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. ( Haworth, D; Hoglund, C; Kassler-Taub, K; Kerwin, L; Martin, A; Masson, C; Osbakken, M; Simon, T; Stumpe, KO, 1998) |
| "To compare the anti-hypertensive efficacy, safety, and tolerability of irbesartan with those of the full dose range of enalapril in patients with mild-to-moderate hypertension." | 5.08 | A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. ( Kassler-Taub, K; Kerwin, L; Mimran, A; Nys, M; Osbakken, M; Owens, D; Ruilope, L, 1998) |
| "The primary objectives of this double-blind study were to compare the antihypertensive efficacy and tolerability of irbesartan and losartan, two angiotensin II (AT1 subtype) receptor antagonists with different pharmacokinetic profiles in patients with mild-to-moderate hypertension." | 5.08 | Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. ( Adler, E; Elliott, W; Kassler-Taub, K; Littlejohn, T; Ruddy, T, 1998) |
| "The SILVER (Study of Irbesartan in Left VEntricular hypertrophy Regression) trial is designed to test the hypothesis that the newly developed angiontensin-II receptor antagonist, irbesartan, will produce a greater reduction in left ventricular (LV) mass than felodipine ER, in a population of hypertensive patients defined by seated diastolic blood pressure (SeDBP) in the range 95-115 mmHg or seated systolic blood pressure (SeSBP) in the range 160-200 mm Hg." | 5.08 | Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression. ( Agabiti Rosei, E; Bregman, B; Brudi, P; Clairefond, P; Cohen, A; Dubourg, O; Gosse, P; Guéret, P; Williams, B, 1998) |
| "There is an incremental clinical benefit of irbesartan over losartan in the treatment of hypertension and diabetic nephropathy which can be substantiated by corresponding preclinical study evidence." | 4.86 | Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan. ( Bramlage, P; Schindler, C, 2010) |
| "Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential hypertension." | 4.85 | Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. ( Falvey, H; Lowy, A; Müller, E; Nixon, RM, 2009) |
| "Irbesartan (Aprovel, Avapro, Irbetan, Karvea), an angiotensin II receptor type 1 antagonist, is approved in many countries worldwide for the treatment of hypertension." | 4.84 | Irbesartan: a review of its use in hypertension and diabetic nephropathy. ( Croom, KF; Plosker, GL, 2008) |
| "Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago." | 4.83 | Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria. ( Gavras, H; Ribeiro, AB, 2006) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 4.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| " Recent clinical trials have demonstrated that telmisartan at a daily dose of 20-80 mg, olmesartan medoxomil at 10-40 mg, and irbesartan at 150-300 mg are effective and safe for the treatment of essential hypertension, severe hypertension and hypertension associated with renal diseases." | 4.82 | [Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan]. ( Ishii, M, 2004) |
| "Irbesartan (Avapro, Aprovel) is a potent and selective angiotensin II subtype 1 receptor antagonist indicated for use in patients with hypertension, including those with type 2 diabetes mellitus and nephropathy." | 4.82 | Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. ( Croom, KF; Curran, MP; Goa, KL; Perry, CM, 2004) |
| "In the first study, olmesartan 10 mg/d was compared with losartan 50 mg/d in 316 patients with mild to moderate hypertension (mean baseline diastolic blood pressure [DBP], 95-114 mm Hg)." | 4.82 | Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. ( Stumpe, KO, 2004) |
| "SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism." | 4.81 | [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002) |
| "Angiotensin II (AII) receptor antagonists, a new class of antihypertensive agents, recently became available for the treatment of clinical hypertension." | 4.79 | Angiotensin II receptor blockers. A new class of antihypertensive drugs. ( Velasquez, MT, 1996) |
| " In the present analysis, we investigated seasonal variation in the antihypertensive treatment effect of the irbesartan/hydrochlorothiazide combination in patients with stage 2 and 3 hypertension." | 4.31 | Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination. ( Huang, QF; Li, Y; Wang, JG; Ye, XF, 2023) |
| "We investigated serum uric acid changes and incident hyperuricemia in relation to the achieved blood pressure (BP) after 12 weeks of antihypertensive therapy with the irbesartan/hydrochlorothiazide combination." | 4.02 | Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination. ( Huang, QF; Li, Y; Wang, JG; Zhang, D, 2021) |
| "Angiotensin II (Ang II) as an important pathogenic factor, has been implicated in the pathogenesis of hypertension and associated renal injury, and inhibition of Ang II can reduce renal inflammation and exert renal protective effects." | 3.96 | Irbesartan may relieve renal injury by suppressing Th22 cells chemotaxis and infiltration in Ang II-induced hypertension. ( Ao, X; Kwadwo Nuro-Gyina, P; Li, X; Lu, Y; Meng, T; Peng, L; Tang, R; Wang, W; Xiao, C; Zhong, Y; Zhou, Q, 2020) |
| "To compare the potential beneficial effects of the angiotensin converting enzyme inhibitor (ACEI) benazepril and the angiotensin II receptor 1 blocker (ARB) irbesartan on vaginal vascular remodeling and fibrosis in female spontaneously hypertensive rats (SHRs)." | 3.96 | Protective effects of irbesartan and benazepril against vaginal vascular remodeling and fibrosis in female spontaneously hypertensive rats. ( Li, N; Liang, W; Ma, R; Wang, Q; Yu, J; Yu, X; Zhao, X; Zhao, Y, 2020) |
| "Participants with untreated hypertension were enrolled from four centres in the community of western Sydney, NSW, Australia, mainly by general practitioners." | 3.94 | Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. ( Atkins, E; Bennett, A; Burke, M; Chalmers, J; Chou, M; Chow, CK; Dehbi, HM; Hillis, G; Hilmer, S; Krum, H; Neal, B; Nelson, M; Patel, A; Peiris, D; Reid, CM; Rodgers, A; Rogers, K; Salam, A; Thakkar, J; Thom, S; Usherwood, T; Vo, K; Webster, R; Woodward, M, 2017) |
| "Although both regimens were effective for reducing BP, increasing amlodipine to 10 mg daily controlled hypertension without elevation of serum uric acid." | 3.88 | Prospective direct comparison of antihypertensive effect and safety between high-dose amlodipine or indapamide in hypertensive patients uncontrolled by standard doses of angiotensin receptor blockers and amlodipine. ( Okamura, K; Okuda, T; Shirai, K; Totake, N; Urata, H, 2018) |
| "Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto (SILK study) is a prospective, multicenter, randomized, and open-label comparative evaluation of the effects of irbesartan and amlodipine on AF recurrence in hypertensive patients with AF who are scheduled to undergo catheter ablation or electrical cardioversion of AF." | 3.88 | Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto: Atrial Fibrillation Suppression Trial (SILK study). ( Fujimoto, K; Iwasa, A; Kaikita, K; Kajiwara, I; Koyama, J; Matsui, K; Matsumura, T; Morihisa, K; Morikami, Y; Ogawa, H; Tsujita, K; Tsunoda, R; Uemura, T; Yamabe, H, 2018) |
| "We surveyed consecutive newly diagnosed, untreated patients with hypertension who started the treatment with a mid-level dose of one of seven ARBs (losartan 50 mg, telmisartan 40 mg, candesartan 8 mg, olmesartan 20 mg, valsartan 80 mg, irbesartan 100 mg, or azilsartan 20 mg)." | 3.83 | The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements. ( Asayama, K; Haga, T; Hosaka, M; Imai, Y; Inoue, R; Kikuya, M; Mano, N; Metoki, H; Murakami, T; Obara, T; Ohkubo, T; Satoh, M, 2016) |
| " The proportion of patients remaining on any hypertension treatment at 12 months and the adherence rate were similar between the losartan cohort (66." | 3.83 | Influence of initial angiotensin receptor blockers on treatment persistence in uncomplicated hypertension: A nation-wide population-based study. ( Ah, YM; Choi, KH; Choi, YJ; Han, N; Kim, B; Kong, J; Lee, HY; Lee, JY; Oh, JM; Shin, WG; Yu, YM, 2016) |
| "5 mg/day, and amlodipine 5 mg/day (baseline), 166 patients were classified as having resistant hypertension (n = 140) or CBP (n = 26) by ambulatory BP monitoring." | 3.83 | Copeptin is increased in resistant hypertension. ( Azizi, M; Bergerot, D; Blanchard, A; Bobrie, G; Courand, PY; Dubourg, J; Forni, V; Frank, M; Menard, J; Mendes, M, 2016) |
| " The PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor blocker; Safety and efficacy in paTieNts with hypERtension) study is a prospective specific clinical use survey examining the efficacy and safety of 12-week treatment with amlodipine (AML) and Angiotensin II Receptor Blocker (ARB) in 5900 hypertensive patients." | 3.81 | The therapeutic advantage of combination antihypertensive drug therapy using amlodipine and irbesartan in hypertensive patients: Analysis of the post-marketing survey data from PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor ( Fukuda, H; Ishibashi, K; Ishimitsu, T; Nagao, M; Nukui, K; Sato, F; Uchida, M, 2015) |
| " After surgery, the AAB-induced hypertension (AABIH) rats were treated with losartan 40 mg/kg/day, candesartan 10 mg/kg/day, irbesartan 10 mg/kg/day per os for 16 weeks." | 3.79 | Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats. ( Inamdar, MN; Kulkarni, C; Kulkarni, KS; Moinuddin, G, 2013) |
| "Irbesartan or emodin or 2 drugs together can inhibit myocardial remodeling in renovascular hypertension rats probably by reducing TGF-β1 and CTGF expression." | 3.78 | Irbesartan and emodin on myocardial remodeling in Goldblatt hypertensive rats. ( Chen, C; Chen, Q; Li, ZG; Liang, Z, 2012) |
| "Hypertension is a major risk factor for renal disease and is common in people with diabetes mellitus." | 3.78 | Renoprotection and renin-angiotensin system blockade in diabetes mellitus. ( Ruilope, LM, 1997) |
| "00 mmol/L, body mass index 29) of men with mild to moderate hypertension, for irbesartan, the total treatment cost was euro 15,146, for losartan euro 15,696 and for valsartan euro 15,613; the quality-adjusted life years (QALYs) were irbesartan 12." | 3.77 | Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. ( Ekman, M; Fragoulakis, V; Maniadakis, N; Papagiannopoulou, V; Yfantopoulos, J, 2011) |
| " In this study, thirteen-week-old spontaneously hypertensive (SHR)/NDmcr-cp rats, representing a genetic model of metabolic syndrome, were treated daily with placebo, irbesartan (30 mg/kg), valsartan (10 mg/kg), or pioglitazone (10 mg/kg) for 4 weeks." | 3.77 | Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ. ( Jin, D; Miyazaki, M; Takai, S, 2011) |
| "For a given decrease in blood pressure, aliskiren improves coronary endothelial function and decreases cardiac hypertrophy in SHR to at least the same degree as ACE inhibition and AT1 receptor blockade." | 3.76 | Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. ( Bouhuizen, AM; Danser, AH; Garrelds, IM; Leijten, F; Moltzer, E; van Esch, JH; van Veghel, R, 2010) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 3.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| "A multicentre, prospective, post-marketing surveillance study was conducted over 9 months in 14 200 patients aged > or =18 years with previously uncontrolled hypertension (either receiving therapy or newly diagnosed), paying particular attention to a subgroup of patients receiving irbesartan/hydrochlorothiazide as first-line combination therapy." | 3.74 | BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan. ( Bramlage, P; Lüders, S; Paar, DW; Schirmer, A; Schrader, J; Thoenes, M, 2007) |
| "Essential hypertension is frequently associated with insulin resistance of skeletal muscle glucose transport, and angiotensin II (ANGII) can contribute to the pathogenesis of both conditions." | 3.73 | Selective angiotensin II receptor antagonism enhances whole-body insulin sensitivity and muscle glucose transport in hypertensive TG(mREN2)27 rats. ( Diehl, CJ; Henriksen, EJ; Kim, JS; Saengsirisuwan, V; Sloniger, JA, 2005) |
| "To observe effects of angiotensin (Ang) II receptor antagonist (AT1) irbesartan and angiotensin-converting enzyme (ACE) inhibitor perindopril on rat myocardium calcineurin expression and sarcoplasmic reticulum Ca(2+)-ATPase activity in the model of pressure-overload cardiac hypertrophy." | 3.73 | Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca2+-ATPase activity in rat cardiac pressure-overload hypertrophy. ( Jiang, QJ; Mao, FF; Xu, G; Zhu, YF, 2006) |
| "The irbesartan in Diabetic Nephropathy Trial (IDNT) demonstrated that treatment of patients with type 2 diabetes, hypertension and nephropathy with irbesartan resulted in a 20% relative reduction of the composite endpoint of doubling serum creatinine, end-stage renal disease or death as compared with amlodipine and placebo (antihypertensive standard therapy)." | 3.73 | [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]. ( Burnier, M; Frei, A; Hess, B; Palmer, AJ, 2006) |
| "Angiotensin II (Ang II) can induce cardiac fibrosis, but the underlying mechanisms are incompletely understood." | 3.72 | Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. ( Belloni, AS; Kreutz, R; Nussdorfer, GG; Paul, M; Pessina, AC; Rossi, GP; Seccia, TM, 2003) |
| "We estimated the cost-effectiveness of irbesartan compared with placebo or amlodipine in the treatment of patients with type 2 diabetes mellitus, hypertension, and overt nephropathy." | 3.72 | The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. ( Annemans, L; Borenstein, J; Chen, RS; Chiou, CF; Lewis, EJ; Palmer, AJ; Rodby, RA; Roze, S; Sengupta, N; Simon, TA; Smitten, A, 2003) |
| "The "Irbesartan in Diabetic Nephropathy Trial" (IDNT), demonstrated a reduction in the combined endpoint of doubling of serum creatinine, end-stage renal disease (ESRD) or death compared to control or amlodipine arms in patients with hypertension, type 2 diabetes and overt nephropathy when treated with irbesartan." | 3.72 | [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension]. ( Annemans, L; Lamotte, M; Palmer, AJ; Ritz, E; Rodby, RA; Roze, S, 2004) |
| "The present study assessed the cost effectiveness of irbesartan, an angiotensin II receptor antagonist, and amlodipine, a calcium channel blocker, in the treatment of Canadian patients with diabetic nephropathy and hypertension." | 3.72 | Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. ( Coyle, D; Rodby, RA, 2004) |
| "Compared with untreated controls, omapatrilat and I + H significantly attenuated hypertension [male control, 198." | 3.72 | Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. ( Beattie, E; Dominiczak, AF; Graham, D; Hamilton, C; Spiers, A, 2004) |
| "Diabetic spontaneously hypertensive rats developed albuminuria and had a reduction in both gene and protein expression of nephrin when compared with control rats." | 3.71 | Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. ( Allen, TJ; Boner, G; Bonnet, F; Cao, Z; Cooper, ME; Kawachi, H, 2001) |
| "To determine the effects of the angiotensin II receptor antagonist irbesartan, the calcium-channel blocker amlodipine, and hydrochlorothiazide/hydralazine on superoxide, NAD(P)H oxidase and nitric oxide bioavailability in spontaneously hypertensive stroke-prone rats (SHRSP)." | 3.71 | Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. ( Brosnan, MJ; Dominiczak, AF; Graham, D; Hamilton, CA; Jardine, E; Lygate, CA, 2002) |
| "The Quadruple UltrA-low-dose tReaTment for hypErTension (QUARTET) double-blind, active-controlled, randomized clinical trial will examine whether ultra-low-dose quadruple combination therapy is more effective than guideline-recommended standard care in lowering blood pressure." | 3.01 | Ultra-low-dose quadruple combination blood pressure-lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol. ( Atkins, ER; Billot, L; Chalmers, J; Chow, CK; Hay, P; Hillis, GS; Neal, B; Nelson, M; Patel, A; Reid, CM; Rodgers, A; Schlaich, M; Usherwood, T; Webster, R, 2021) |
| "Intradialytic hypertension is estimated at 5-15% of hemodialysis patients and is associated with poor prognosis." | 2.90 | The effects of nebivolol and irbesartan on postdialysis and ambulatory blood pressure in patients with intradialytic hypertension: a randomized cross-over study. ( Angeloudi, E; Balaskas, I; Bikos, A; Kalaitzidis, R; Karpetas, A; Liakopoulos, V; Loutradis, C; Panagoutsos, S; Papagianni, A; Pasadakis, P; Raptis, V; Sarafidis, PA, 2019) |
| "There is a lack of research on the effect of low dose of angiotensin receptor blockers combined with spironolactone, and the effect of high dose of angiotensin receptor blockers alone on the urinary albumin excretion rate (UAER) in elderly patients with early type 2 diabetic nephropathy (DN)." | 2.87 | Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy. ( Chen, X; Chen, Y; Li, Y; Liu, P; Wang, Y; Zhang, F, 2018) |
| "Generic irbesartan treatment in patients with mild-to-moderate essential hypertension has shown effective antihypertensive effects comparable with the branded irbesartan treatment, with similar incidence of adverse effects." | 2.87 | Comparison of efficacy and safety between two different irbesartan, generic vs branded, in the treatment of Korean patients with mild-to-moderate hypertension: an 8-week, multicenter, randomized, open-label, Phase IV clinical study. ( Han, SH; Hwang, GS; Kim, HS; Kim, IJ; Kwon, HM; Lee, KJ; Oh, GC; Park, CG; Park, SH; Yoo, BS, 2018) |
| " Both drugs equally reduced SBP in the last 6 h of the dosing interval and homogeneously reduced SBP throughout the 24 h." | 2.82 | Zofenopril or irbesartan plus hydrochlorothiazide in elderly patients with isolated systolic hypertension untreated or uncontrolled by previous treatment: a double-blind, randomized study. ( Arca, M; Berra, S; Bucci, M; Calabrò, P; Fulgheri, PL; Ghione, S; Modesti, PA; Omboni, S; Pirvu, O; Popescu, E; Portaluppi, F; Pozzilli, P; Taddei, S; Velican, VG; Villani, GQ; Vladoianu, M; Volpe, M, 2016) |
| " Use of additional antihypertensive medication, ultrafiltration volume, and dialysis dosage were not different." | 2.79 | No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients. ( Bibby, BM; Christensen, KL; Jensen, JD; Jensen, LT; Jespersen, B; Kjaergaard, KD; Novosel, MK; Peters, CD; Sloth, E; Strandhave, C; Tietze, IN, 2014) |
| " There were no differences between 4 dosing regimens in laboratory and clinical parameters of safety and tolerability." | 2.79 | [Fixed irbesartan/amlodipine combination: efficacy and safety of the use of four dosing regimens in patients with arterial hypertension]. ( Kobalava, ZhD, 2014) |
| "Treatment of patients with type 2 diabetes with Irbesartan decreased urinary excretion of MG-H1, G-H1 and 3-NT, which may result from decreased exposure to these AGEs." | 2.77 | Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. ( Adaikalakoteswari, A; Parving, HH; Rabbani, N; Rossing, K; Rossing, P; Tarnow, L; Thornalley, PJ, 2012) |
| "Arterial hypertension affects endothelial function and arterial stiffness." | 2.77 | Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study. ( Dall'Armi, V; Fini, M; Iellamo, F; Marazzi, G; Spoletini, I; Vitale, C; Volterrani, M, 2012) |
| " Safety profile was assessed by recording adverse events reported by patients or observed by the investigator." | 2.77 | I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospec ( Bobrie, G, 2012) |
| " Safety profile was assessed by recording adverse events reported by patients or observed by the investigator." | 2.77 | I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prosp ( Bobrie, G, 2012) |
| "To investigate the effects and safety of Western medicine combined with Chinese medicine (CM) based on syndrome differentiation in the treatment of elderly polarized hypertension (PHPT), or isolated systolic hypertension with low diastolic blood pressure (DBP)." | 2.77 | Clinical study of western medicine combined with Chinese medicine based on syndrome differentiation in the patients with polarized hypertension. ( Chen, SL; Chen, XL; Liu, XY; Mei, WY; Xu, WM, 2012) |
| "Aliskiren treatment led to a 60% decrease in PRA from baseline, whereas irbesartan increased PRA by 99% (both P<0." | 2.76 | Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. ( Bartlett, M; Dole, WP; Hanefeld, M; Jung, T; Krone, W; Meyer, HF; Prescott, MF; Rajman, I; Yeh, CM, 2011) |
| " drugs with duration of action longer than the 24-h dosing interval) may allow an adequate blood pressure (BP) reduction to be maintained despite missed doses." | 2.76 | Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril. ( Brede, Y; Burnier, M; Lowy, A, 2011) |
| " Treatment-emergent adverse event rates were similar between treatment groups regardless of the presence of diabetes or body mass index (BMI) status." | 2.76 | A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review. ( Neutel, JM, 2011) |
| " Dosage of felodipine were doubled after 4 weeks if the blood pressure were > or = 140/ 90 mm Hg (1 mm Hg = 0." | 2.76 | [Effect of different combined antihypertensive regimen on the erectile function in male hypertensive patients]. ( Bai, F; Chang, P; Guo, XY; Hu, H; Li, XL; Liu, PJ; Ma, RX; Yang, LQ; Yu, J; Zhao, F, 2011) |
| "Most patients inadvertently miss an occasional dose of antihypertensive therapy, and hence drugs that provide sustained blood-pressure (BP) reduction beyond the 24-h dosing interval are desirable." | 2.75 | Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. ( Botha, J; Bush, C; Jung, W; Keefe, DL; Palatini, P; Shlyakhto, E, 2010) |
| "When aliskiren was administered as a monotherapy, or in combination with other blockers of the RAS, changes in PRA were closely correlated with baseline PRA." | 2.74 | Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively. ( Dicker, P; O'Brien, ET; Stanton, AV, 2009) |
| "Valsartan is an angiotensin receptor blocker (ARB) with a well-established efficacy and safety profile in hypertensive patients, but with relatively few data in patients on hemodialysis (HD)." | 2.73 | Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study). ( Baier, M; Bambauer, R; Handrock, R; Kirchertz, EJ; Leidig, M; Leinung, D; Schmieder, RE; Szabã, T, 2008) |
| " The article also discusses the methods for preparation of irbesartan, its physical-chemical properties, analytical methods for its determination, pharmacological-toxicological properties, and dosing information." | 2.72 | Irbesartan (a comprehensive profile). ( Al-Kahtani, HM; Alanazi, Z; Bakheit, AH; Darwish, HW; Darwish, IA, 2021) |
| "Severe hypertension is difficult to control." | 2.72 | Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. ( Bhaumik, A; Franklin, SS; Lapuerta, P; Neutel, JM; Oparil, S; Ptaszynska, A, 2006) |
| "The primary outcomes of the Irbesartan Diabetic Nephropathy Trial were doubling of serum creatinine levels, end-stage renal disease, and death from any cause." | 2.71 | Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. ( Berl, T; Drury, PL; Esmatjes, E; Goldhaber, SZ; Hricik, D; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Parikh, CR; Pfeffer, MA; Porush, JG; Raz, I; Rouleau, JL; Vanhille, P; Wiegmann, TB; Wolfe, BM, 2003) |
| " Irbesartan therapy at a dosage of 150300 mg was instituted as monotherapy or associated with hydrochlorothiazide, 12." | 2.71 | [Effect of anti-hypertensive therapy with irbesartan on the absolute cardiovascular risk]. ( Aranda, P; Calvo, C; Coca, A; de la Sierra, A; Luque, M; Marín-Iranzo, R; Ruilope, LM, 2003) |
| " The dosage was doubled if necessary." | 2.71 | Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. ( Bianchetti, MG; Edefonti, A; Fossali, E; Gartenmann, AC; Schmidtko, J; Simonetti, GD; von Vigier, RO, 2003) |
| "Thus, 115 hypertensive patients with left ventricular hypertrophy were randomized to receive double-blind irbesartan or atenolol, with additional therapy if needed." | 2.71 | Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). ( Kahan, T; Lind, L; Malmqvist, K; Nyström, F; Ohman, KP, 2003) |
| "In hypertensive patients with type II diabetes mellitus, the combination delapril-manidipine may determine a greater improvement of the fibrinolytic function than the respective monotherapy, while the association irbesartan-hydrochlorothiazide may worsen it." | 2.71 | Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, E; Fogari, R; Mugellini, A; Preti, P; Zoppi, A, 2004) |
| "Hypertension is often poorly controlled, despite its importance and despite the availability of very effective treatments." | 2.71 | Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study. ( Burnier, M; Ferrari, P; Hess, L; Muggli, F; Pechere-Bertschi, A, 2004) |
| "During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction (MI)." | 2.71 | Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy. ( Aguilar, D; Berl, T; Gans, DJ; Goldhaber, SZ; Levey, AS; Lewis, EJ; Lewis, JB; Pfeffer, MA; Porush, JG; Rouleau, JL, 2004) |
| " The plasma concentration of irbesartan at 24 h after dosing on the 27th day and at 6 h after dosing on the 28th day was detected using fluorescence-high-performance liquid chromatography." | 2.71 | CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. ( Hong, X; Jiang, S; Mao, G; Tang, G; Xing, H; Xu, X; Yu, Y; Zhang, S; Zhang, Y, 2005) |
| "Thirty percent had type 2 diabetes mellitus, 46% had metabolic syndrome, and baseline blood pressure was 154." | 2.71 | The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. ( Bakris, GL; Cushman, WC; Ferdinand, KC; Neutel, JM; Ofili, EO; Saunders, E; Sowers, JR; Weber, MA, 2005) |
| "Patients with high blood pressure are often overweight or even obese." | 2.71 | [Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice]. ( Bramlage, P; Kirch, W; Sharma, AM, 2004) |
| "Patients with hypertension and left ventricular hypertrophy (n = 66) with a seated diastolic BP 90-115 mmHg (average of three measurements one minute apart by nurses)." | 2.70 | Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study. ( Kahan, T; Malmqvist, K; Nyström, F; Ohman, KP, 2002) |
| "Primary aldosteronism is a specifically treatable and potentially curable form of secondary hypertension." | 2.70 | Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. ( Chiandussi, L; Milan, A; Morello, F; Mulatero, P; Paglieri, C; Rabbia, F; Veglio, F, 2002) |
| " Plasma irbesartan concentrations were determined by a validated high-performance liquid chromatography/fluorescence method from blood samples taken predose, up to 24 hours after dosing on Day 1, and up to 48 hours after the final dose." | 2.70 | The pharmacokinetics of irbesartan in hypertensive children and adolescents. ( Adcock, KG; Ford, NF; Hadjilambris, OW; Marino, MR; Sakarcan, A; Slugg, P; Stewart, JJ; Tenney, F; Vachharajani, NN; Wells, TG; Wilson, JT, 2001) |
| "Losartan has been shown to increase urinary uric acid excretion and hence to lower serum uric acid levels." | 2.70 | Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. ( Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G, 2001) |
| " All doses of irbesartan were well tolerated with no evidence of dose-related adverse effects." | 2.69 | Safety of irbesartan in the treatment of mild to moderate systemic hypertension. ( Davies, R; Freitag, SA; Gelarden, RT; Kassler-Taub, KB; Simon, TA, 1998) |
| " At week 6, the dosage of irbesartan or placebo was doubled for seated diastolic blood pressure > or = 90 mmHg." | 2.69 | The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. ( Lin, CS; MacNeil, D; Osbakken, M; Rosenstock, J; Rossi, L, 1998) |
| "Essential hypertension is often accompanied by abnormalities of the coagulation/fibrinolytic system, predisposing to a procoagulant state." | 2.69 | Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. ( Hatzizacharias, AN; Krespi, PG; Kyriakidis, MK; Makris, TK; Stavroulakis, GA; Triposkiadis, FK; Tsoukala, CG; Votteas, VV, 2000) |
| "High blood pressure is a very common problem in the adult and elderly population, both in developed and developing countries." | 2.52 | The cost-effectiveness of irbesartan for hypertension. ( Borghi, C; Cicero, AF; Urso, R, 2015) |
| "Stroke is a major cause of mortality and disability worldwide." | 2.49 | Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. ( Ito, T; Kawahara, K; Kikuchi, K; Maruyama, I; Miura, N; Morimoto-Yamashita, Y; Murai, Y; Tanaka, E; Tancharoen, S, 2013) |
| "The drug is indicated for the treatment of hypertension and renal impairment in patients with type 2 diabetes mellitus (T2D) and hypertension, and its tolerability and safety profile have been extensively investigated and reported to be similar to placebo." | 2.48 | The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review. ( Borghi, C; Cicero, AF, 2012) |
| "Irbesartan reduces left ventricular hypertrophy and increases probability of maintenance of sinus rhythm after cardioversion of atrial fibrillation." | 2.48 | [Irbesartan in clinical practice]. ( Malishevskiĭ, MV, 2012) |
| "Incident cancer cases were compared in patients randomized to ARBs versus controls." | 2.47 | Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. ( , 2011) |
| "Arterial hypertension is an independent risk factor for cardiovascular diseases and one of the major causes for mortality worldwide." | 2.45 | Rational of the use of aliskiren in hypertension and beyond. ( Savvatis, K; Schultheiss, HP; Tschöpe, C; Westermann, D, 2009) |
| "Hypertension is an important risk factor for cardiovascular disease (CVD), particularly in patients with comorbid obesity, diabetes, metabolic disease, or end-organ damage." | 2.44 | The importance of integrated risk management when treating patients with hypertension: benefits of angiotensin II receptor antagonist therapy. ( Ruilope, LM; Segura, J, 2008) |
| "The mean +/- SD cumulative incidence of ESRD was reduced by 8." | 2.44 | Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis. ( Palmer, AJ; Ray, JA; Valentine, WJ, 2007) |
| "Diabetes (particularly type 2 diabetes) represents a global health problem of epidemic proportions." | 2.43 | Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. ( Burnier, M; Zanchi, A, 2006) |
| "Proteinuria was reduced on average by 33% in the irbesartan group as compared with 6% in the amlodipine group and 10% in the placebo group." | 2.42 | Treatment of diabetic nephropathy with angiotensin II receptor antagonist. ( Lewis, EJ; Lewis, JB, 2003) |
| "Hypertension affects approximately 25% of the adult population." | 2.42 | The antihypertensive response to irbesartan treatment from a pharmacogenetic perspective. ( Kurland, L, 2003) |
| "Candesartan is a novel high-affinity type 1 AT(1)-receptor blocker characterized by prolonged binding to and slow dissociation from the receptor." | 2.42 | [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension]. ( Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM, 2004) |
| "Telmisartan is an angiotensin Type 1 (AT(1))-receptor antagonist being used in the treatment of hypertension." | 2.42 | Telmisartan - killing two birds with one stone. ( Doggrell, SA, 2004) |
| " The selected studies were included in a meta-analysis of the dose-response relationship for each drug." | 2.41 | The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. ( Elmfeldt, D; Meredith, P; Olofsson, B, 2002) |
| " Further research is necessary to determine which AT1RBs and which dosing regimens are optimal." | 2.41 | Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation. ( Mancini, GB, 2002) |
| " Irbesartan is well absorbed, does not require biotransformation to an active metabolite to exert its antihypertensive activity, offers a large volume of distribution, has a half-life that is sufficient to allow once-daily dosing, is associated with a strong and consistent dose-response and has been demonstrated to provide a level of angiotensin II antagonism that is statistically superior to that offered by some other ARBs." | 2.41 | Irbesartan: review of pharmacology and comparative properties. ( Adams, MA; Trudeau, L, 2000) |
| " Based on these pharmacokinetic and safety data, no dosage adjustments of IRBE are necessary for patients with RI, HI, or HF, or based on patient age, gender, or race." | 2.41 | Pharmacokinetics of irbesartan are not altered in special populations. ( Marino, MR; Vachharajani, NN, 2002) |
| " The drug is effective in the elderly and dosage adjustment is not required in these patients or in those with renal or hepatic failure." | 2.40 | Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. ( Gillis, JC; Markham, A, 1997) |
| " Irbesartan displays linear, dose related pharmacokinetics and, with the exception of tasosartan's active metabolite, has the longest elimination half-life of the AIIRA (11 to 15 h)." | 2.40 | The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ( Brunner, HR, 1997) |
| " Once daily dosing provides full 24 h blood pressure control with blood pressure reductions equivalent to those of twice daily dosing, and long-term control with monotherapy in a high percentage of patients." | 2.40 | Clinical overview of irbesartan: a new angiotensin II receptor antagonist. ( Pouleur, HG, 1997) |
| "5-2 h after administration) and a long half-life (11-15 h) that provides 24-h blood pressure control with a single daily dose." | 2.40 | Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist. ( Ruilope, L, 1997) |
| "Candesartan is an insurmountable blocker with a slow dissociation from the AT1 receptor, and it has been shown to effectively reduce BP in humans and in a variety of genetic and experimental models of hypertension." | 2.40 | Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection. ( Morsing, P, 1999) |
| "Their use in congestive heart failure and renal disease is under investigation." | 2.40 | Angiotensin-II receptor antagonists: their place in therapy. ( Kirk, JK, 1999) |
| "Hypertension is a key risk factor for ischemic heart disease and atherosclerosis." | 1.72 | Different Approaches in Manipulating Ratio Spectra for Analyzing Amlodipine Besylate and Irbesartan Combination. ( El Mously, DA; El-Sayed, GM; Hassan, NY; Mostafa, NM, 2022) |
| "Hypertension is a common cardiovascular disease in clinical scenario." | 1.51 | ALDH2 improved irbesartan treatment efficacy among rats with hypertension. ( Chang, F; Gao, R; Huangfu, W; Wang, M, 2019) |
| "The present study was carried out to investigate the pharmacokinetic and pharmacodynamic drug interaction of irbesartan with glipizide after single and multi dose treatment in normal and hypertensive rat models to evaluate the safety and effectiveness of the combination." | 1.46 | Influence of Single and Multi Dose Treatment of Glipizide on Pharmacokinetics and Pharmacodynamics of Irbesartan in Normal and Hypertensive Rats. ( Anusha, A; Goverdhan, P; Krishna Murthy, B; Narendar, D, 2017) |
| "Aggressive treatment of hypertension resulted in complete resolution of the clinical and radiologic features of the syndrome." | 1.43 | Does this patient have hypertensive encephalopathy? ( Argyropoulou, MI; Christopoulou, F; Elisaf, M; Kosta, P; Rizos, EC, 2016) |
| " Urinary norepinephrine excretion and oxidative stress in the brain were decreased in both IRB and IRB/TCM groups without any adverse effect on the metabolic profile." | 1.42 | Combining irbesartan and trichlormethiazide enhances blood pressure reduction via inhibition of sympathetic activity without adverse effects on metabolism in hypertensive rats with metabolic syndrome. ( Hirooka, Y; Nishihara, M; Sunagawa, K, 2015) |
| "In the WT mice, Ang Ⅱ induced cardiac hypertrophy as well as vascular remodeling and perivascular fibrosis of the intramyocardial arteries and monocyte/macrophage infiltration in the heart (p＜0." | 1.42 | Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4. ( Fukai, T; Itoh, S; Matsuda, S; Matsuzaki, M; Murata, T; Umemoto, S; Yoshimura, K, 2015) |
| "Compound 4 can also inhibit the prostate cancer in vitro and in vivo." | 1.38 | Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects. ( Chen, ZL; Da, YJ; Liang, LS; Nie, YY; Xin, T; Yan, YJ; Ye, Y; Yuan, WD, 2012) |
| " A total of 1061 hypertensives were recruited and received daily oral dosage of 150 mg irbesartan for 4 weeks." | 1.37 | Effects of protein coding polymorphisms in the kallikrein 1 gene on baseline blood pressure and antihypertensive response to irbesartan in Chinese hypertensive patients. ( Hsu, YH; Jiang, S; Venners, SA; Wang, X; Xing, H; Xu, X; Zhang, Y, 2011) |
| " Adverse events were also recorded." | 1.36 | The efficacy and safety of irbesartan in primary hypertension even if a dose is missed: Results from the NO PROBLEM Study. ( Abali, G; Aytemir, K; Deveci, O; Kabakci, G; Kaya, BE; Kocabas, U; Ozkutlu, H; Tokgozoglu, L; Tulumen, E, 2010) |
| " These findings may explain the known interaction of telmisartan with digoxin and suggest that it may modulate the bioavailability of drugs whose absorption is restricted by P-gp and possibly also by BCRP or MRP2." | 1.36 | Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. ( Benndorf, RA; Böger, RH; Divac, N; Haefeli, WE; Herzog, M; Sauer, A; Schwedhelm, E; Weiss, J, 2010) |
| "Compared with the placebo-treated group, proteinuria was significantly lower in the irbesartan- and efonidipine-treated groups, but not in the amlodipine-treated group." | 1.36 | Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Takai, S, 2010) |
| "The metabolic syndrome is a cluster of cardiovascular risk factors leading to an increased risk for the subsequent development of diabetes and cardiovascular morbidity and mortality." | 1.34 | Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. ( Bramlage, P; Kintscher, U; Paar, WD; Thoenes, M; Unger, T, 2007) |
| " Described herein are our efforts directed toward improving both the pharmacokinetic profile as well as the AT(1) and ET(A) receptor potency of 3." | 1.33 | Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. ( Baska, RA; Beyer, SM; Carlson, KE; Dickinson, KE; Ewing, WR; Fadnis, L; Gu, Z; Humphreys, WG; Kowala, MC; Lan, SJ; Macor, JE; Monshizadegan, H; Murugesan, N; Tellew, JE; Valentine, MT; Yang, Y; Zahler, R, 2005) |
| "In conclusion, the treatment of high blood pressure lowers circulating IL-6 in young hypertensive patients." | 1.33 | Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects. ( Badimón, L; Fernández-Real, JM; Vázquez-Oliva, G; Vilaseca, M; Zamora, A, 2005) |
| " BP was measured before dosing on the 1st and 28th days of treatment." | 1.33 | Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in rural Chinese patients with essential hypertension. ( Hong, X; Jiang, S; Mao, G; Tang, G; Wen, Y; Xu, X; Yu, Y; Zhang, S; Zhang, Y, 2005) |
| "Cumulative incidence of ESRD, time to onset of ESRD, life expectancy (LE), quality-adjusted life years (QALY) and costs were projected over 25 years for 1,000 simulated patients, from a third party payer perspective." | 1.33 | [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy]. ( Lehnert, H; Palmer, AJ; Ritz, E; Rodby, RA; Roze, S; Valentine, WJ, 2006) |
| " Additionally, we studied the effect of irbesartan on dose-response curves for the vasoconstriction induced by exogenous Ang II." | 1.32 | Sympatho-inhibitory actions of irbesartan in pithed spontaneously hypertensive and Wistar-Kyoto rats. ( Balt, JC; Mathy, MJ; Pfaffendorf, M; van Zwieten, PA, 2003) |
| " Thus, AT(1) blockade with irbesartan, at an oral daily dosage that gave a slight but significant reduction of systolic blood pressure, largely counteracts the development of myocyte hypertrophy and associated functional alterations." | 1.32 | Treatment with irbesartan counteracts the functional remodeling of ventricular myocytes from hypertensive rats. ( Cerbai, E; De Paoli, P; Lonardo, G; Mugelli, A; Sartiani, L, 2003) |
| "Treating patients with hypertension, type 2 diabetes and overt nephropathy using irbesartan was both cost- and life-saving compared with amlodipine and control." | 1.32 | An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. ( Annemans, L; Cordonnier, DJ; Lamotte, M; Palmer, AJ; Rodby, RA; Roze, S, 2003) |
| "Treating patients with hypertension, type 2 diabetes and overt nephropathy using irbesartan was both cost- and life-saving compared to amlodipine and control in the Spanish setting." | 1.32 | [Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective]. ( Annemans, L; de Alvaro, F; Lamotte, M; Palmer, AJ; Rodby, RA; Roze, S, 2004) |
| " We compared the efficacy of an endothelin-receptor antagonist (darusentan), an angiotensin-receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide, HCTZ) to prevent and regress pulse pressure (PP) elevation and remodeling of large and small arteries, in a rat model of ISH obtained by the chronic administration of warfarin and vitamin K1 (WK)." | 1.31 | Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension. ( Dao, HH; De Champlain, J; Essalihi, R; Graillon, JF; Larivière, R; Moreau, P, 2002) |
| "In pediatric patients with chronic kidney diseases, irbesartan given once a day for 18 weeks significantly reduces arterial pressure and proteinuria, with an excellent tolerability and side effect profile." | 1.31 | Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases. ( Bianchetti, MG; Casaulta-Aebischer, C; Fossali, E; Franscini, LM; Pfister, R; Von Vigier, RO, 2002) |
| "Captopril treatment reduced blood pressure (163+/-3 mmHg versus diabetic 201+/-3 mmHg), but not albumin excretion rate (43." | 1.31 | Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. ( Allen, TJ; Bonnet, F; Cao, Z; Cooper, ME; Davis, B, 2001) |
| "We tested the hypothesis that long-term administration of the specific angiotensin II subtype 1 (AT1)-receptor blocker BMS-186295 will regress hypertrophy and modify left ventricular angiotensin converting enzyme (ACE) expression in rats with ascending aortic stenosis." | 1.30 | Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. ( Benedict, CR; Bishop, SP; Chafizadeh, E; Douglas, PS; Ho, KK; Lee, MA; Lindpaintner, K; Lorell, BH; Weigner, M; Weinberg, EO, 1997) |
| " A dose-response curve to Ang II was plotted for cumulative concentrations (from 10(-9) to 10(-6) mol/L) in endothelium-denuded aortic rings (pD(2)=7." | 1.30 | Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. ( Díez, J; Fortuño, A; Fortuño, MA; Muñiz, P; Ravassa, S; Rodriguez, JA; Zalba, G, 1999) |
| "To investigate the haemodynamic and morphological effects resulting from the chronic administration to young spontaneously hypertensive rats (SHR) of a new selective angiotensin II subtype 1 (AT1) receptor antagonist, SR 47436/BMS-186295 (SR/BMS) both during and after the treatment period." | 1.29 | Early and late haemodynamic and morphological effects of angiotensin II subtype 1 receptor blockade during genetic hypertension development. ( Bruneval, P; Fornes, P; Giudicelli, JF; Nisato, D; Richer, C; Vacher, E, 1995) |
Research
Studies (456)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 44 (9.65) | 18.2507 |
| 2000's | 262 (57.46) | 29.6817 |
| 2010's | 121 (26.54) | 24.3611 |
| 2020's | 29 (6.36) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Schmidt, B | 1 |
| Schieffer, B | 3 |
| Murugesan, N | 2 |
| Gu, Z | 2 |
| Fadnis, L | 2 |
| Tellew, JE | 1 |
| Baska, RA | 2 |
| Yang, Y | 2 |
| Beyer, SM | 1 |
| Monshizadegan, H | 2 |
| Dickinson, KE | 1 |
| Valentine, MT | 1 |
| Humphreys, WG | 1 |
| Lan, SJ | 1 |
| Ewing, WR | 1 |
| Carlson, KE | 1 |
| Kowala, MC | 2 |
| Zahler, R | 1 |
| Macor, JE | 2 |
| Da, YJ | 1 |
| Yuan, WD | 1 |
| Xin, T | 1 |
| Nie, YY | 1 |
| Ye, Y | 1 |
| Yan, YJ | 1 |
| Liang, LS | 1 |
| Chen, ZL | 1 |
| Chow, CK | 4 |
| Atkins, ER | 3 |
| Hillis, GS | 3 |
| Nelson, MR | 2 |
| Reid, CM | 4 |
| Schlaich, MP | 1 |
| Hay, P | 3 |
| Rogers, K | 2 |
| Billot, L | 3 |
| Burke, M | 3 |
| Chalmers, J | 4 |
| Neal, B | 4 |
| Patel, A | 3 |
| Usherwood, T | 4 |
| Webster, R | 3 |
| Rodgers, A | 4 |
| Eltayeb, A | 1 |
| Khong, TK | 1 |
| El Mously, DA | 1 |
| Mostafa, NM | 1 |
| Hassan, NY | 1 |
| El-Sayed, GM | 1 |
| Ye, XF | 3 |
| Huang, QF | 5 |
| Li, Y | 8 |
| Wang, JG | 5 |
| Yan, P | 1 |
| Luo, Y | 1 |
| Zhang, J | 2 |
| Liu, H | 2 |
| Chen, J | 2 |
| Wang, J | 4 |
| Dong, G | 1 |
| Ge, M | 1 |
| Wang, Z | 4 |
| Zhai, J | 2 |
| Zhang, T | 2 |
| He, L | 2 |
| Ma, S | 2 |
| Zuo, Q | 2 |
| Zhang, G | 2 |
| Wang, Y | 3 |
| Guo, Y | 2 |
| Wang, H | 2 |
| Lu, Z | 1 |
| Liu, T | 2 |
| Zhao, L | 1 |
| Gao, T | 1 |
| Lu, X | 1 |
| Gao, B | 1 |
| Eworuke, E | 2 |
| Shinde, M | 1 |
| Hou, L | 1 |
| Paterson, MJ | 1 |
| Jensen, PB | 1 |
| Maro, JC | 1 |
| Rai, A | 1 |
| Scarnecchia, D | 1 |
| Pennap, D | 1 |
| Woronow, D | 1 |
| Ghosh, RE | 1 |
| Welburn, S | 1 |
| Pottegard, A | 1 |
| Platt, RW | 1 |
| Lee, H | 2 |
| Bradley, MC | 1 |
| Hedenmalm, K | 1 |
| Quinten, C | 1 |
| Kurz, X | 1 |
| Bradley, M | 1 |
| Zhao, X | 2 |
| Chen, Y | 3 |
| Yang, G | 1 |
| Li, X | 3 |
| Tang, X | 1 |
| Yang, Q | 2 |
| Peng, L | 3 |
| Li, J | 2 |
| Liang, Z | 2 |
| Li, A | 1 |
| Wang, W | 3 |
| Huang, M | 1 |
| Jiang, W | 1 |
| Xie, M | 1 |
| Tang, T | 1 |
| Liang, H | 1 |
| Desai, AS | 1 |
| Webb, DJ | 1 |
| Taubel, J | 1 |
| Casey, S | 1 |
| Cheng, Y | 1 |
| Robbie, GJ | 1 |
| Foster, D | 1 |
| Huang, SA | 1 |
| Rhyee, S | 1 |
| Sweetser, MT | 1 |
| Bakris, GL | 5 |
| Chye, A | 1 |
| Lung, T | 1 |
| Nolde, JM | 1 |
| Figtree, GA | 1 |
| Jansen, S | 1 |
| Marschner, S | 1 |
| Schlaich, M | 2 |
| Zhang, L | 1 |
| Xiao, X | 1 |
| Hu, X | 1 |
| Tang, R | 2 |
| Wang, X | 4 |
| Huangfu, W | 1 |
| Chang, F | 1 |
| Wang, M | 1 |
| Gao, R | 1 |
| Zhong, Y | 1 |
| Lu, Y | 1 |
| Xiao, C | 1 |
| Meng, T | 1 |
| Ao, X | 1 |
| Kwadwo Nuro-Gyina, P | 1 |
| Zhou, Q | 2 |
| Nakagawa, N | 1 |
| Sato, N | 1 |
| Saijo, Y | 1 |
| Morimoto, H | 1 |
| Koyama, S | 1 |
| Ogawa, Y | 1 |
| Uekita, K | 1 |
| Maruyama, J | 1 |
| Ohta, T | 1 |
| Nakamura, Y | 1 |
| Takeuchi, T | 1 |
| Hasebe, N | 1 |
| Ma, R | 3 |
| Zhao, Y | 2 |
| Yu, X | 1 |
| Li, N | 1 |
| Wang, Q | 1 |
| Liang, W | 1 |
| Yu, J | 6 |
| Dai, B | 1 |
| Wang, ZZ | 1 |
| Zhang, H | 1 |
| Han, MX | 1 |
| Zhang, GX | 1 |
| Chen, JW | 1 |
| Nelson, M | 2 |
| Theodorakopoulou, M | 1 |
| Loutradis, C | 3 |
| Bikos, A | 3 |
| Angeloudi, E | 2 |
| Schoina, M | 1 |
| Raptis, V | 3 |
| Liakopoulos, V | 3 |
| Papagianni, A | 3 |
| Sarafidis, P | 2 |
| Kalaitzidis, RG | 1 |
| Balafa, O | 1 |
| Dounousi, E | 1 |
| Stagikas, D | 1 |
| Tsimihodimos, V | 1 |
| Huang, C | 1 |
| Huang, Y | 1 |
| Zhong, Q | 1 |
| Cai, A | 1 |
| Feng, YQ | 1 |
| Darwish, IA | 1 |
| Darwish, HW | 1 |
| Bakheit, AH | 1 |
| Al-Kahtani, HM | 1 |
| Alanazi, Z | 1 |
| Weng, J | 1 |
| Chen, M | 1 |
| Guo, R | 1 |
| Yang, S | 1 |
| Liu, D | 1 |
| Fang, D | 1 |
| Pathak, AS | 1 |
| Rojas, M | 1 |
| Stouffer, GA | 1 |
| Yang, L | 3 |
| Ding, Y | 1 |
| Zhang, D | 2 |
| Qin, H | 1 |
| Liu, L | 1 |
| Di, C | 1 |
| Zhuang, Q | 1 |
| Yin, H | 1 |
| Kario, K | 2 |
| Tomitani, N | 1 |
| Kanegae, H | 1 |
| Ishii, H | 1 |
| Uchiyama, K | 1 |
| Yamagiwa, K | 1 |
| Shiraiwa, T | 1 |
| Katsuya, T | 1 |
| Yoshida, T | 1 |
| Kanda, K | 1 |
| Hasegawa, S | 1 |
| Hoshide, S | 1 |
| Hsu, CH | 1 |
| Yu, SM | 1 |
| Lau, SC | 1 |
| Chen, YL | 1 |
| Pei, D | 1 |
| Liu, IC | 1 |
| Anusha, A | 1 |
| Narendar, D | 1 |
| Krishna Murthy, B | 1 |
| Goverdhan, P | 1 |
| Tani, S | 1 |
| Asayama, K | 2 |
| Oiwa, K | 1 |
| Harasawa, S | 1 |
| Okubo, K | 1 |
| Takahashi, A | 1 |
| Tanabe, A | 1 |
| Ohkubo, T | 2 |
| Hirayama, A | 1 |
| Kushiro, T | 1 |
| Okamura, K | 1 |
| Shirai, K | 1 |
| Totake, N | 1 |
| Okuda, T | 1 |
| Urata, H | 1 |
| Yamabe, H | 1 |
| Kaikita, K | 1 |
| Matsumura, T | 1 |
| Iwasa, A | 1 |
| Koyama, J | 1 |
| Uemura, T | 1 |
| Morikami, Y | 1 |
| Tsunoda, R | 1 |
| Morihisa, K | 1 |
| Fujimoto, K | 1 |
| Kajiwara, I | 1 |
| Matsui, K | 1 |
| Tsujita, K | 1 |
| Ogawa, H | 2 |
| Haneef, J | 1 |
| Chadha, R | 1 |
| Liu, P | 3 |
| Chen, X | 2 |
| Zhang, F | 1 |
| Laurent, S | 1 |
| Mancia, G | 3 |
| Poulter, N | 1 |
| Karpetas, A | 1 |
| Kalaitzidis, R | 1 |
| Panagoutsos, S | 2 |
| Pasadakis, P | 2 |
| Balaskas, I | 1 |
| Sarafidis, PA | 1 |
| Han, SH | 2 |
| Oh, GC | 1 |
| Kwon, HM | 1 |
| Park, CG | 3 |
| Kim, IJ | 1 |
| Hwang, GS | 1 |
| Yoo, BS | 1 |
| Park, SH | 1 |
| Lee, KJ | 1 |
| Kim, HS | 2 |
| Afkou, Z | 1 |
| Tzanis, G | 1 |
| Pyrgidis, N | 1 |
| Balaskas, E | 1 |
| Zebekakis, P | 1 |
| Parati, G | 2 |
| Byrd, JB | 1 |
| Chertow, GM | 1 |
| Bhalla, V | 1 |
| Jeong, JH | 1 |
| Hanevold, C | 1 |
| Harris, RA | 1 |
| Kapuku, G | 1 |
| Pollock, J | 1 |
| Pollock, D | 1 |
| Harshfield, G | 1 |
| Taguchi, I | 2 |
| Toyoda, S | 2 |
| Takano, K | 1 |
| Arikawa, T | 1 |
| Kikuchi, M | 2 |
| Ogawa, M | 1 |
| Abe, S | 1 |
| Node, K | 1 |
| Inoue, T | 4 |
| Garnock-Jones, KP | 1 |
| Fukuda, D | 1 |
| Sata, M | 1 |
| Sheng, CS | 1 |
| Ma, GS | 1 |
| Dai, QY | 1 |
| Kusunoki, H | 1 |
| Taniyama, Y | 1 |
| Rakugi, H | 2 |
| Morishita, R | 1 |
| Peters, CD | 2 |
| Kjærgaard, KD | 1 |
| Jespersen, B | 2 |
| Christensen, KL | 2 |
| Jensen, JD | 2 |
| Moinuddin, G | 1 |
| Inamdar, MN | 1 |
| Kulkarni, KS | 1 |
| Kulkarni, C | 1 |
| Satoh, M | 2 |
| Nagasu, H | 1 |
| Haruna, Y | 1 |
| Ihoriya, C | 1 |
| Kadoya, H | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Zhao, F | 4 |
| Lin, X | 2 |
| Hu, H | 3 |
| Bai, F | 4 |
| Mori, M | 1 |
| Takahashi, S | 1 |
| Masaki, M | 1 |
| Komamura, K | 1 |
| Goda, A | 1 |
| Hirotani, S | 1 |
| Otsuka, M | 1 |
| Nakabo, A | 1 |
| Fukui, M | 1 |
| Fujiwara, S | 1 |
| Sugahara, M | 1 |
| Lee-Kawabata, M | 1 |
| Tsujino, T | 1 |
| Koshiba, M | 1 |
| Masuyama, T | 1 |
| Kikuchi, K | 1 |
| Tancharoen, S | 1 |
| Ito, T | 1 |
| Morimoto-Yamashita, Y | 1 |
| Miura, N | 1 |
| Kawahara, K | 1 |
| Maruyama, I | 1 |
| Murai, Y | 1 |
| Tanaka, E | 1 |
| Jekell, A | 1 |
| Malmqvist, K | 20 |
| Wallén, NH | 1 |
| Mörtsell, D | 2 |
| Kahan, T | 24 |
| Saseen, JJ | 1 |
| Ghushchyan, V | 1 |
| Kaila, S | 1 |
| Allen, RR | 1 |
| Nair, KV | 1 |
| Gialama, F | 1 |
| Maniadakis, N | 2 |
| Rizos, CV | 2 |
| Liberopoulos, EN | 2 |
| Tellis, K | 1 |
| DiNicolantonio, JJ | 1 |
| Tselepis, AD | 1 |
| Elisaf, MS | 2 |
| Agabiti-Rosei, E | 2 |
| Manolis, A | 2 |
| Zava, D | 1 |
| Omboni, S | 3 |
| Lin, JW | 1 |
| Chang, CH | 1 |
| Caffrey, JL | 1 |
| Wu, LC | 1 |
| Lai, MS | 1 |
| Linz, D | 1 |
| Mahfoud, F | 1 |
| Linz, B | 1 |
| Hohl, M | 1 |
| Schirmer, SH | 1 |
| Wirth, KJ | 1 |
| Böhm, M | 4 |
| Degirmenci, H | 2 |
| Açikel, M | 1 |
| Bakirci, EM | 2 |
| Duman, H | 2 |
| Demirelli, S | 2 |
| Tas, H | 1 |
| Simsek, Z | 2 |
| Karakelleoglu, S | 1 |
| Aksakal, E | 1 |
| Erol, MK | 1 |
| Kjaergaard, KD | 1 |
| Strandhave, C | 1 |
| Tietze, IN | 1 |
| Novosel, MK | 1 |
| Bibby, BM | 1 |
| Jensen, LT | 1 |
| Sloth, E | 1 |
| Nishihara, M | 1 |
| Hirooka, Y | 1 |
| Sunagawa, K | 1 |
| Hamur, H | 1 |
| Inci, S | 1 |
| Askın, L | 1 |
| Arısoy, A | 1 |
| Lazoglu, Z | 1 |
| Takenaka, T | 1 |
| Ohno, Y | 1 |
| Miyazaki, T | 1 |
| Nishiyama, A | 1 |
| Ishii, N | 1 |
| Suzuki, H | 1 |
| Azizi, M | 2 |
| Perdrix, L | 1 |
| Bobrie, G | 5 |
| Frank, M | 2 |
| Chatellier, G | 1 |
| Ménard, J | 2 |
| Plouin, PF | 1 |
| Zoccali, C | 1 |
| Mallamaci, F | 1 |
| Kobalava, ZhD | 1 |
| Borghi, C | 3 |
| Urso, R | 1 |
| Cicero, AF | 5 |
| Matsuda, S | 1 |
| Umemoto, S | 1 |
| Yoshimura, K | 1 |
| Itoh, S | 1 |
| Murata, T | 1 |
| Fukai, T | 1 |
| Matsuzaki, M | 1 |
| Ishimitsu, T | 1 |
| Fukuda, H | 1 |
| Uchida, M | 1 |
| Ishibashi, K | 1 |
| Sato, F | 1 |
| Nukui, K | 1 |
| Nagao, M | 1 |
| Qiu, B | 1 |
| Du, JL | 1 |
| Deng, SB | 1 |
| Liu, YJ | 1 |
| She, Q | 1 |
| Chida, R | 1 |
| Hisauchi, I | 1 |
| Komatsu, T | 1 |
| Hori, Y | 1 |
| Nakahara, S | 1 |
| Sakai, Y | 1 |
| Motozato, K | 1 |
| Miura, S | 2 |
| Shiga, Y | 2 |
| Kusumoto, T | 1 |
| Adachi, S | 1 |
| Fujisawa, K | 1 |
| Saku, K | 2 |
| Jiang, S | 7 |
| Venners, SA | 3 |
| Hsu, YH | 3 |
| Weinstock, J | 1 |
| Wang, B | 2 |
| Xing, H | 6 |
| Xu, X | 7 |
| Modesti, PA | 2 |
| Taddei, S | 1 |
| Ghione, S | 1 |
| Portaluppi, F | 1 |
| Pozzilli, P | 1 |
| Volpe, M | 1 |
| Arca, M | 1 |
| Calabrò, P | 1 |
| Fulgheri, PL | 1 |
| Bucci, M | 1 |
| Berra, S | 1 |
| Villani, GQ | 1 |
| Vladoianu, M | 1 |
| Popescu, E | 1 |
| Velican, VG | 1 |
| Pirvu, O | 1 |
| Christopoulou, F | 1 |
| Rizos, EC | 1 |
| Kosta, P | 1 |
| Argyropoulou, MI | 1 |
| Elisaf, M | 2 |
| Hayashi, M | 1 |
| Takeshita, K | 1 |
| Uchida, Y | 1 |
| Yamamoto, K | 1 |
| Matsushita, T | 1 |
| Murohara, T | 1 |
| Haga, T | 1 |
| Hosaka, M | 1 |
| Obara, T | 1 |
| Metoki, H | 1 |
| Murakami, T | 1 |
| Kikuya, M | 1 |
| Inoue, R | 1 |
| Mano, N | 1 |
| Imai, Y | 1 |
| Ah, YM | 1 |
| Lee, JY | 1 |
| Choi, YJ | 1 |
| Kong, J | 1 |
| Kim, B | 1 |
| Choi, KH | 1 |
| Han, N | 1 |
| Yu, YM | 1 |
| Oh, JM | 1 |
| Shin, WG | 1 |
| Lee, HY | 1 |
| Kimura, S | 1 |
| Sekiya-Soga, Y | 1 |
| Kato, Y | 1 |
| Mizutani, M | 1 |
| Ohashi, H | 1 |
| Afzal, S | 1 |
| Sattar, MA | 1 |
| Johns, EJ | 1 |
| Abdulla, MH | 1 |
| Akhtar, S | 1 |
| Hashmi, F | 1 |
| Abdullah, NA | 1 |
| Seccia, TM | 2 |
| Caroccia, B | 1 |
| Gioco, F | 1 |
| Piazza, M | 1 |
| Buccella, V | 1 |
| Guidolin, D | 1 |
| Guerzoni, E | 1 |
| Montini, B | 1 |
| Petrelli, L | 1 |
| Pagnin, E | 1 |
| Ravarotto, V | 1 |
| Belloni, AS | 4 |
| Calò, LA | 1 |
| Rossi, GP | 4 |
| Kim, SH | 1 |
| Jo, SH | 1 |
| Lee, SC | 1 |
| Lee, SY | 1 |
| Yoon, MH | 1 |
| Lee, HL | 1 |
| Lee, NH | 2 |
| Ha, JW | 1 |
| Kim, DW | 1 |
| Han, GR | 1 |
| Hyon, MS | 1 |
| Cho, DG | 1 |
| Kim, YD | 1 |
| Ryu, GH | 1 |
| Kim, CH | 1 |
| Kim, KS | 1 |
| Chung, MH | 1 |
| Chae, SC | 1 |
| Seung, KB | 1 |
| Oh, BH | 1 |
| Mendes, M | 1 |
| Dubourg, J | 1 |
| Blanchard, A | 1 |
| Bergerot, D | 1 |
| Courand, PY | 1 |
| Forni, V | 1 |
| Grassi, G | 1 |
| Seravalle, G | 1 |
| Brambilla, G | 1 |
| Dell'Oro, R | 1 |
| Trevano, FQ | 1 |
| Fici, F | 1 |
| van Bortel, L | 1 |
| Thakkar, J | 1 |
| Bennett, A | 1 |
| Hillis, G | 1 |
| Vo, K | 1 |
| Atkins, E | 1 |
| Chou, M | 1 |
| Dehbi, HM | 1 |
| Salam, A | 1 |
| Peiris, D | 1 |
| Krum, H | 2 |
| Woodward, M | 1 |
| Hilmer, S | 1 |
| Thom, S | 1 |
| Malacco, E | 1 |
| Napoli, C | 1 |
| Leidig, M | 1 |
| Bambauer, R | 1 |
| Kirchertz, EJ | 1 |
| Szabã, T | 1 |
| Handrock, R | 1 |
| Leinung, D | 1 |
| Baier, M | 1 |
| Schmieder, RE | 7 |
| Croxtall, JD | 1 |
| Keating, GM | 1 |
| Xue, B | 1 |
| Johnson, AK | 1 |
| Hay, M | 1 |
| Croom, KF | 2 |
| Plosker, GL | 1 |
| Negro, R | 1 |
| Ekman, M | 2 |
| Bienfait-Beuzon, C | 1 |
| Jackson, J | 1 |
| Ruilope, LM | 4 |
| Segura, J | 2 |
| Guntekin, U | 1 |
| Gunes, Y | 1 |
| Tuncer, M | 1 |
| Simsek, H | 1 |
| Gunes, A | 1 |
| Zhang, S | 4 |
| Mao, G | 3 |
| Hong, X | 4 |
| Yu, Y | 3 |
| Zhang, Y | 7 |
| Tang, G | 3 |
| Kawano, Y | 1 |
| Sato, Y | 1 |
| Yoshinaga, K | 1 |
| Belousov, IuB | 1 |
| Shestakova, MV | 1 |
| Belousov, DIu | 1 |
| Lewin, AJ | 1 |
| Weir, MR | 3 |
| Derosa, G | 4 |
| Ferrari, I | 2 |
| Nixon, RM | 1 |
| Müller, E | 1 |
| Lowy, A | 2 |
| Falvey, H | 1 |
| Schulz, EG | 2 |
| Battegay, E | 1 |
| Neumann, L | 1 |
| Schmidt-Weitmann, S | 1 |
| Brockes, C | 1 |
| Bramlage, P | 15 |
| Ariyoshi, Y | 1 |
| Mizumoto, K | 1 |
| Palatini, P | 1 |
| Jung, W | 1 |
| Shlyakhto, E | 1 |
| Botha, J | 1 |
| Bush, C | 1 |
| Keefe, DL | 2 |
| Liljedahl, S | 1 |
| Lind, L | 16 |
| Arnlöv, J | 1 |
| Gersak, K | 1 |
| Cvijic, M | 1 |
| Cerar, LK | 1 |
| Lapuerta, P | 10 |
| Franklin, S | 2 |
| Stanton, AV | 1 |
| Dicker, P | 2 |
| O'Brien, ET | 1 |
| Persson, F | 2 |
| Rossing, P | 3 |
| Reinhard, H | 1 |
| Juhl, T | 1 |
| Stehouwer, CD | 3 |
| Schalkwijk, C | 1 |
| Danser, AH | 2 |
| Boomsma, F | 2 |
| Frandsen, E | 1 |
| Parving, HH | 9 |
| Durand-Zaleski, I | 1 |
| Desai, N | 1 |
| Pirk, O | 1 |
| Hacker, C | 1 |
| Ali, K | 1 |
| Rajkumar, C | 1 |
| Fantin, F | 1 |
| Schiff, R | 1 |
| Bulpitt, CJ | 1 |
| Kappert, K | 1 |
| Tsuprykov, O | 1 |
| Kaufmann, J | 1 |
| Fritzsche, J | 1 |
| Ott, I | 1 |
| Goebel, M | 1 |
| Bähr, IN | 1 |
| Hässle, PL | 1 |
| Gust, R | 1 |
| Fleck, E | 1 |
| Unger, T | 4 |
| Stawowy, P | 1 |
| Kintscher, U | 2 |
| Delea, TE | 1 |
| Sofrygin, O | 1 |
| Palmer, JL | 1 |
| Lau, H | 1 |
| Munk, VC | 1 |
| Sung, J | 1 |
| Charney, A | 1 |
| Sullivan, SD | 1 |
| Neutel, JM | 11 |
| Franklin, SS | 4 |
| Bhaumik, A | 5 |
| Oparil, S | 3 |
| Parhofer, KG | 2 |
| Birkeland, KI | 1 |
| DeFronzo, R | 1 |
| Del Prato, S | 1 |
| Ptaszynska, A | 4 |
| Kabakci, G | 2 |
| Kaya, BE | 1 |
| Tulumen, E | 1 |
| Kocabas, U | 1 |
| Abali, G | 1 |
| Deveci, O | 1 |
| Aytemir, K | 1 |
| Tokgozoglu, L | 1 |
| Ozkutlu, H | 1 |
| Schwertfeger, M | 1 |
| Whaley-Connell, A | 1 |
| Nistala, R | 1 |
| Habibi, J | 1 |
| Hayden, MR | 1 |
| Schneider, RI | 1 |
| Johnson, MS | 1 |
| Tilmon, R | 1 |
| Rehmer, N | 1 |
| Ferrario, CM | 1 |
| Sowers, JR | 4 |
| Westermann, D | 1 |
| Savvatis, K | 1 |
| Schultheiss, HP | 1 |
| Tschöpe, C | 2 |
| Schindler, C | 1 |
| Weiss, J | 1 |
| Sauer, A | 1 |
| Divac, N | 1 |
| Herzog, M | 1 |
| Schwedhelm, E | 2 |
| Böger, RH | 2 |
| Haefeli, WE | 1 |
| Benndorf, RA | 1 |
| Krone, W | 1 |
| Hanefeld, M | 1 |
| Meyer, HF | 1 |
| Jung, T | 1 |
| Bartlett, M | 1 |
| Yeh, CM | 1 |
| Rajman, I | 1 |
| Prescott, MF | 1 |
| Dole, WP | 1 |
| Milionis, HJ | 1 |
| Kostapanos, MS | 1 |
| Florentin, M | 1 |
| Kostara, CE | 1 |
| Fragoulakis, V | 1 |
| Papagiannopoulou, V | 1 |
| Yfantopoulos, J | 1 |
| Chen, GF | 1 |
| Wagner, L | 1 |
| Sasser, JM | 1 |
| Zharikov, S | 1 |
| Moningka, NC | 1 |
| Baylis, C | 1 |
| Takai, S | 2 |
| Jin, D | 2 |
| Sakonjo, H | 1 |
| Miyazaki, M | 2 |
| van Esch, JH | 1 |
| Moltzer, E | 1 |
| van Veghel, R | 1 |
| Garrelds, IM | 1 |
| Leijten, F | 1 |
| Bouhuizen, AM | 1 |
| Rong, X | 1 |
| Ebihara, K | 1 |
| Zhao, M | 1 |
| Kusakabe, T | 1 |
| Tomita, T | 1 |
| Murray, M | 1 |
| Nakao, K | 1 |
| Alexandru, N | 2 |
| Popov, D | 2 |
| Dragan, E | 2 |
| Andrei, E | 2 |
| Georgescu, A | 2 |
| Xu, D | 2 |
| Liu, PJ | 2 |
| Guo, XY | 2 |
| Chang, P | 2 |
| Li, XL | 2 |
| Chen, XH | 1 |
| Shen, XP | 1 |
| De Luis, DA | 1 |
| Conde, R | 1 |
| Gonzalez Sagrado, M | 1 |
| Aller, R | 1 |
| Izaola, O | 1 |
| Perez Castrillon, JL | 1 |
| Romero, E | 1 |
| Castro, MJ | 1 |
| Asmar, R | 2 |
| Tebbe, U | 2 |
| Lüders, S | 3 |
| Cuneo, A | 1 |
| Sistig, P | 1 |
| de Haan, F | 2 |
| Schmieder, R | 1 |
| Paar, WD | 4 |
| Schrader, J | 3 |
| Burnier, M | 11 |
| Brede, Y | 1 |
| Vongpatanasin, W | 2 |
| Arbique, D | 2 |
| Arbique, G | 1 |
| Adams-Huet, B | 2 |
| Mitchell, JH | 1 |
| Victor, RG | 1 |
| Thomas, GD | 1 |
| Neumann, CL | 1 |
| Menne, J | 1 |
| Rieken, EM | 1 |
| Fischer, N | 1 |
| Weber, MH | 1 |
| Haller, H | 1 |
| Lethen, H | 1 |
| Tries, HP | 1 |
| Kersting, S | 1 |
| Lambertz, H | 1 |
| Rabbani, N | 1 |
| Adaikalakoteswari, A | 1 |
| Rossing, K | 1 |
| Tarnow, L | 1 |
| Thornalley, PJ | 1 |
| Engelen, L | 1 |
| Ferreira, I | 1 |
| Hovind, P | 1 |
| Teerlink, T | 1 |
| Schalkwijk, CG | 1 |
| Simonenko, VB | 1 |
| Medvedev, IN | 1 |
| Tolmachev, VV | 1 |
| Holtkamp, FA | 1 |
| de Zeeuw, D | 4 |
| de Graeff, PA | 1 |
| Laverman, GD | 1 |
| Berl, T | 5 |
| Remuzzi, G | 2 |
| Packham, D | 1 |
| Lewis, JB | 7 |
| Lambers Heerspink, HJ | 1 |
| Khan, M | 1 |
| Kamal, AK | 1 |
| Jonk, AM | 1 |
| Houben, AJ | 1 |
| Schaper, NC | 1 |
| de Leeuw, PW | 1 |
| Serné, EH | 1 |
| Smulders, YM | 1 |
| Bamias, A | 1 |
| Manios, E | 1 |
| Karadimou, A | 1 |
| Michas, F | 1 |
| Lainakis, G | 1 |
| Constantinidis, C | 1 |
| Deliveliotis, C | 1 |
| Zakopoulos, N | 1 |
| Dimopoulos, MA | 1 |
| Fogari, R | 4 |
| Mugellini, A | 3 |
| Circelli, M | 1 |
| Cremonesi, G | 1 |
| Shang, W | 1 |
| Han, P | 1 |
| Yang, CB | 1 |
| Gu, XW | 1 |
| Zhang, W | 1 |
| Xu, LP | 2 |
| Fu, ST | 1 |
| Su, DF | 2 |
| Xie, HH | 2 |
| Tiryaki, O | 1 |
| Usalan, C | 1 |
| Buyukhatipoglu, H | 1 |
| Sayiner, ZA | 1 |
| Kilisli, H | 1 |
| Ram, CV | 1 |
| Ramaswamy, K | 1 |
| Qian, C | 1 |
| Biskupiak, J | 1 |
| Ryan, A | 1 |
| Quah, R | 1 |
| Russo, PA | 1 |
| Vitale, C | 1 |
| Marazzi, G | 1 |
| Iellamo, F | 1 |
| Spoletini, I | 1 |
| Dall'Armi, V | 1 |
| Fini, M | 1 |
| Volterrani, M | 1 |
| Yang, LQ | 1 |
| Ma, RX | 1 |
| Nako, H | 1 |
| Kataoka, K | 1 |
| Koibuchi, N | 1 |
| Dong, YF | 1 |
| Toyama, K | 1 |
| Yamamoto, E | 1 |
| Yasuda, O | 1 |
| Ichijo, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Leung, ES | 1 |
| Hamilton-Bruce, MA | 1 |
| Stocks, N | 1 |
| Koblar, SA | 1 |
| Celik, T | 1 |
| Yilmaz, MI | 1 |
| Titorencu, I | 1 |
| Tarziu, C | 1 |
| Ghiorghe, S | 1 |
| Badila, E | 1 |
| Bartos, D | 1 |
| Morii, J | 1 |
| Sugihara, M | 1 |
| Arimura, T | 1 |
| Sako, H | 1 |
| Zhang, B | 1 |
| Uehara, Y | 1 |
| Ando, H | 1 |
| Ushijima, K | 1 |
| Hosohata, K | 1 |
| Saito, T | 1 |
| Fujimura, A | 1 |
| Raheja, P | 1 |
| Price, A | 1 |
| Auchus, RJ | 1 |
| Chen, SL | 1 |
| Liu, XY | 1 |
| Xu, WM | 1 |
| Mei, WY | 1 |
| Chen, XL | 1 |
| Chen, C | 1 |
| Chen, Q | 1 |
| Li, ZG | 1 |
| Al Balushi, KA | 1 |
| Habib, JQ | 1 |
| Al-Zakwani, I | 1 |
| Malishevskiĭ, MV | 1 |
| Tong, XL | 1 |
| Lian, FM | 1 |
| Ji, HY | 1 |
| Xu, GC | 1 |
| Hu, YH | 1 |
| Zhao, LH | 1 |
| Xia, L | 1 |
| Chen, XY | 1 |
| Chan, MH | 1 |
| Zhang, LL | 1 |
| Gao, W | 1 |
| Zhen, Z | 1 |
| Zhou, SP | 1 |
| Chang, B | 1 |
| Tsuruoka, S | 1 |
| Kai, H | 1 |
| Usui, J | 1 |
| Morito, N | 1 |
| Saito, C | 1 |
| Yoh, K | 1 |
| Yamagata, K | 1 |
| Kotsiuruba, AV | 2 |
| Svishchenko, IeP | 2 |
| Bukhanevich, OM | 2 |
| Kosiakova, HV | 1 |
| Berdyshev, AH | 1 |
| Radchenko, VV | 2 |
| Mishchenko, LA | 1 |
| Hula, NM | 2 |
| Hasford, J | 1 |
| Mimran, A | 3 |
| Simons, WR | 1 |
| Franchi, F | 1 |
| Lazzeri, C | 1 |
| Foschi, M | 1 |
| Tosti-Guerra, C | 1 |
| Barletta, G | 1 |
| Nolly, H | 1 |
| Workman, D | 1 |
| He, W | 1 |
| Roniker, B | 1 |
| Krause, S | 1 |
| Fakouhi, K | 1 |
| Nyström, F | 11 |
| Ohman, KP | 9 |
| Dao, HH | 1 |
| Essalihi, R | 1 |
| Graillon, JF | 1 |
| Larivière, R | 1 |
| De Champlain, J | 2 |
| Moreau, P | 1 |
| Andrade, RJ | 1 |
| Lucena, MI | 1 |
| Fernández, MC | 1 |
| Vega, JL | 1 |
| García-Cortés, M | 1 |
| Casado, M | 1 |
| Guerrero-Sanchez, E | 1 |
| Pulido-Fernandez, F | 1 |
| Zukowska-Szczechowska, E | 1 |
| Gosek, K | 1 |
| Grzeszczak, W | 1 |
| Hallberg, P | 6 |
| Karlsson, J | 8 |
| Kurland, L | 13 |
| Melhus, H | 11 |
| Eguchi, K | 1 |
| Shimada, K | 1 |
| Sasso, FC | 1 |
| Carbonara, O | 1 |
| Persico, M | 1 |
| Iafusco, D | 1 |
| Salvatore, T | 1 |
| D'Ambrosio, R | 1 |
| Torella, R | 1 |
| Cozzolino, D | 1 |
| Edner, M | 6 |
| Bergfeldt, L | 2 |
| Haneda, M | 1 |
| Sugimoto, T | 1 |
| Graham, MR | 1 |
| Allcock, NM | 1 |
| Elmfeldt, D | 1 |
| Olofsson, B | 1 |
| Meredith, P | 1 |
| Franscini, LM | 1 |
| Von Vigier, RO | 3 |
| Pfister, R | 1 |
| Casaulta-Aebischer, C | 1 |
| Fossali, E | 3 |
| Bianchetti, MG | 3 |
| Bernadet-Monrozies, P | 1 |
| Rostaing, L | 1 |
| Kamar, N | 1 |
| Durand, D | 1 |
| Mulatero, P | 1 |
| Rabbia, F | 1 |
| Milan, A | 1 |
| Paglieri, C | 1 |
| Morello, F | 1 |
| Chiandussi, L | 1 |
| Veglio, F | 1 |
| Karpov, IuA | 1 |
| Mancini, GB | 1 |
| Angulo, E | 2 |
| Robles, NR | 2 |
| Grois, J | 2 |
| Barquero, A | 2 |
| Pérez Miranda, M | 1 |
| Mehed', OF | 1 |
| Balt, JC | 1 |
| Mathy, MJ | 1 |
| Pfaffendorf, M | 1 |
| van Zwieten, PA | 1 |
| Kreutz, R | 1 |
| Paul, M | 1 |
| Nussdorfer, GG | 3 |
| Pessina, AC | 3 |
| Michaëlsson, K | 4 |
| Hunsicker, LG | 6 |
| Pfeffer, MA | 3 |
| Porush, JG | 3 |
| Rouleau, JL | 3 |
| Drury, PL | 2 |
| Esmatjes, E | 3 |
| Hricik, D | 2 |
| Parikh, CR | 1 |
| Raz, I | 4 |
| Vanhille, P | 2 |
| Wiegmann, TB | 3 |
| Wolfe, BM | 2 |
| Locatelli, F | 4 |
| Goldhaber, SZ | 3 |
| Lewis, EJ | 9 |
| Coca, A | 6 |
| Calvo, C | 4 |
| de la Sierra, A | 4 |
| Aranda, P | 1 |
| Luque, M | 1 |
| Marín-Iranzo, R | 1 |
| Cerbai, E | 1 |
| De Paoli, P | 1 |
| Sartiani, L | 1 |
| Lonardo, G | 1 |
| Mugelli, A | 1 |
| Alföldi, S | 1 |
| Wen, SY | 1 |
| Sun, OJ | 1 |
| Wang, SQ | 1 |
| Terra, SG | 1 |
| Polónia, J | 1 |
| Diogo, D | 1 |
| Caupers, P | 1 |
| Damasceno, A | 1 |
| Gambini, D | 1 |
| Sala, F | 1 |
| Gianotti, R | 1 |
| Cusini, M | 1 |
| Ito, S | 1 |
| Sidorenko, BA | 2 |
| Preobrazhenskiĭ, DV | 2 |
| Stetsenko, TM | 2 |
| Tarykina, EV | 1 |
| Tsurko, VV | 1 |
| Rodby, RA | 12 |
| Chiou, CF | 1 |
| Borenstein, J | 1 |
| Smitten, A | 1 |
| Sengupta, N | 1 |
| Palmer, AJ | 13 |
| Roze, S | 11 |
| Annemans, L | 8 |
| Simon, TA | 2 |
| Chen, RS | 1 |
| Gartenmann, AC | 1 |
| Simonetti, GD | 2 |
| Schmidtko, J | 1 |
| Edefonti, A | 1 |
| Liljedahl, U | 7 |
| Syvänen, AC | 7 |
| Lamotte, M | 5 |
| Cordonnier, DJ | 2 |
| Pu, Q | 2 |
| Larouche, I | 1 |
| Schiffrin, EL | 5 |
| Gaudio, C | 1 |
| Ferri, FM | 1 |
| Giovannini, M | 1 |
| Pannarale, G | 1 |
| Puddu, PE | 1 |
| Vittore, A | 1 |
| Fera, MS | 1 |
| Vizza, CD | 1 |
| Fedele, F | 1 |
| Dominiak, P | 1 |
| Häuser, W | 1 |
| Sobrino, J | 1 |
| Gómez, E | 1 |
| López-Paz, JE | 1 |
| Sierra, C | 1 |
| Bragulat, E | 2 |
| Ritz, E | 4 |
| Tellew, J | 1 |
| Carlson, K | 1 |
| Ryan, C | 1 |
| Kane, B | 1 |
| Beyer, S | 1 |
| Arthur, S | 1 |
| Dickinson, K | 1 |
| Perrone, M | 1 |
| Ferrer, P | 1 |
| Giancarli, M | 1 |
| Baumann, J | 1 |
| Bird, E | 1 |
| Panchal, B | 1 |
| Trippodo, N | 1 |
| Barrish, J | 1 |
| Larrousse, M | 1 |
| Foruny Olcina, JR | 1 |
| Moreira Vicente, VF | 1 |
| Gómez García, M | 1 |
| Morell Hita, JL | 1 |
| Ishii, M | 1 |
| Mavromoustakos, T | 1 |
| Zoumpoulakis, P | 1 |
| Kyrikou, I | 1 |
| Zoga, A | 1 |
| Siapi, E | 1 |
| Zervou, M | 1 |
| Daliani, I | 1 |
| Dimitriou, D | 1 |
| Pitsas, A | 1 |
| Kamoutsis, C | 1 |
| Laggner, P | 1 |
| Coyle, D | 2 |
| Shimamura, T | 1 |
| Masui, M | 1 |
| Torii, M | 1 |
| Nakajima, M | 1 |
| Soplevenko, AV | 1 |
| Ivanova, NA | 1 |
| Waeber, B | 3 |
| Morales-Olivas, FJ | 1 |
| Arístegui, I | 1 |
| Estañ, L | 1 |
| Rodicio, JL | 1 |
| Moreno, A | 1 |
| Gil, V | 1 |
| Ferrón, G | 1 |
| Velasco, O | 2 |
| Billberger, K | 1 |
| Preti, P | 1 |
| Zoppi, A | 1 |
| Corradi, L | 1 |
| Fogari, E | 2 |
| Graham, D | 2 |
| Hamilton, C | 1 |
| Beattie, E | 1 |
| Spiers, A | 1 |
| Dominiczak, AF | 2 |
| Curran, MP | 1 |
| Goa, KL | 1 |
| Perry, CM | 1 |
| Bilous, RW | 1 |
| Wang, JM | 1 |
| Zhu, ZS | 1 |
| Zhang, MC | 1 |
| Zou, Y | 1 |
| Li, JJ | 1 |
| Li, MJ | 1 |
| Jiang, XJ | 1 |
| Li, XY | 1 |
| Koh, KK | 1 |
| Chung, WJ | 1 |
| Ahn, JY | 1 |
| Jin, DK | 1 |
| Park, GS | 1 |
| Kang, WC | 1 |
| Ahn, TH | 1 |
| Shin, EK | 1 |
| Germanò, G | 1 |
| Sanguigni, V | 1 |
| Pignatelli, P | 1 |
| Caccese, D | 1 |
| Lenti, L | 1 |
| Ragazzo, M | 1 |
| Lauro, R | 1 |
| Violi, F | 1 |
| Ferrari, P | 1 |
| Hess, L | 1 |
| Pechere-Bertschi, A | 2 |
| Muggli, F | 1 |
| Schneider, MP | 3 |
| Klingbeil, AU | 2 |
| Delles, C | 2 |
| Ludwig, M | 2 |
| Kolloch, RE | 2 |
| Krekler, M | 5 |
| Stumpe, KO | 4 |
| Schute, LL | 1 |
| Sharma, AM | 3 |
| Kirch, W | 5 |
| Bünte, C | 1 |
| Witte, J | 1 |
| Hoeper, K | 1 |
| Drexler, H | 2 |
| Aguilar, D | 1 |
| Gans, DJ | 1 |
| Levey, AS | 1 |
| Chen, R | 4 |
| Gabriel, S | 3 |
| Carita, P | 3 |
| de Alvaro, F | 5 |
| Schunkert, H | 1 |
| Berglund, L | 1 |
| Pittrow, D | 2 |
| Lehnert, H | 3 |
| Doggrell, SA | 2 |
| Llewelyn, DE | 1 |
| Garcia-Puig, J | 2 |
| Honorato, J | 1 |
| Parrondo, I | 1 |
| Smith, DH | 2 |
| Dubiel, R | 1 |
| Jones, M | 1 |
| Widimský, J | 1 |
| Zizka, J | 1 |
| Haas, T | 1 |
| Atkins, RC | 2 |
| Briganti, EM | 1 |
| Braden, G | 1 |
| Champion de Crespigny, PJ | 1 |
| DeFerrari, G | 2 |
| Drury, P | 1 |
| Müller-Brunotte, R | 4 |
| Gradman, AH | 1 |
| Lins, RL | 1 |
| Nussberger, J | 4 |
| Chiang, Y | 1 |
| Bedigian, MP | 1 |
| Tepliakov, AT | 1 |
| Stepacheva, TA | 1 |
| Ivannikova, OA | 1 |
| Pushnikova, EIu | 1 |
| Kaliuzhin, VV | 1 |
| Malakhovich, EV | 1 |
| Makushkin, EV | 1 |
| Zenevich, MV | 1 |
| Vázquez-Oliva, G | 1 |
| Fernández-Real, JM | 1 |
| Zamora, A | 1 |
| Vilaseca, M | 1 |
| Badimón, L | 1 |
| Dimopoulos-Xicki, L | 1 |
| Haas, M | 1 |
| Gaddi, A | 1 |
| Ciccarelli, L | 1 |
| Herlitz, H | 1 |
| Palmgren, E | 1 |
| Widgren, B | 1 |
| Aurell, M | 1 |
| Pohl, M | 1 |
| Hess, B | 3 |
| Greminger, P | 1 |
| Koylan, N | 1 |
| Acarturk, E | 1 |
| Canberk, A | 1 |
| Caglar, N | 1 |
| Caglar, S | 1 |
| Erdine, S | 1 |
| Guneri, S | 1 |
| Ilerigelen, B | 1 |
| Onder, R | 1 |
| Sagkan, O | 1 |
| Buyukozturk, K | 1 |
| Sun, NL | 1 |
| Jing, S | 1 |
| García-Donaire, JA | 1 |
| Pohl, MA | 2 |
| Blumenthal, S | 1 |
| Eisner, G | 1 |
| Gilbert, RE | 1 |
| de Faria, JB | 1 |
| Mangili, R | 1 |
| Moore, J | 1 |
| Reisin, E | 1 |
| Schernthaner, G | 1 |
| Spitalewitz, S | 1 |
| Tindall, H | 1 |
| Famularo, G | 1 |
| Minisola, G | 1 |
| Nicotra, GC | 1 |
| De Simone, C | 1 |
| Matos, JP | 1 |
| de Lourdes Rodrigues, M | 1 |
| Ismerim, VL | 1 |
| Boasquevisque, EM | 1 |
| Genelhu, V | 1 |
| Francischetti, EA | 1 |
| Strutz, F | 1 |
| Saunders, E | 4 |
| Cushman, WC | 3 |
| Ferdinand, KC | 3 |
| Ofili, EO | 3 |
| Weber, MA | 5 |
| Delonca, J | 1 |
| Moulin, C | 1 |
| Giacomino, A | 1 |
| Postel-Vinay, N | 1 |
| Dang, A | 1 |
| Liu, G | 1 |
| Chen, G | 1 |
| Song, W | 1 |
| Sloniger, JA | 1 |
| Saengsirisuwan, V | 1 |
| Diehl, CJ | 1 |
| Kim, JS | 1 |
| Henriksen, EJ | 1 |
| Zanchi, A | 1 |
| Wen, Y | 1 |
| Cipollone, F | 1 |
| Fazia, ML | 1 |
| Mezzetti, A | 1 |
| Germino, FW | 1 |
| Smith, D | 1 |
| Jiang, QJ | 1 |
| Xu, G | 1 |
| Mao, FF | 1 |
| Zhu, YF | 1 |
| Frei, A | 2 |
| Turner, CL | 1 |
| Wilkinson, IB | 1 |
| Kirkpatrick, PJ | 1 |
| Ribeiro, AB | 2 |
| Gavras, H | 1 |
| Valentine, WJ | 5 |
| Ray, JA | 4 |
| Spinas, GA | 1 |
| Brändle, M | 1 |
| Konrad, M | 1 |
| Rizzi, M | 1 |
| Shen, FM | 1 |
| Zhang, XF | 1 |
| Jiang, YY | 1 |
| Tschöpe, R | 1 |
| Ogiwara, T | 1 |
| Ahn, JC | 1 |
| Hong, SJ | 1 |
| Kim, EJ | 1 |
| Lee, SJ | 1 |
| Park, SM | 2 |
| Seo, HS | 1 |
| Oh, DJ | 1 |
| Ruggenenti, P | 1 |
| Ring, M | 1 |
| Bella, JN | 1 |
| Luchtefeld, M | 1 |
| Bandlow, N | 1 |
| Tietge, UJ | 1 |
| Grote, K | 1 |
| Pfeilschifter, J | 1 |
| Kaszkin, M | 1 |
| Beck, S | 1 |
| Tucker, DM | 1 |
| Laville, M | 1 |
| O'Brien, E | 1 |
| Barton, J | 1 |
| Mulcahy, D | 1 |
| Jensen, C | 1 |
| Stanton, A | 1 |
| Dang, AM | 1 |
| Liu, GZ | 1 |
| Zhang, YH | 1 |
| Chen, GL | 1 |
| Muszbek, N | 1 |
| Ernsberger, P | 1 |
| Koletsky, RJ | 1 |
| Jordan, J | 1 |
| Engeli, S | 1 |
| Boye, SW | 1 |
| Le Breton, S | 1 |
| Thoenes, M | 3 |
| Held, C | 2 |
| D'Angelo, A | 1 |
| Salvadeo, S | 1 |
| Gravina, A | 1 |
| Fassi, R | 1 |
| Ruilope, L | 3 |
| Pieske, B | 1 |
| López, B | 1 |
| González, A | 1 |
| Díez, J | 3 |
| Mayer, MA | 1 |
| Höcht, C | 1 |
| Gironacci, M | 1 |
| Opezzo, JA | 1 |
| Taira, CA | 1 |
| Fernández, BE | 1 |
| Puyó, AM | 1 |
| Rodby, R | 1 |
| Soroka, S | 1 |
| Levin, A | 1 |
| Muirhead, N | 1 |
| de Cotret, PR | 1 |
| Palmer, A | 1 |
| Flack, JM | 2 |
| Santschi, V | 1 |
| Wuerzner, G | 1 |
| Bugnon, O | 1 |
| Schirmer, A | 1 |
| Paar, DW | 1 |
| Ubaid-Girioli, S | 1 |
| Ferreira-Melo, SE | 1 |
| Souza, LA | 1 |
| Nogueira, EA | 1 |
| Yugar-Toledo, JC | 1 |
| Moreno, H | 1 |
| Münzel, F | 1 |
| Tu, X | 1 |
| Xie, Y | 1 |
| Shi, S | 1 |
| Cox, D | 1 |
| Donovan, M | 1 |
| De Obaldia, ME | 1 |
| Cable, G | 1 |
| Neutel, J | 1 |
| Belsey, JD | 1 |
| Vyssoulis, GP | 1 |
| Karpanou, EA | 1 |
| Kyvelou, SM | 1 |
| Adamopoulos, DN | 1 |
| Antonakoudis, GC | 1 |
| Deligeorgis, AD | 1 |
| Cokkinos, DV | 1 |
| Stefanadis, CI | 1 |
| Coronel, F | 1 |
| Cigarrán, S | 1 |
| García-Mena, M | 1 |
| Herrero, JA | 1 |
| Calvo, N | 1 |
| Pérez-Flores, I | 1 |
| Busch, M | 1 |
| Franke, S | 1 |
| Wolf, G | 1 |
| Rohde, RD | 1 |
| Stein, G | 1 |
| Hashemi, N | 1 |
| Vacher, E | 1 |
| Fornes, P | 2 |
| Richer, C | 2 |
| Bruneval, P | 1 |
| Nisato, D | 1 |
| Giudicelli, JF | 2 |
| van den Meiracker, AH | 1 |
| Admiraal, PJ | 1 |
| Janssen, JA | 1 |
| Kroodsma, JM | 1 |
| de Ronde, WA | 1 |
| Sissmann, J | 2 |
| Blankestijn, PJ | 1 |
| Mulder, PG | 1 |
| Man In 't Veld, AJ | 1 |
| Velasquez, MT | 1 |
| Weinberg, EO | 1 |
| Lee, MA | 1 |
| Weigner, M | 1 |
| Lindpaintner, K | 1 |
| Bishop, SP | 1 |
| Benedict, CR | 1 |
| Ho, KK | 1 |
| Douglas, PS | 1 |
| Chafizadeh, E | 1 |
| Lorell, BH | 1 |
| Bragat, AC | 1 |
| Blumenfeld, J | 1 |
| Sealey, JE | 1 |
| Larochelle, P | 1 |
| Marbury, TC | 1 |
| Sareli, P | 1 |
| Krieger, EM | 1 |
| Reeves, RA | 4 |
| Gillis, JC | 1 |
| Markham, A | 1 |
| Brunner, HR | 5 |
| Pouleur, HG | 1 |
| Zanchetti, A | 1 |
| Man in't Veld, AJ | 1 |
| Haworth, D | 1 |
| Hoglund, C | 1 |
| Kerwin, L | 2 |
| Martin, A | 1 |
| Simon, T | 1 |
| Masson, C | 1 |
| Kassler-Taub, K | 7 |
| Osbakken, M | 4 |
| Decosterd, L | 1 |
| Armagnac, C | 1 |
| Bouroudian, M | 1 |
| Nys, M | 2 |
| Owens, D | 1 |
| Littlejohn, T | 2 |
| Elliott, W | 1 |
| Ruddy, T | 1 |
| Adler, E | 1 |
| Pool, JL | 1 |
| Guthrie, RM | 1 |
| Littlejohn, TW | 1 |
| Raskin, P | 2 |
| Shephard, AM | 1 |
| Wilson, TW | 1 |
| Wright, J | 1 |
| Kassler-Taub, KB | 2 |
| Lin, CS | 2 |
| Pouleur, H | 1 |
| Gelarden, RT | 1 |
| Freitag, SA | 1 |
| Davies, R | 1 |
| Cohen, A | 1 |
| Bregman, B | 1 |
| Agabiti Rosei, E | 1 |
| Williams, B | 2 |
| Dubourg, O | 1 |
| Clairefond, P | 1 |
| Brudi, P | 1 |
| Gosse, P | 1 |
| Guéret, P | 1 |
| Brown, MJ | 1 |
| Morsing, P | 1 |
| Lim, PO | 1 |
| Naas, AA | 1 |
| Struthers, AD | 1 |
| MacDonald, TM | 1 |
| Rosenstock, J | 1 |
| Rossi, L | 1 |
| MacNeil, D | 1 |
| Bunt, T | 2 |
| Chung, O | 1 |
| Csikós, T | 1 |
| Kulbertus, H | 1 |
| Kirk, JK | 1 |
| Fortuño, A | 2 |
| Muñiz, P | 1 |
| Ravassa, S | 1 |
| Rodriguez, JA | 1 |
| Fortuño, MA | 2 |
| Zalba, G | 2 |
| Kochar, M | 1 |
| Guthrie, R | 2 |
| Triscari, J | 1 |
| Kaplan, NM | 1 |
| Flack, J | 1 |
| Reeves, R | 2 |
| Saini, R | 3 |
| Chrysant, SG | 1 |
| Marbury, T | 1 |
| Howe, P | 1 |
| Phillips, P | 1 |
| Intengan, HD | 1 |
| Thibault, G | 1 |
| Li, JS | 1 |
| Spence, JD | 2 |
| Giner, V | 1 |
| Maillard, MP | 1 |
| Mazzolai, L | 1 |
| Daven, V | 1 |
| Centeno, C | 1 |
| Petkun, W | 1 |
| Sacchetto, A | 1 |
| Rizzoni, D | 1 |
| Bova, S | 1 |
| Porteri, E | 1 |
| Mazzocchi, G | 2 |
| Bahcelioglu, M | 1 |
| Conlin, PR | 1 |
| Saito, I | 1 |
| Benedict, C | 1 |
| Bunt, AM | 1 |
| Adams, MA | 1 |
| Trudeau, L | 1 |
| Hansson, L | 1 |
| Chiou, KR | 1 |
| Chen, CH | 1 |
| Ding, PY | 1 |
| Chen, YT | 1 |
| Ting, CT | 1 |
| Huang, JL | 1 |
| Chiang, AH | 1 |
| Liu, CP | 1 |
| Tseng, CJ | 1 |
| Chao, CT | 1 |
| Chang, MS | 1 |
| Grossman, E | 1 |
| Messerli, FH | 1 |
| Wong, W | 1 |
| Howes, L | 1 |
| Makris, TK | 1 |
| Stavroulakis, GA | 1 |
| Krespi, PG | 1 |
| Hatzizacharias, AN | 1 |
| Triposkiadis, FK | 1 |
| Tsoukala, CG | 1 |
| Votteas, VV | 1 |
| Kyriakidis, MK | 1 |
| Goldsmith, DJ | 1 |
| Reidy, J | 1 |
| Scoble, J | 1 |
| Mallion, JM | 1 |
| Badguet, JP | 1 |
| Descombes, E | 1 |
| Fellay, G | 1 |
| Lacourcière, Y | 1 |
| Wassmann, S | 1 |
| Bäumer, AT | 1 |
| Strehlow, K | 1 |
| van Eickels , M | 1 |
| Grohé, C | 1 |
| Ahlbory, K | 1 |
| Rösen, R | 1 |
| Nickenig, G | 1 |
| Touyz, RM | 1 |
| He, G | 1 |
| El Mabrouk, M | 1 |
| Benseñor, IM | 1 |
| Lotufo, PA | 1 |
| Leenen, FH | 1 |
| Yuan, B | 1 |
| Peers, A | 1 |
| Campbell, DJ | 1 |
| Wintour, EM | 1 |
| Dodic, M | 1 |
| Cao, Z | 2 |
| Bonnet, F | 2 |
| Davis, B | 1 |
| Allen, TJ | 2 |
| Cooper, ME | 2 |
| Beaumont, FJ | 1 |
| San José, G | 1 |
| Hägg, A | 5 |
| Osbakken, MD | 1 |
| Ostergern, J | 1 |
| Sakarcan, A | 1 |
| Tenney, F | 1 |
| Wilson, JT | 1 |
| Stewart, JJ | 1 |
| Adcock, KG | 1 |
| Wells, TG | 1 |
| Vachharajani, NN | 3 |
| Hadjilambris, OW | 1 |
| Slugg, P | 1 |
| Ford, NF | 1 |
| Marino, MR | 3 |
| Coats, AJ | 1 |
| De Rosa, ML | 1 |
| de Cristofaro, A | 1 |
| Rossi, M | 1 |
| Baiano, A | 1 |
| Cardace, P | 1 |
| Albanese, L | 1 |
| Vigorito, C | 1 |
| Kawachi, H | 1 |
| Boner, G | 1 |
| Clarke, WR | 1 |
| Rohde, R | 1 |
| Bröchner-Mortensen, J | 1 |
| Gomis, R | 1 |
| Andersen, S | 1 |
| Arner, P | 1 |
| Bloomgarden, ZT | 1 |
| von zur Mühlen, B | 1 |
| Millgård, J | 1 |
| Würzner, G | 1 |
| Gerster, JC | 1 |
| Chiolero, A | 1 |
| Maillard, M | 1 |
| Fallab-Stubi, CL | 1 |
| Jover, B | 1 |
| Herizi, A | 1 |
| Casellas, D | 1 |
| Park, JB | 1 |
| Brosnan, MJ | 1 |
| Hamilton, CA | 1 |
| Lygate, CA | 1 |
| Jardine, E | 1 |
| Liberopoulos, E | 1 |
| Christides, D | 1 |
| Gil-Extremera, B | 1 |
| Aguilera, MT | 1 |
| Martín-Hidalgo, A | 1 |
| Marín, R | 1 |
| Ortlepp, JR | 1 |
| Breuer, J | 1 |
| Eitner, F | 1 |
| Kluge, K | 1 |
| Kluge, R | 1 |
| Floege, J | 1 |
| Hollweg, G | 1 |
| Hanrath, P | 1 |
| Joost, HG | 1 |
| Domergue, V | 1 |
| Gervais, M | 1 |
| Trabold, F | 1 |
| Ohman, P | 2 |
| Kotridis, P | 1 |
| Kokkas, B | 1 |
| Karamouzis, M | 1 |
| Sakadamis, G | 1 |
| Kanonidis, I | 1 |
| Dadous, G | 1 |
| Karantona, C | 1 |
| Gouli, O | 1 |
| Karadoumanis, J | 1 |
| Papadopoulos, PC | 1 |
| Papadopoulos, CL | 1 |
| Korlipara, K | 1 |
| van Rossum, P | 1 |
| Villa, G | 1 |
| Silvert, B | 1 |
| Cavallin, M | 1 |
| Sartore, S | 1 |
| Rapi, J | 1 |
Clinical Trials (28)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Low Versus Standard Dialysate Sodium on 48h Ambulatory BP in Patients With Intradialytic Hypertension[NCT05430438] | 30 participants (Actual) | Interventional | 2022-06-01 | Completed | |||
| Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan - a Double Blind Randomised Study[NCT00791830] | Phase 3 | 82 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Randomized, Double-blind Evaluation of the Effects of Irbesartan and Atenolol on Cardiovascular Structure and Function in Subjects With Hypertension and Left Ventricular Hypertrophy[NCT00389168] | Phase 2/Phase 3 | 115 participants (Actual) | Interventional | 1995-04-30 | Completed | ||
| Efficacy and Safety of Coadministered Irbesartan and Atorvastatin in Patients With Hypertension and Hyperlipidemia[NCT01442987] | Phase 3 | 230 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Management of Resistant Hypertension -Pharmacokinetic Assessment of Different Antihypertensive Regimen -Comparison of Two Treatment Strategies: Increase Sodium Depletion or Combined Blockage of Renin-angiotensin System (RAS)[NCT00224549] | Phase 4 | 180 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Developing a Heart Failure Polypill to Improve Outcomes at a Safety Net Hospital: A Pilot Crossover Randomized Controlled Trial[NCT06029712] | Phase 2 | 40 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| A 2 x 5-week Multicenter, Cross-over Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan 80 mg Compared to Irbesartan 150 mg in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis[NCT00171080] | Phase 3 | 86 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Impact of Estrogen + Estradiol Receptor Alpha Modulator Therapy on Oxidative Stress in Post-menopausal Women With and Without Sleep Apnea[NCT03981341] | Phase 3 | 36 participants (Anticipated) | Interventional | 2019-11-01 | Recruiting | ||
| A Nine-week, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg Compared to Irbesartan 300 mg and Ramipril 10 mg in the Setting of a Missed Dose in Patients With Essential Hypertension[NCT00343551] | Phase 3 | 654 participants | Interventional | 2006-05-31 | Completed | ||
| A Randomized, Double-Blind, Parallel-Group, Cross-Over, 4-Period, 4 Treatment, Within-Subject Placebo-Controlled Study to Assess the Reno-Protective Effect of Renin Inhibition With Aliskiren as an Alternative to Irbesartan in Type 2 Patients With Incipien[NCT00464880] | Phase 1/Phase 2 | 24 participants | Interventional | 2005-09-30 | Completed | ||
| Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome[NCT00110422] | Phase 4 | 400 participants | Interventional | 2005-11-30 | Completed | ||
| Mechanisms of Muscle Blood Flow Dysregulation and Exercise Intolerance in Chronic Kidney Disease[NCT02664519] | 32 participants (Actual) | Interventional | 2016-01-31 | Terminated (stopped due to No funding support and not adequate number of subjects are recruited for the study) | |||
| The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension[NCT01996449] | Phase 2 | 14 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension[NCT01238705] | Phase 4 | 280 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| Neural Mechanisms of Thiazide-induced Insulin Resistance[NCT00353652] | Phase 4 | 166 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Irbesartan Monotherapy in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy[NCT00957554] | Phase 3 | 435 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Amlodipine Monotherapy in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy[NCT00956644] | Phase 3 | 406 participants (Anticipated) | Interventional | 2009-07-31 | Completed | ||
| Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)[NCT02354170] | Phase 2 | 16 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Treatment of Essential Hypertension With Rasilez. Evaluation of Different Methods of Blood Pressure Measurements - Efficacy and Safety Evaluation[NCT01060865] | Phase 4 | 50 participants (Actual) | Interventional | 2010-03-31 | Terminated (stopped due to The participants signed an old version of the informed consent.) | ||
| Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies: a Cross-over Randomized Clinical Trail[NCT05402397] | Phase 4 | 40 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| Angiotensin Converting Enzyme Inhibitors & Angiotensin Receptor Blocker in the Treatment of Type 2 Diabetic Patients Adverse Drug Effects and Drug Interactions- a Survey in an Internal Medicine Department.[NCT00437775] | 300 participants | Observational | 2007-01-31 | Recruiting | |||
| Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension[NCT01444833] | 35 participants (Anticipated) | Interventional | 2008-10-31 | Recruiting | |||
| A 12-week Randomized Double-blind Parallel Group Study to Evaluate the Efficacy and Safety of the Combination Aliskiren With HCTZ Compared to Irbesartan or Amlodipine With HCTZ or HCTZ Alone in Hypertensive Patients With BMI ≥ 30 kg/m2 Not Adequately Resp[NCT00219115] | Phase 3 | 493 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Pre-existing Microalbuminuria Predicting Contrast-induced Acute Kidney Injury (CIAKI) Following Coronary Angiography (CAG)[NCT02808845] | 800 participants (Anticipated) | Observational | 2016-12-31 | Not yet recruiting | |||
| Irbesartan Versus Placebo in Combination With Standard Cardiovascular Protection ACE-I Therapy With Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk[NCT00095290] | Phase 4 | 400 participants | Interventional | 2004-09-30 | Completed | ||
| Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-05-25 | Recruiting | ||
| Determinants of Diabetic Nephropathy in American Indians[NCT01878045] | 141 participants (Actual) | Observational | 2013-11-07 | Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.) | |||
| Double-blind, Randomized, Parallel Design Study Comparing Effectiveness of Losartan vs. Hydrochlorothiazide in Reversing or Preventing the Progression of the Remodeling of Resistance Arteries in Pre-hypertensive Pre-diabetic Subjects[NCT00388388] | Phase 2 | 1 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Few subjects recruited, sponsor withdrew support.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Blood Pressure
Difference in Diastolic Blood Pressure. Repeated measures multivariable analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Atenolol | -16.3 |
| Irbesartan | -18.8 |
Effects on Carotid Artery Wall Thickness
Changes in common carotid artery intima-media thickness, assessed by ultrasonography. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | mm (Mean) |
|---|---|
| Atenolol | 0.03 |
| Irbesartan | -0.01 |
Number of Participants With Serious Adverse Events
Safety was assessed by non-directed questions, and all observed and volunteered adverse events were recorded at each study visit. Serious adverse events were defined by, and reported according to the regulations of good clinical practice (GCP). none were considered related to the study medication. (NCT00389168)
Timeframe: Treatment period was baseline to 48 weeks
| Intervention | Participants (Number) |
|---|---|
| Atenolol | 5 |
| Irbesartan | 5 |
Changes in Left Ventricular Mass Index
Repeated measures multivariate analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks. Data are presented as left ventricular mass in gram (g) indexed for body mass index (in m^2). (NCT00389168)
Timeframe: Baseline and 48 weeks
| Intervention | g/m^2 (Mean) | ||
|---|---|---|---|
| 12 weeks | 24 weeks | 48 weeks | |
| Atenolol | -1 | -6 | -14 |
| Irbesartan | -9 | -14 | -26 |
Changes of Venous Plasma Angiotensin II as a Marker of the Renin-Angiotensin-Aldosterone System
Venous plasma concentrations of angiotensin II were measured in order to study the possible associations between the activity of the renin-angiotensin-aldosteone system and changes in left ventricular mass. Further analyses of other components of the renin-angiotensin-aldosterone system and of other hormonal system (e.g. the sympathetic nervous system) have also been performed and published. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Data were log-transformed to avoid skewness before statistical evaluation. However, tabular data are given as mean values with 95% confidence to improve readability. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | pmol/L (Mean) | ||
|---|---|---|---|
| Weel 12 | Week 24 | Week 48 | |
| Atenolol | -1.0 | -0.8 | -0.2 |
| Irbesartan | 3.0 | 3.3 | 10.0 |
Left Ventricular Diastolic Function Assessed by the E/A Ratio
Changes in left ventricular diastolic function from baseline to week 48 will be evaluated as the difference in E/A ratio. Conventional pulsed wave Doppler echocardiography was used for recordings of mitral inflow in. The peak of early (E) and late (A) mitral flow velocities were measured, and the E/A-ratio was calculated. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Some echocardiographic recordings at some time point may be of insufficient quality or missing, and the number of observations may not always correspond to the total number of participants at all time points. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | ratio (Mean) | ||
|---|---|---|---|
| Week 12 | Week 24 | Week 48 | |
| Atenolol | 0.18 | 0.16 | 0.13 |
| Irbesartan | 0.10 | 0.04 | 0.10 |
Muscle Sympathetic Nerve Activity at Rest
measurement of sympathetic nerve activity by microneurography (intraneural microelectrodes) (NCT01996449)
Timeframe: 8 weeks post treatment initiation
| Intervention | bursts/minute (Mean) |
|---|---|
| Amlodipine | 41 |
| Eplerenone | 43.8 |
Muscle Sympathetic Nerve Activity During Exercise
measurement of sympathetic nerve activity by microneurography (intraneural microelectrodes) during arm cycling exercise (NCT01996449)
Timeframe: 8 weeks post treatment initiation
| Intervention | bursts/minute (Mean) |
|---|---|
| Amlodipine | 47 |
| Eplerenone | 51 |
24-hour Ambulatory Systolic Blood Pressure
(NCT00353652)
Timeframe: Measured at 3 months
| Intervention | mmHg (Mean) |
|---|---|
| Study#1: Chlorthalidone (CTD), Titrated Dose | 127.4 |
| Study #1: Spironolactone (SP), Titrated Dose | 128.6 |
| Study# 2 Chlorthalidone (CTD), Fixed Dose | 123.5 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose | 121.6 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose | 119.8 |
HOMA-IR
assessment of insulin resistance calculated by multiplying fasting plasma insulin (mU/l) with fasting plasma glucose (mmol/l) divided by 22.5. (NCT00353652)
Timeframe: 3 months
| Intervention | mU/l*mmol/l (Median) |
|---|---|
| Study#1: Chlorthalidone (CTD), Titrated Dose | 1.91 |
| Study #1: Spironolactone (SP), Titrated Dose | 1.33 |
| Study# 2 Chlorthalidone (CTD), Fixed Dose | 1.87 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose | 0.85 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose | 1.42 |
Insulin
fasting plasma insulin (NCT00353652)
Timeframe: 3 months
| Intervention | mU/liter (Median) |
|---|---|
| Study#1: Chlorthalidone (CTD), Titrated Dose | 8.24 |
| Study #1: Spironolactone (SP), Titrated Dose | 7.6 |
| Study# 2 CTD Fixed Dose 25 mg/d | 7.6 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose | 4.87 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose | 6.8 |
Sympathetic Baroreflex Sensitivity
slope relating percent change in SNA (% change in total activity from baseline) to diastolic BP. (NCT00353652)
Timeframe: 3 months
| Intervention | % change from baseline per mmHg (Mean) |
|---|---|
| Study#1: Chlorthalidone (CTD), Titrated Dose | -9.1 |
| Drug: Study #1: Spironolactone (SP), Titrated Dose | -15.2 |
| Study# 2 Chlorthalidone (CTD), Fixed Dose | -12.9 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose | -11.3 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose | -12.0 |
Sympathetic Nerve Activity
(NCT00353652)
Timeframe: Measured at 3 months
| Intervention | bursts/min (Mean) |
|---|---|
| Study#1: Chlorthalidone (CTD), Titrated Dose | 46 |
| Study #1: Spironolactone (SP), Titrated Dose | 40 |
| Study# 2 Chlorthalidone (CTD), Fixed Dose | 49 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose | 42 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose | 52 |
Reviews
83 reviews available for avapro and Hypertension
| Article | Year |
|---|---|
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzi | 2003 |
Treating hypertension with a pill containing very low doses of four antihypertensive agents compared with standard dose irbesartan.
Topics: Antihypertensive Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Hyp | 2022 |
Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2023 |
Irbesartan (a comprehensive profile).
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephr | 2021 |
Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy.
Topics: Adult; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Drug Therapy, Combin | 2013 |
Pharmacological and clinical properties of AIMIX® combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Comp | 2013 |
Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.
Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Benzoates; Biphenyl Compou | 2013 |
Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2013 |
The cost-effectiveness of irbesartan for hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2015 |
Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.
Topics: Administration, Oral; Amlodipine; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Press | 2017 |
Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2017 |
Irbesartan: a review of its use in hypertension and diabetic nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabe | 2008 |
Endothelial effects of antihypertensive treatment: focus on irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular | 2008 |
The importance of integrated risk management when treating patients with hypertension: benefits of angiotensin II receptor antagonist therapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiovascular Diseases; Causality; Cer | 2008 |
Irbesartan and hydrochlorothiazide association in the treatment of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood | 2009 |
Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Bipheny | 2009 |
Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2009 |
[Pharmacological properties and clinical efficacy of the long-active angiotensin receptor blocker (ARB) irbesartan].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Delay | 2009 |
The risks and benefits of initial irbesartan/hydrochlorothiazide combination therapy in patients with severe hypertension.
Topics: Antihypertensive Agents; Biphenyl Compounds; Drug Therapy, Combination; Humans; Hydrochlorothiazide; | 2009 |
The value of irbesartan in the management of hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Blood Pressur | 2009 |
Rational of the use of aliskiren in hypertension and beyond.
Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl C | 2009 |
Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan.
Topics: Administration, Oral; Angiotensin II; Antihypertensive Agents; Biological Availability; Biphenyl Com | 2010 |
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biphenyl Compounds; Case-Contro | 2011 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Diabetes Comp | 2011 |
The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2012 |
[Irbesartan in clinical practice].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2012 |
Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity.
Topics: Acute Disease; Biopsy, Needle; Biphenyl Compounds; Chemical and Drug Induced Liver Injury; Cholestas | 2002 |
[Irbesartan--antihypertensive treatment in patients with heart failure and diabetes mellitus].
Topics: Antihypertensive Agents; Biphenyl Compounds; Diabetes Complications; Heart Failure; Humans; Hyperten | 2002 |
[What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension].
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; | 2002 |
[Diabetic nephropathy].
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; | 2002 |
[Evidence based treatment of diabetic nephropathy].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseas | 2002 |
The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2002 |
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2002 |
[Clinical hypertensiology: analysis of trials completed in 2001-2002].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2002 |
Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
Topics: Acrylates; Aged; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Coronary A | 2002 |
[Diurnal blood pressure control in the optimal treatment of hypertension].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphen | 2003 |
[Antihypertensive therapy in renal dysfunction].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl C | 2003 |
Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Creatinin | 2003 |
The antihypertensive response to irbesartan treatment from a pharmacogenetic perspective.
Topics: Antihypertensive Agents; Biphenyl Compounds; Cytochrome P-450 CYP2D6; Humans; Hypertension; Irbesart | 2003 |
[Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2004 |
Efforts to understand the molecular basis of hypertension through drug:membrane interactions.
Topics: Amino Acids; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Binding Sites; Biphen | 2004 |
[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Bipheny | 2004 |
AT1-receptor antagonism in hypertension: what has been learned with irbesartan?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2003 |
Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds | 2004 |
Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2004 |
Telmisartan - killing two birds with one stone.
Topics: 3T3-L1 Cells; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl | 2004 |
Editorial overview: The 'sartans': is it premature to consider PPARgamma receptor agonism a bonus?
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Cardiovascular Dise | 2005 |
An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compound | 2005 |
Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compound | 2006 |
Role of angiotensin II receptor blockers in atherosclerotic plaque stability.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Biphenyl Compounds; Caroti | 2006 |
Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds | 2006 |
[Renin-angiotensin system].
Topics: Adipocytes; Amides; Angiotensin-Converting Enzyme 2; Antihypertensive Agents; Biphenyl Compounds; Fu | 2006 |
Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Antihypertensive | 2007 |
Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
Topics: Antihypertensive Agents; Biphenyl Compounds; Cohort Studies; Computer Simulation; Costs and Cost Ana | 2007 |
Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; D | 2007 |
Angiotensin II receptor blockers. A new class of antihypertensive drugs.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1996 |
Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biological Availability; | 1997 |
The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Interactions; Hu | 1997 |
Clinical overview of irbesartan: a new angiotensin II receptor antagonist.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as To | 1997 |
Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetic | 1997 |
Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood | 1997 |
Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 1997 |
Clinical overview of irbesartan: expanding the therapeutic window in hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Contr | 1997 |
Irbesartan treatment in hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Ena | 1998 |
A look through the new therapeutic window: irbesartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Contr | 1998 |
Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1999 |
Angiotensin II receptor pharmacology and AT1-receptor blockers.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzi | 1999 |
Angiotensin-II receptor antagonists: their place in therapy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 1999 |
Angiotensin II receptor antagonists in the treatment of hypertension.
Topics: Algorithms; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazole | 1999 |
[Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Antihypertensive Age | 1999 |
Angiotensin II antagonists for hypertension: are there differences in efficacy?
Topics: Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Humans; | 2000 |
Irbesartan: review of pharmacology and comparative properties.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Dose- | 2000 |
Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?
Topics: Acrylates; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2000 |
Angiotensin receptor antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2000 |
Putting the efficacy of candesartan cilexetil into perspective: a review of new comparative data.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 2000 |
Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2001 |
Drug interactions with irbesartan.
Topics: Antihypertensive Agents; Area Under Curve; Biphenyl Compounds; Drug Interactions; Food; Half-Life; H | 2001 |
[Current treatment of diabetic nephropathy in patients with type II diabetes mellitus. Most recent progress].
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Melli | 2001 |
Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2002 |
Pharmacokinetics of irbesartan are not altered in special populations.
Topics: Adolescent; Adult; Aged; Biphenyl Compounds; Child; Female; Heart Failure; Humans; Hypertension; Irb | 2002 |
[Irbesartan: a new possibility in the treatment of hypertension].
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Benzimidazoles; Benz | 2002 |
Trials
184 trials available for avapro and Hypertension
| Article | Year |
|---|---|
Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial.
Topics: Amlodipine; Antihypertensive Agents; Australia; Bisoprolol; Blood Pressure; Double-Blind Method; Dru | 2021 |
Effect of administration of low-dose irbesartan and hydrochlorothiazide combined with levamlodipine at different times on the circadian rhythm of blood pressure and the levels of MMPs and TIMPs in non-dipper patients with grade 1 and 2 hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Hu | 2023 |
Initial treatment with a single capsule containing half-dose quadruple therapy vs standard-dose dual therapy in hypertensive patients (QUADUAL): Study protocol for a randomized, blinded, crossover trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Double-Blind Method; Drug T | 2023 |
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.
Topics: Angiotensinogen; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Die | 2023 |
Assessment of suitable antihypertensive therapies: Combination with high-dose amlodipine/irbesartan vs triple combination with amlodipine/irbesartan/indapamide (ASAHI-AI study).
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2020 |
Ultra-low-dose quadruple combination blood pressure-lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol.
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Bisoprolol; Calcium Channel Blocke | 2021 |
The Effects of Nebivolol and Irbesartan on Ambulatory Aortic Blood Pressure and Arterial Stiffness in Hemodialysis Patients with Intradialytic Hypertension.
Topics: Aged; Aorta; Blood Pressure; Cross-Sectional Studies; Female; Humans; Hypertension; Irbesartan; Male | 2021 |
Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitorin
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure Monitoring, A | 2017 |
The effects of increasing calcium channel blocker dose vs. adding a diuretic to treatment regimens for patients with uncontrolled hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Calcium Channe | 2017 |
Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph | 2018 |
The effects of nebivolol and irbesartan on postdialysis and ambulatory blood pressure in patients with intradialytic hypertension: a randomized cross-over study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Over Stu | 2019 |
Comparison of efficacy and safety between two different irbesartan, generic vs branded, in the treatment of Korean patients with mild-to-moderate hypertension: an 8-week, multicenter, randomized, open-label, Phase IV clinical study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Drugs | 2018 |
Nebivolol reduces short-term blood pressure variability more potently than irbesartan in patients with intradialytic hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Cross-Over Studies; Fem | 2019 |
Angiotensin II receptor blocker attenuates stress pressor response in young adult African Americans.
Topics: Adolescent; Adult; Angiotensin Receptor Antagonists; Black or African American; Blood Pressure; Case | 2019 |
Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension.
Topics: Adolescent; Adult; Aged; Albuminuria; Antihypertensive Agents; Asian People; Biphenyl Compounds; Blo | 2013 |
Renal and cardiovascular effects of irbesartan in dialysis patients--a randomized controlled trial protocol (SAFIR study).
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Double-Blind Method; Hemodynamics; Huma | 2013 |
The effect of combined antihypertensive treatment (felodipine with either irbesartan or metoprolol) on erectile function: a randomized controlled trial.
Topics: Adult; Antihypertensive Agents; Biphenyl Compounds; Drug Therapy, Combination; Erectile Dysfunction; | 2013 |
Long-term effects of irbesartan on plasma aldosterone concentration and left atrial volume in hypertensive patients.
Topics: Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atrial Remodeling; Biphenyl | 2014 |
Markers of inflammation, endothelial activation, and arterial stiffness in hypertensive heart disease and the effects of treatment: results from the SILVHIA study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2013 |
Combining rosuvastatin with angiotensin-receptor blockers of different PPARγ-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Angiotensin II Type 1 Receptor Blockers; Aryld | 2015 |
Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Captopril; Case-Control Studie | 2014 |
No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Arterial Pressure; Biphenyl | 2014 |
Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.
Topics: Adolescent; Adult; Aged; Aldosterone; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers | 2014 |
[Fixed irbesartan/amlodipine combination: efficacy and safety of the use of four dosing regimens in patients with arterial hypertension].
Topics: Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Dose-Response Relatio | 2014 |
The effects of a low-salt diet on the efficacy of different antihypertensive drug regimens.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diet, Sodium-R | 2015 |
Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Female; Humans; Hypertension; | 2015 |
Efficacy and safety of two single-pill fixed-dose combinations of angiotensin II receptor blockers/calcium channel blockers in hypertensive patients (EXAMINER study).
Topics: Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Dose-Response Relatio | 2016 |
Zofenopril or irbesartan plus hydrochlorothiazide in elderly patients with isolated systolic hypertension untreated or uncontrolled by previous treatment: a double-blind, randomized study.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambula | 2016 |
Blood Pressure and Cholesterol-lowering Efficacy of a Fixed-dose Combination With Irbesartan and Atorvastatin in Patients With Hypertension and Hypercholesterolemia: A Randomized, Double-blind, Factorial, Multicenter Phase III Study.
Topics: Aged; Antihypertensive Agents; Atorvastatin; Biphenyl Compounds; Blood Pressure; Cholesterol; Double | 2016 |
Multicenter Randomized Double-Blind Comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the Treatment of Isolated Systolic Hypertension in Elderly Patients: Results of the NEHIS Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Belgium; Biphenyl Compounds; Blood Pressure; Doubl | 2017 |
Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.
Topics: Administration, Oral; Amlodipine; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Press | 2017 |
Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study).
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Cross-Over Studies; Female; Humans; Hypertension; | 2008 |
Comparison of the effects of quinapril and irbesartan on P-wave dispersion in hypertensive patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2008 |
A randomized trial of the effect of an angiotensin II receptor blocker SR47436 (irbesartan) on 24-hour blood pressure in patients with essential hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Blood Pres | 2008 |
[Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Co | 2008 |
Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diver
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Body Mass Index; Body Weight; Cluster Analysis; D | 2008 |
Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
Topics: Adult; Aged; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibito | 2010 |
The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SI
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Comorbidity; Echocardiography, D | 2009 |
Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively.
Topics: Amides; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Drug Therapy, Combination; Fuma | 2009 |
Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amides; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; D | 2009 |
Irbesartan improves arterial compliance more than lisinopril.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2009 |
Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Cell M | 2009 |
Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Bi | 2009 |
Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND).
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, T | 2010 |
Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome.
Topics: Adult; Aged; Amides; Antihypertensive Agents; Biphenyl Compounds; Blood Glucose; Cardiovascular Dise | 2011 |
Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; C-React | 2010 |
Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Body Mas | 2010 |
[Effect between felodipine plus irbesartan and felodipine plus metoprolol regimen on the sexual function in young and middle-aged women with hypertension].
Topics: Adolescent; Adult; Antihypertensive Agents; Biphenyl Compounds; Felodipine; Female; Humans; Hyperten | 2010 |
Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Biphenyl Compoun | 2010 |
Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy: impact of age and gender.
Topics: Adolescent; Adult; Age Factors; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; D | 2010 |
Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril.
Topics: Aged; Amides; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; | 2011 |
Blood pressure telemonitoring is useful to achieve blood pressure control in inadequately treated patients with arterial hypertension.
Topics: Adult; Aged; Algorithms; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pressure | 2011 |
Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria.
Topics: Albuminuria; Amino Acids; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Bendrofl | 2012 |
Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Diabetes | 2011 |
Acute angiotensin II receptor blockade improves insulin-induced microvascular function in hypertensive individuals.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Glucose; Blood Pressure; Calcium Channel | 2011 |
A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review.
Topics: Antihypertensive Agents; Biphenyl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Doub | 2011 |
Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Benzopyrans; | 2012 |
[Effect of different combined antihypertensive regimen on the erectile function in male hypertensive patients].
Topics: Adult; Antihypertensive Agents; Biphenyl Compounds; Drug Therapy, Combination; Erectile Dysfunction; | 2011 |
Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension.
Topics: Adolescent; Adult; Antihypertensive Agents; Biphenyl Compounds; Felodipine; Female; Humans; Hyperten | 2012 |
Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study).
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl | 2012 |
Relationship between the receptor occupancy profile and pleiotropic effects of angiotensin II receptor blockers.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Area Under Curve; Benzimida | 2013 |
Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients.
Topics: Action Potentials; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chlorthalidone; Cros | 2012 |
I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospec
Topics: Adult; Africa, Northern; Aged; Aged, 80 and over; Amlodipine; Analysis of Variance; Angiotensin II T | 2012 |
I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prosp
Topics: Adult; Africa, Northern; Aged; Aged, 80 and over; Amlodipine; Analysis of Variance; Angiotensin II T | 2012 |
Clinical study of western medicine combined with Chinese medicine based on syndrome differentiation in the patients with polarized hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diastole; Drugs, Chin | 2012 |
Prospective multicenter clinical trial of Chinese herbal formula JZQG (Jiangzhuoqinggan) for hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl | 2013 |
Effects of irbesartan on inflammatory cytokine concentrations in patients with chronic glomerulonephritis.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents, Non-Steroidal; Biphe | 2013 |
[Effect of irbesartan, an antagonist of AT-1 receptors for angiotensin II, on L-arginine metabolism in arterial hypertension].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Arginase; Arginine; Biphe | 2002 |
Cardiac autonomic tone during trandolapril-irbesartan low-dose combined therapy in hypertension: a pilot project.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Autonomic Nervous System; | 2002 |
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiot | 2002 |
Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study.
Topics: Adult; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Pressure; Blood Pressure Determi | 2002 |
The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
Topics: Adult; Aged; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Atenolol; Biphenyl Compounds; B | 2002 |
Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.
Topics: Adult; Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Cross-Over Studies; Diabetes Mellit | 2002 |
Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.
Topics: Aldosterone; Amlodipine; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Confounding Factors, | 2002 |
[Comparison of the antihypertensive activity of fosinopril and irbesartan].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Blood P | 2002 |
B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2003 |
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp | 2003 |
[Effect of anti-hypertensive therapy with irbesartan on the absolute cardiovascular risk].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cohort Studies; Dose- | 2003 |
Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood.
Topics: Adolescent; Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Bl | 2003 |
Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy.
Topics: Adipocytes; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Double-Blind Method; Female; Geno | 2003 |
Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy.
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Biphenyl Compounds; Blood Pressure; Female; Heart Rat | 2003 |
Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atenolol; Biphenyl Co | 2003 |
Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Circadian Rhythm; Drug Combinatio | 2003 |
Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Antihypertensive Agents; Atenolol; Bipheny | 2004 |
Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; E | 2003 |
Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Topics: Antihypertensive Agents; Atenolol; Biphenyl Compounds; Double-Blind Method; Female; Genotype; Humans | 2004 |
Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Dihydropyridine | 2004 |
An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Cohort Studies; Cost-Benefit Analysis; Diab | 2004 |
Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension.
Topics: Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Brachial Ar | 2004 |
Enhanced platelet release of superoxide anion in systemic hypertension: role of AT1 receptors.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood P | 2004 |
Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Drug Combinations; Female; Guidel | 2004 |
Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |
Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Topics: Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Pressure; Endothelin-1; Female; Genotyp | 2004 |
Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphe | 2004 |
Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy.
Topics: Adult; Aged; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropa | 2004 |
Comparative effects of fosinopril and irbesartan on hematopoiesis in essential hypertensives.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Co | 2004 |
The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Di | 2004 |
[IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2003 |
How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive diabetics.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Diabetic Angiopathies; Diabet | 2004 |
Microalbuminuria in hypertensive patients: evaluation of one-year treatment with irbesartan.
Topics: Albuminuria; Algorithms; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Female; Follow | 2005 |
Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Antihypertens | 2004 |
Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2005 |
[Irbesartan in the treatment of arterial hypertension].
Topics: Angiotensin I; Antihypertensive Agents; Biphenyl Compounds; Female; Humans; Hypertension; Irbesartan | 2000 |
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Amlodipine; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nep | 2005 |
Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Diastole; Echocardiography; Fema | 2005 |
Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
Topics: Administration, Oral; Amides; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diastole; | 2005 |
[Antihypertensive and antiischemic effectiveness and safety of the AT1-receptor blocker irbesartranin arterial hypertension in patients with prior myocardial infarction].
Topics: Administration, Oral; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2004 |
Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension.
Topics: Adult; Analysis of Variance; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Double-B | 2005 |
Effect of irbesartan monotherapy compared with ACE inhibitors and calcium-channel blockers on patient compliance in essential hypertension patients: a multicenter, open-labeled, three-armed study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; | 2005 |
[The control rate of irbesartan/hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; China; Drug Combinations; Huma | 2005 |
CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population.
Topics: Administration, Oral; Adult; Alleles; Angiotensin II Type 1 Receptor Blockers; Aryl Hydrocarbon Hydr | 2005 |
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Di | 2005 |
Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2005 |
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabete | 2005 |
[Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compou | 2005 |
A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pr | 2005 |
Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population.
Topics: Angiotensin II Type 1 Receptor Blockers; Asian People; Biphenyl Compounds; Blood Pressure; China; Do | 2006 |
Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agent | 2005 |
Use of antihypertension agents for the suppression of arterial pulse pressure waveforms in patients with intracranial aneurysms.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Brain; Cross-Over Studies; | 2006 |
Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy.
Topics: Antihypertensive Agents; Biphenyl Compounds; Black People; Blood Pressure; Drug Combinations; Female | 2006 |
[Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2004 |
Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Child; Chil | 2006 |
Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Block | 2006 |
Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Biphenyl Compounds; Cells, Cultured; Corona | 2007 |
Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
Topics: Adult; Aged; Aged, 80 and over; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2007 |
Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double- | 2006 |
[The effects of angiotensin II receptor blockers in hypertensive patients complicating hyperuricaemia].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Double-Blind Method; Female; Fol | 2006 |
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; | 2007 |
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; | 2007 |
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; | 2007 |
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; | 2007 |
Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Biphenyl Co | 2007 |
Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Com | 2007 |
Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Diastole; Double-Blind Method; E | 2007 |
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convertin | 2007 |
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convertin | 2007 |
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convertin | 2007 |
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convertin | 2007 |
Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive | 2007 |
Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Cross-Sectional Studies; Drug Monitoring; | 2007 |
Aldosterone escape with diuretic or angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biph | 2007 |
A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.
Topics: Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pres | 2008 |
Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2007 |
Initial combination therapy with irbesartan/hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapy.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diureti | 2007 |
The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl | 2007 |
Predictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: a secondary analysis of the irbesartan/hydrochlorothiazide blood pressure reductions in diverse patient populations (INCLUSIVE) study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Diabetes Mellitu | 2008 |
Beneficial effect of angiotensin II type 1 receptor blocker antihypertensive treatment on arterial stiffness: the role of smoking.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Biphenyl Compounds; Blood Flo | 2008 |
[Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Disease | 2008 |
Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Atenolol; Biphenyl | 2008 |
Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arginine; Biphen | 2008 |
The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2008 |
Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension.
Topics: Adult; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Body Weigh | 1995 |
Effect of high-performance liquid chromatography on plasma angiotensin II measurements in treated and untreated normotensive and hypertensive patients.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Blood Chem | 1997 |
Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 1997 |
Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetic | 1997 |
Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood | 1997 |
Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; | 1998 |
Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 1998 |
A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 1998 |
Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 1998 |
Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diuretics; Dose-Response Relation | 1998 |
Dose-related efficacy of irbesartan for hypertension: an integrated analysis.
Topics: Adolescent; Adult; Antihypertensive Agents; Biphenyl Compounds; Data Interpretation, Statistical; Do | 1998 |
Safety of irbesartan in the treatment of mild to moderate systemic hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Double-Blind Method; Drug Administration S | 1998 |
Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression.
Topics: Adolescent; Adult; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Calcium Channel Bloc | 1998 |
Irbesartan reduces QT dispersion in hypertensive individuals.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Dou | 1999 |
The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Demography; Drug Therapy, | 1998 |
Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diuretics; Double-Blind Method; Drug Co | 1999 |
The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diuretics; Double-Blind Method; D | 1999 |
Long-term safety and antihypertensive efficacy of irbesartan: pooled results of five open-label studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzothiadiazines; Biphenyl Com | 1999 |
The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 1999 |
Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biomarkers; Biphenyl Comp | 1999 |
Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; | 2000 |
Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Coagulatio | 2000 |
A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl | 2000 |
Regression of left ventricular hypertrophy in human hypertension with irbesartan.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Atenolol; Biphenyl Compo | 2001 |
The pharmacokinetics of irbesartan in hypertensive children and adolescents.
Topics: Administration, Oral; Adolescent; Antihypertensive Agents; Area Under Curve; Biphenyl Compounds; Chi | 2001 |
Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Drug Administr | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compou | 2001 |
A clinical trial in type 2 diabetic nephropathy.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Calcium Channel Block | 2001 |
Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Bi | 2001 |
Treatment with irbesartan or atenolol improves endothelial function in essential hypertension.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Bi | 2001 |
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Chronic Disease; Cross-Over Studies; Double-Blind | 2001 |
Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihyper | 2002 |
A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambula
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; | 2002 |
Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (
Topics: Aged; Alleles; Angiotensin Receptor Antagonists; Angiotensinogen; Antihypertensive Agents; Atenolol; | 2002 |
Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atrial Natriuretic Factor; B | 2002 |
An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pressure | 2002 |
Other Studies
192 other studies available for avapro and Hypertension
| Article | Year |
|---|---|
Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics.
Topics: Administration, Oral; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihyperten | 2005 |
Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Antineoplastic Agents; Cell Line | 2012 |
Different Approaches in Manipulating Ratio Spectra for Analyzing Amlodipine Besylate and Irbesartan Combination.
Topics: Amlodipine; Antihypertensive Agents; Humans; Hypertension; Irbesartan; Spectrophotometry; Tetrazoles | 2022 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Seasonal variation in the effect of antihypertensive treatment with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2023 |
Canagliflozin ameliorates epithelial-mesenchymal transition in high-salt diet-induced hypertensive renal injury through restoration of sirtuin 3 expression and the reduction of oxidative stress.
Topics: Animals; Canagliflozin; Catalase; Diet; Epithelial-Mesenchymal Transition; Fibrosis; Humans; Hyperte | 2023 |
Virtual Screening of Novel 24-Dehydroxysterol Reductase (
Topics: Animals; Cardiovascular Diseases; Cholesterol; Desmosterol; Diabetes Mellitus, Type 2; Hypertension; | 2023 |
Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cana | 2023 |
A collaborative study of the impact of N-nitrosamines presence and ARB recall on ARB utilization - results from IQVIA™ Disease Analyzer Germany.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Germany; Humans; Hyperte | 2023 |
Cost-effectiveness of ultra-low-dose quadruple combination therapy for high blood pressure.
Topics: Cost-Benefit Analysis; Humans; Hypertension; Irbesartan; Quality-Adjusted Life Years | 2023 |
Expression of LRG-1 in mice with hypertensive renal damage and its significance.
Topics: Angiotensin II; Animals; Collagen Type I; Creatinine; Fibronectins; Hypertension; Irbesartan; Kidney | 2023 |
Canagliflozin and irbesartan ameliorate renal fibrosis via the TGF-β1/Smad signaling pathway in Dahl salt-sensitive rats.
Topics: Animals; Blood Pressure; Canagliflozin; Fibrosis; Hypertension; Irbesartan; Kidney; Kidney Diseases; | 2023 |
ALDH2 improved irbesartan treatment efficacy among rats with hypertension.
Topics: Aldehyde Dehydrogenase, Mitochondrial; Animals; Antihypertensive Agents; Gene Expression Regulation; | 2019 |
Irbesartan may relieve renal injury by suppressing Th22 cells chemotaxis and infiltration in Ang II-induced hypertension.
Topics: Angiotensin II; Animals; Cell Differentiation; Cell Survival; Chemotaxis; Cytokines; Hypertension; I | 2020 |
Protective effects of irbesartan and benazepril against vaginal vascular remodeling and fibrosis in female spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; B | 2020 |
Antihypertensive properties of a traditional Chinese medicine GAO-ZI-YAO in elderly spontaneous hypertensive rats.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Blood Pressure; Cytokine | 2020 |
Adherence to Treatment, Arterial Stiffness and Cognitive Function in Irbesartan- Treated Newly Diagnosed Hypertensive Patients.
Topics: Aged; Antihypertensive Agents; Cognition; Female; Humans; Hypertension; Irbesartan; Male; Medication | 2021 |
Prevalence of and risk factors for abnormal left ventricular geometrical patterns in hypertensive subjects administered irbesartan.
Topics: Aged; Antihypertensive Agents; Cross-Sectional Studies; Electrocardiography; Female; Heart Ventricle | 2021 |
The antihypertensive effect of irbesartan in spontaneously hypertensive rats is associated with improvement of the leptin-adiponectin imbalance.
Topics: Adiponectin; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2021 |
Expression of Cyr61 in ApoE
Topics: Amides; Amlodipine; Angiotensin II; Animals; Antihypertensive Agents; Apolipoproteins E; Blood Press | 2021 |
Effects of irbesartan on phenotypic alterations in monocytes and the inflammatory status of hypertensive patients with left ventricular hypertrophy.
Topics: Aged; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antihyperte | 2021 |
Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2021 |
Irbesartan suppresses lipopolysaccharide (LPS)-induced blood-brain barrier (BBB) dysfunction by inhibiting the activation of MLCK/MLC.
Topics: Actomyosin; Animals; Behavior, Animal; Blood-Brain Barrier; Capillary Permeability; Cell Line; Depre | 2021 |
Restless legs syndrome/Willis-Ekbom disease in type 2 diabetes as the initial manifestation of Parkinson's disease and major cardiovascular disease.
Topics: Aged; Amines; Analgesics; Anticonvulsants; Antihypertensive Agents; Antiparkinson Agents; Aspirin; B | 2017 |
Influence of Single and Multi Dose Treatment of Glipizide on Pharmacokinetics and Pharmacodynamics of Irbesartan in Normal and Hypertensive Rats.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Bio | 2017 |
Prospective direct comparison of antihypertensive effect and safety between high-dose amlodipine or indapamide in hypertensive patients uncontrolled by standard doses of angiotensin receptor blockers and amlodipine.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biph | 2018 |
Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto: Atrial Fibrillation Suppression Trial (SILK study).
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Atrial Fibrillation; Biphenyl Compounds; Blood P | 2018 |
Antioxidant-Based Eutectics of Irbesartan: Viable Multicomponent Forms for the Management of Hypertension.
Topics: Animals; Antihypertensive Agents; Antioxidants; Ascorbic Acid; Biphenyl Compounds; Calorimetry, Diff | 2018 |
Perindopril 3.5 mg/amlodipine 2.5 mg versus renin-angiotensin system inhibitor monotherapy as first-line treatment in hypertension: a combined analysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Female; Humans; Hypert | 2018 |
Hypertension Hot Potato - Anatomy of the Angiotensin-Receptor Blocker Recalls.
Topics: Angiotensin II Type 1 Receptor Blockers; Dimethylnitrosamine; Drug Contamination; Drug Recalls; Huma | 2019 |
Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Antihypertensive Age | 2013 |
Expanded roles of the renin-angiotensin system.
Topics: Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Antihypertensive Agents; Antioxid | 2013 |
Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Disease Models, Animal; Epithe | 2013 |
Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2013 |
Hypertension promotes islet morphological changes with vascular injury on pre-diabetic status in SHRsp rats.
Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Disease Models, Animal; Hydral | 2014 |
Maintaining goal blood pressures after switching from olmesartan to other angiotensin receptor blockers.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; B | 2013 |
Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl | 2014 |
Effect of obstructive respiratory events on blood pressure and renal perfusion in a pig model for sleep apnea.
Topics: Aldosterone; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Disea | 2014 |
Comparison of effects of nebivolol, carvedilol and irbesartan on left ventricular hypertrophy associated with hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Carbazoles; C | 2014 |
Combining irbesartan and trichlormethiazide enhances blood pressure reduction via inhibition of sympathetic activity without adverse effects on metabolism in hypertensive rats with metabolic syndrome.
Topics: Animals; Antihypertensive Agents; Antioxidants; Biphenyl Compounds; Blood Pressure; Heart Rate; Hype | 2015 |
Assessment of effect of irbesartan and nebivolol on the left atrium volume and deformation in the patients with mild-moderate hypertension.
Topics: Antihypertensive Agents; Benzopyrans; Biphenyl Compounds; Blood Pressure; Diastole; Echocardiography | 2014 |
Calcitriol supplementation improves endothelium-dependent vasodilation in rat hypertensive renal injury.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Calcitriol; Di | 2014 |
Pleiotropic effects of angiotensin II blockers in hemodialysis patients: myth or reality?
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Female; Heart Ventricles; Humans; Hyper | 2014 |
Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4.
Topics: Adrenergic alpha-Agonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Bipheny | 2015 |
The therapeutic advantage of combination antihypertensive drug therapy using amlodipine and irbesartan in hypertensive patients: Analysis of the post-marketing survey data from PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pressure | 2015 |
Interactive Effect of the KCNJ11 Ile337Val Polymorphism and Cigarette Smoking on the Antihypertensive Response to Irbesartan in Chinese Hypertensive Patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Bipheny | 2016 |
Does this patient have hypertensive encephalopathy?
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Brain; Carbazoles; Carvedilol; Computed Tom | 2016 |
Angiotensin receptor blocker improves a stress-induced prothrombotic state in a murine model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Humans; Hypertension; Irbesart | 2016 |
The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl | 2016 |
Influence of initial angiotensin receptor blockers on treatment persistence in uncomplicated hypertension: A nation-wide population-based study.
Topics: Acrylates; Adult; Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cohort Studies; Female | 2016 |
[Effect of the angiotensin II receptor antagonist (ARB), Irbesartan, on urinary markers in hypertensive patients].
Topics: Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Female; Humans; Hypertension; Irbe | 2016 |
Interaction between irbesartan, peroxisome proliferator-activated receptor (PPAR-γ), and adiponectin in the regulation of blood pressure and renal function in spontaneously hypertensive rats.
Topics: Adiponectin; Administration, Oral; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compou | 2016 |
Endothelin-1 Drives Epithelial-Mesenchymal Transition in Hypertensive Nephroangiosclerosis.
Topics: Actins; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Biphenyl Compounds | 2016 |
Copeptin is increased in resistant hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; Blood Pressure; Co | 2016 |
Irbesartan/Hydrochlorothiazide : in moderate to severe hypertension.
Topics: Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Humans; Hy | 2008 |
Central estrogen inhibition of angiotensin II-induced hypertension in male mice and the role of reactive oxygen species.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure | 2008 |
Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Cost-Benefit Analysis; | 2008 |
Renin-angiotensin-aldosterone system gene polymorphisms and antihypertensive response to irbesartan in Chinese hypertensives.
Topics: Angiotensinogen; Antihypertensive Agents; Asian People; Biphenyl Compounds; Blood Pressure; China; F | 2008 |
[How to follow-up on the recommendations of the ESH/ESC guidelines for different kinds of blood pressure measurement methods].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2009 |
Angiotensin II receptor blockers in pregnancy: a report of five cases.
Topics: Abnormalities, Drug-Induced; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphe | 2009 |
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
Topics: Albuminuria; Amides; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic | 2009 |
The efficacy and safety of irbesartan in primary hypertension even if a dose is missed: Results from the NO PROBLEM Study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; B | 2010 |
Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pr | 2009 |
Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat.
Topics: Albuminuria; Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Comp | 2010 |
Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Animals; ATP Binding Cassette Transporter, Subfa | 2010 |
Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agen | 2011 |
Effects of angiotensin type 1 receptor blockade on arginine and ADMA synthesis and metabolic pathways in fawn-hooded hypertensive rats.
Topics: Amidohydrolases; Angiotensin II Type 1 Receptor Blockers; Animals; Arginine; Biphenyl Compounds; Cit | 2010 |
Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure; Ca | 2010 |
Effects of protein coding polymorphisms in the kallikrein 1 gene on baseline blood pressure and antihypertensive response to irbesartan in Chinese hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Bipheny | 2011 |
Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Angiotens | 2010 |
Irbesartan treatment up-regulates hepatic expression of PPARalpha and its target genes in obese Koletsky (fa(k)/fa(k)) rats: a link to amelioration of hypertriglyceridaemia.
Topics: Animals; Biphenyl Compounds; Blotting, Western; Gene Expression; Hypertension; Hypertriglyceridemia; | 2010 |
Platelet activation in hypertension associated with hypercholesterolemia: effects of irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antioxidants; Biphenyl Co | 2011 |
Follow-up of cardiovascular risk markers in hypertensive patients treated with irbesartan: results of the i-SEARCH Plus Registry.
Topics: Aged; Albuminuria; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; C-Reactive Protein; Card | 2010 |
Functional sympatholysis is impaired in hypertensive humans.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Electrocardiogra | 2011 |
Functional sympatholysis is impaired in hypertensive humans.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Electrocardiogra | 2011 |
Functional sympatholysis is impaired in hypertensive humans.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Electrocardiogra | 2011 |
Functional sympatholysis is impaired in hypertensive humans.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Electrocardiogra | 2011 |
Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; China; Chromatography, Hig | 2011 |
Improvement of coronary microvascular function after Angiotensin receptor blocker treatment with irbesartan in patients with systemic hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; Bl | 2011 |
[Effect of irbesartan of the function of hemocoagulative component of hemostasis in patients with arterial hypertension during metabolic syndrome].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Female; | 2010 |
Atrial fibrillation, is warfarin the only option for stroke prevention?
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp | 2011 |
The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Antineoplastic Agents; Benzopyr | 2011 |
Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ.
Topics: Adiponectin; Adipose Tissue; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bip | 2011 |
Synergism of irbesartan and amlodipine on hemodynamic amelioration and organ protection in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Baroreflex; Biphenyl Compounds; Blood Pressure; Drug S | 2011 |
Effects of lisinopril, irbesartan, and amlodipine on the thrombogenic variables in the early and late stages of the treatment in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2012 |
Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compou | 2011 |
Novel mechanism of angiotensin II-induced cardiac injury in hypertensive rats: the critical role of ASK1 and VEGF.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Biphenyl Compounds; Blood Pressure; Blo | 2012 |
Funny turn.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Diagnosis, Differential; Diagnostic Tests, Routin | 2011 |
The beneficial effects of nebivolol on endothelial functions in arterial hypertension.
Topics: Benzopyrans; Biphenyl Compounds; Blood Pressure; Ethanolamines; Female; Humans; Hydrochlorothiazide; | 2012 |
Circulating microparticles and endothelial progenitor cells in atherosclerosis: pharmacological effects of irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Biphenyl Compounds; Blood Pressur | 2012 |
Irbesartan and emodin on myocardial remodeling in Goldblatt hypertensive rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl | 2012 |
Comparative efficacy of irbesartan/ hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure: a retrospective observational study in Oman.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabete | 2013 |
A population-based European cohort study of persistence in newly diagnosed hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2002 |
Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Arteries; Biphenyl Compounds; Calcinosis; Collage | 2002 |
Irbesartan substitution for valsartan or losartan in treating hypertension.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Female; Humans; Hypertension; Irb | 2002 |
Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases.
Topics: Adolescent; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pre | 2002 |
[Effect of irbesartan--angiotensin II type I receptor inhibitor on oxidative metabolism of lipids in essential hypertension].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Human | 2002 |
Sympatho-inhibitory actions of irbesartan in pithed spontaneously hypertensive and Wistar-Kyoto rats.
Topics: Adrenergic alpha-Agonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting | 2003 |
Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Antihypertensive Agents; Biphenyl Compounds; | 2003 |
Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp | 2003 |
Treatment with irbesartan counteracts the functional remodeling of ventricular myocytes from hypertensive rats.
Topics: Action Potentials; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiomegaly; Cell | 2003 |
Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray.
Topics: Alleles; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Biphenyl Compounds; Cytochrome P-45 | 2003 |
[Dangerous deficits in management of hypertensive diabetic patients. A kidney check is far from standard procedure].
Topics: Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes | 2003 |
Cardiology patient page. Angiotensin receptor blockers.
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Bip | 2003 |
Influence of two doses of irbesartan on non-dipper circadian blood pressure rhythm in salt-sensitive black hypertensives under high salt diet.
Topics: Adult; Angiotensin Receptor Antagonists; Biphenyl Compounds; Black People; Blood Pressure; Circadian | 2003 |
Exanthematous reaction to irbesartan.
Topics: Aged; Biopsy, Needle; Biphenyl Compounds; Drug Eruptions; Drug Therapy, Combination; Exanthema; Foll | 2003 |
[Fast-acting sartan. High blood pressure therapy without long waiting time].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2003 |
The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Cost-Benefit Analysis; Diabete | 2003 |
An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
Topics: Adult; Age of Onset; Aged; Angiotensin-Converting Enzyme Inhibitors; Belgium; Biphenyl Compounds; Ca | 2003 |
Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype | 2003 |
[Dosage equivalents of AT1-receptor antagonists available in Germany].
Topics: Acrylates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2003 |
[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Computer Simulation; Creatinine; Diabetes M | 2004 |
Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood | 2004 |
[Irbesartan-induced acute hepatitis].
Topics: Acute Disease; Antihypertensive Agents; Biphenyl Compounds; Chemical and Drug Induced Liver Injury; | 2004 |
Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada.
Topics: Adult; Aged; Amlodipine; Biphenyl Compounds; Cohort Studies; Cost-Benefit Analysis; Diabetic Nephrop | 2004 |
Hypotensive and prophylactic effects of angiotensin II subtype 1 receptor antagonist, irbesartan, in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Biphenyl Comp | 2004 |
The KARTAN study: a postmarketing assessment of Irbesartan in patients with hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Female; | 2004 |
Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences.
Topics: Animals; Antihypertensive Agents; Biological Availability; Biphenyl Compounds; Blood Pressure; Carba | 2004 |
Diverse effects of long-term treatment with imidapril and irbesartan on cell growth signal, apoptosis and collagen type I expression in the left ventricle of spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype | 2004 |
[Health economic aspects of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
Topics: Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Germany; Health Care Costs; | 2004 |
[Arterial hypertension in adipose patients. Rationale for a prospective medical care study in the family physician practice].
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl | 2004 |
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patien
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Calcium Chann | 2004 |
[Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective].
Topics: Antihypertensive Agents; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabe | 2004 |
[A threat to cardiovascular risk patients. "Activated renin-angiotensin system promotes end organ damage" (interview by Waldtraud Paukstadt)].
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; | 2004 |
Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment.
Topics: Analysis of Variance; Antihypertensive Agents; Apolipoproteins B; Atenolol; Biphenyl Compounds; Fema | 2004 |
[Test for microalbuminuria. Life saving for hypertensive and diabetic patients].
Topics: Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Coronary Artery Disease; Diabetic Nephropa | 2004 |
Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.
Topics: Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cost Savings; Diabetes Mel | 2005 |
Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects.
Topics: Adult; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Case-Control Studies; Cell Adhes | 2005 |
[Therapeutic implications of ACE-gene polymorphism].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Association of cigarette smoking with steady-state plasma concentration of irbesartan in male Chinese with hypertension.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; China; Humans; Hypertension; Irbesartan | 2005 |
Failure of angiotensin II to suppress plasma renin activity in normotensive subjects with a positive family history of hypertension.
Topics: Adult; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Dos | 2005 |
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetic Nephr | 2005 |
Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Data Collection; | 2005 |
[Good blood pressure control even in overweight patients].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pr | 2005 |
[Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2005 |
Acute pancreatitis associated with irbesartan therapy.
Topics: Acute Disease; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Human | 2005 |
Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; | 2005 |
Selective angiotensin II receptor antagonism enhances whole-body insulin sensitivity and muscle glucose transport in hypertensive TG(mREN2)27 rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biological Transport; Biphenyl Com | 2005 |
Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in rural Chinese patients with essential hypertension.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Asian People; Atrial Natriuretic Factor; Biphenyl Co | 2005 |
Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca2+-ATPase activity in rat cardiac pressure-overload hypertrophy.
Topics: Animals; Biphenyl Compounds; Calcineurin; Calcium-Transporting ATPases; Cardiomegaly; Disease Models | 2006 |
[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Ca | 2006 |
Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2006 |
Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs.
Topics: Animals; Antihypertensive Agents; Aorta; Atenolol; Baroreflex; Biphenyl Compounds; Blood Pressure; C | 2006 |
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
Topics: Adult; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphe | 2006 |
[Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ].
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compo | 2006 |
[Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Computer Simulation; Costs and Cost Ana | 2006 |
Efficacy of irbesartan on left ventricular mass and arterial stiffness in hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Aorta; Biphenyl Compounds; Female; Humans; Hyp | 2006 |
What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Di | 2006 |
Treatment of diastolic dysfunction in hypertensive left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2006 |
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cost-Benefit Analysis; Dia | 2006 |
Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis.
Topics: Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Cohort Studies; Comorbidity; Costs and Cos | 2007 |
Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
Topics: Abdominal Fat; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Comp | 2007 |
[Treatment of hypertension can do more. Using chances for organ protection].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular | 2006 |
[Successful high dosage fixed combination. 7 of 10 patients achieve target blood pressure].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure | 2006 |
Hypothalamic angiotensinergic-noradrenergic systems interaction in fructose induced hypertension.
Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Fructose; Hypertension; Hypothalamus; Insulin | 2008 |
Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Canada; Cost-Benefit Analysis; Diabetes | 2007 |
BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2007 |
[Long-term follow-up of cardiovascular risk markers in patients with hypertension. Rationale, design, and baseline characteristics of the i-Search Plus Registry].
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl | 2007 |
Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Biphenyl Compounds; Blood | 2008 |
Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2008 |
Early and late haemodynamic and morphological effects of angiotensin II subtype 1 receptor blockade during genetic hypertension development.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Biphenyl Compounds; Hemod | 1995 |
Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Aortic Valve Stenosis; Bi | 1997 |
[Irbesartan--a new AT1-receptor antagonist (AT1-blocker). Angiotensin-II-receptor antagonists: perspectives of a new therapeutic principle, Wiesbaden, 6 April 1997].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Humans | 1997 |
Irbesartan for hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Controlled Clinical T | 1998 |
[Irbesartan--current trends in the management of hypertension].
Topics: Antihypertensive Agents; Biphenyl Compounds; Humans; Hypertension; Irbesartan; Tetrazoles | 1998 |
Problems with interpreting the data in Kassler-Taub et al's article comparing irbesartan and losartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Decis | 1999 |
[Drug clinics. Drug of the month. Irbesartan (Aprovel)].
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biological | 1999 |
An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Humans; Hypertension; | 1999 |
Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Biphenyl Compounds; Calcium; Cells, Culture | 1999 |
Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats : effects of angiotensin receptor antagonism and converting enzyme inhibition.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compou | 1999 |
Efficacy of angiotensin II antagonists in hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 1999 |
AT1-receptor blockers.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Heart | 2000 |
[Organ protection in hypertensive type 2 diabetic patients. Double chance with AT1 blockers].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2000 |
Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms.
Topics: Adrenal Cortex Hormones; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; A | 2000 |
Headache in mild-to-moderate hypertension and its reduction by irbesartan therapy.
Topics: Adult; Antihypertensive Agents; Biphenyl Compounds; Female; Headache; Humans; Hypertension; Incidenc | 2000 |
Renal arterial intervention and angiotensin blockade in atherosclerotic nephropathy.
Topics: Aged; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arterioscleros | 2000 |
End-stage renal failure after irbesartan prescription in a diabetic patient with previously stable chronic renal insufficiency.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Captopril; Diab | 2000 |
Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 2001 |
p38 Map kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cells, Cultured; Coll | 2001 |
Headache, hypertension, and irbesartan therapy.
Topics: Antihypertensive Agents; Biphenyl Compounds; Headache; Humans; Hypertension; Irbesartan; Tetrazoles | 2001 |
Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade.
Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Ag | 2001 |
The peripheral renin-angiotensin system is not involved in the hypertension of sheep exposed to prenatal dexamethasone.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensinogen; Animals; Antihypertensive Agents; | 2001 |
Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats.
Topics: Albuminuria; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2001 |
Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction?
Topics: Acetylcholine; Animals; Antihypertensive Agents; Aorta; Biphenyl Compounds; Blood Pressure; Endothel | 2001 |
Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension.
Topics: Albuminuria; Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Di | 2001 |
[Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as To | 2001 |
Angiotensin II receptor blockers and nephropathy trials.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; | 2001 |
Influence of irbesartan and enalapril on changes of renal function associated with the established phase of l-NAME hypertension.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2001 |
[Irbesartan in hypertension. A plus for therapy compliance].
Topics: Antihypertensive Agents; Biphenyl Compounds; Humans; Hypertension; Irbesartan; Patient Compliance; T | 2001 |
Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aort | 2002 |
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout.
Topics: Antihypertensive Agents; Biphenyl Compounds; Gout; Humans; Hypertension; Irbesartan; Losartan; Tetra | 2002 |
Preventing nephropathy in patients with type 2 diabetes.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2002 |
Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2002 |
Coronary dilatation reserve in experimental hypertension and chronic heart failure: effects of blockade of the renin-angiotensin system.
Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Coronary Vessels; Gene Deletion; Heart; Heart | 2001 |
[Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].
Topics: Albuminuria; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
Aortic smooth muscle cell phenotypic modulation and fibrillar collagen deposition in angiotensin II-dependent hypertension.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Geneticall | 2002 |